Latest News - Neuro News webeditor@bibamedical.com http://www.cxvascular.com/ Affino Atom Generator BIBA Medical Ltd 2014-09-20T12:56:23Z Codman Neuro gains exclusive rights to market and promote PulseRider in Europe, the Middle East and Africa http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/codman-neuro-gains-exclusive-rights-to-market-and-promote-pulserider-in-europe-the-middle-east-and-africa 2014-09-09T19:45:00Z 2014-09-09T19:45:00Z <div id="ImageMain1" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/codman-neuro-gains-exclusive-rights-to-market-and-promote-pulserider-in-europe-the-middle-east-and-africa"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/PulseRider_main_MPreview.jpg" border="0" vspace="5" /></a></div><div id="Introduction1" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Codman Neuro, part of DePuy Synthes Companies of Johnson &amp; Johnson, has announced that it has reached an exclusive distribution agreement with Pulsar Vascular to market and promote that company&rsquo;s PulseRider in Europe, the Middle East and Africa. PulseRideris a minimally invasive device intended for use with embolic coils in the treatment of unruptured wide-neck intracranial aneurysms originating on or near a bifurcation. The device received initial CE mark approval in Europe in late 2013. The agreement was entered into by one of Codman Neuro&rsquo;s EU affiliated companies.</strong></span></p> </div><div id="Text11" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The announcement was made at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress. This distribution agreement marks the latest expansion of Codman Neuro&rsquo;s neurovascular portfolio, which includes a wide range of products for haemorrhagic and ischaemic stroke, cerebral aneurysms and other neurovascular and neurological diseases and conditions. PulseRider is a self-expanding nitinol implant that is used in conjunction with embolic coils to bridge the neck of cerebral aneurysms.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are excited about this new agreement with Pulsar Vascular and the greater access physicians and their patients in Europe will now have to a potentially lifesaving endovascular procedure,&rdquo; says P Laxmin Laxminarain, worldwide president of Codman Neuro. &ldquo;There is a significant unmet clinical need in the treatment of unruptured, wide-neck bifurcation aneurysms, and we hope to help fill it with this innovative device.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Repairing wide-neck intracranial aneurysms is a challenging endovascular procedure&nbsp;and treatment options are extremely limited,&rdquo; says Monika Killer-Oberpfalzer, Paracelsus Medical University Salzburg, Austria. &ldquo;We welcome technology specifically designed to enhance our ability to treat these complex aneurysms more easily with less risk in the hope that more lives can be saved.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />PulseRider is limited to investigational use only in the United States and has not been approved by the US Food and Drug Administration (FDA) for distribution.</span></p></div> IMRIS sterile wireless imaging coil and Monteris laser technologies combine for first time inside a VISIUS Surgical Theatre with iMRI http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imris-sterile-wireless-imaging-coil-and-monteris-laser-technologies-combine-for-first-time-inside-a-visius-surgical-theatre-with-imri 2014-09-09T19:00:00Z 2014-09-09T19:00:00Z <div id="ImageMain2" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imris-sterile-wireless-imaging-coil-and-monteris-laser-technologies-combine-for-first-time-inside-a-visius-surgical-theatre-with-imri"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/035/IMRIS_VISIUS_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction2" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>IMRIS has announced that the company&rsquo;s InSitu wireless coil and Monteris NeuroBlate laser ablation system have been used together for the first time at a leading United States neuroscience centre. This combination brought improved visualisation and workflow in removing a patient&rsquo;s low-grade glioma brain tumour inside a VISIUS Surgical Theatre.</strong></span></p> </div><div id="Text12" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Using the sterile InSitu wireless coil with the NeuroBlate system&nbsp; streamlines the workflow for transitioning between intraoperative&nbsp; imaging and surgery and provides high-quality MR images for&nbsp; navigation,&rdquo; says Monteris president and chief executive officer John E Schellhorn.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The InSitu Coil is a sterile, wireless, ultra-lightweight and disposable imaging coil that eliminates the need to manage cables and heavy imaging coils typically draped and removed between intraoperative scans. Instead, this coil is secured directly to the sterile field, and provides an open window for direct access to the operative site for the manipulation of the NeuroBlate robotic laser thermotherapy probe or other surgical tools. The NeuroBlate System, a type of laser interstitial thermal therapy (LITT), applies focused energy under MR-guidance to ablate tumours through a minimally invasive approach, while the system&rsquo;s cooling technology helps avoid damage to adjacent&nbsp; healthy tissue.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The InSitu wireless coil enhances the image quality of MR images acquired by the VISIUS iMR scanner. The InSitu Coil remains in a consistent position during the procedure, eliminating the small fluctuations in the MR images that may be caused if using a coil that requires repositioning between scans.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The experience of neurosurgeons has demonstrated that employing MR imaging and software-based visualisation with the Monteris system allows the ablation of targeted tissue using minimally invasive techniques through very small holes in the skull,&rdquo; Schellhorn adds.</span></p></div> Revive SE thrombectomy device approved in China, South Korea and Taiwan http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/revive-se-thrombectomy-device-approved-in-china-south-korea-and-taiwan 2014-09-08T19:38:00Z 2014-09-08T19:38:00Z <div id="ImageMain3" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/revive-se-thrombectomy-device-approved-in-china-south-korea-and-taiwan"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/042/Codman_Revive_SE_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction3" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Codman Neuro, part of<em>&nbsp;</em>DePuy Synthes Companies of Johnson &amp; Johnson, has announced regulatory approval from the China Food and Drug Administration (CFDA), South Korea&rsquo;s Ministry of Food and Drug Safety (MFDS), and the Taiwan Food and Drug Administration (TFDA) for the company&rsquo;s Revive SE Thrombectomy Device, a next-generation self-expanding clot removal device intended to restore blood flow in patients with acute ischaemic stroke secondary to intracranial occlusive vessel disease.</strong></span></p> </div><div id="Text13" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The Revive SE Device is designed to ease navigation through small and tortuous blood vessels and arteries in the cerebral vasculature. The new device enables rapid restoration of blood flow to the brain during an acute ischaemic stroke.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are pleased to offer the Revive SE device in these countries, which have a high incidence of stroke and an increasing need for new and advanced treatment options,&rdquo; says&nbsp;P Laxmin Laxminarain, worldwide president of Codman Neuro. &ldquo;Codman Neuro continues to expand its presence throughout the world with existing and new solutions that fill clinical needs and improve patient care.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Revive SE Device, which is also available in Europe, features a closed-ended soft distal tip to capture clots and large fragments with minimal trauma, and a narrow and tall strut design to better penetrate and engage more clot.&nbsp;Clinicians may use the Revive SE Device for the non-surgical removal of emboli and thrombi, with aspiration and with the injection or infusion of contrast media and other fluids.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Revive SE Thrombectomy Device is not currently approved for distribution in the United States.</span></p></div> Understanding the brain’s pulse shows promise for managing concussion http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/understanding-the-brains-pulse-shows-promise-for-managing-concussion 2014-09-08T17:57:00Z 2014-09-08T17:57:00Z <div id="Introduction4" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>An article published in the <a href="http://journals.lww.com/cjsportsmed/Pages/default.aspx" target="_blank"><em>Clinical Journal of Sport Medicine </em></a>&mdash; &ldquo;Detection of Concussion Using Cranial Accelerometry&rdquo; by Paul S Auerbach, Jennifer G Baine, Megan L Schott, Amy Greenhaw, Monika G Acharya and Wade S Smith &mdash; has shown that the Jan Medical Nautilus BrainPulse technology has detected a consistent pattern correlated with concussion. This paper provides the first indication that the measurement of brain motion due to pulsatile blood flow can detect physiological changes in the brain correlated with concussion. Out of 84 players enrolled in the Stanford University Medical School Institutional Review Board-approved protocol, BrainPulse detected 10 out of 13 confirmed concussions for a 77% sensitivity; and 79 out of 91 recordings were confirmed to not have a concussion for an 87% specificity.</strong></span></p> </div><div id="Text14" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Paul Lovoi, founder and chief executive officer of Jan Medical, states, &ldquo;While these findings are very encouraging, additional trials will be necessary to establish this technology as an objective measure of concussion, studies that we are currently undertaking.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The study was conducted at a Northern California high school over the course of one football season involving the majority of both the varsity and junior varsity players. All the players were recorded with the BrainPulse at the beginning of the season prior to any potentially concussive contact. Over the course of the season, SCAT2 (Sports Concussion Assessment Tool) was used to assist in the clinical determination of concussion. &ldquo;This new discovery holds promise to provide a more objective measure of concussion so as to allow a safer return to play and the protection of our youth in contact sports,&rdquo; says Wade Smith, vice chair of Neurology at UCSF.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The brain has a normal pulse driven by the cardiac cycle. The impact of this pulse on the skull can in turn be detected and measured. The Nautilus BrainPulse from Jan Medical is designed to measure the normal brain pulse as well as disruptions of the brain pulse. By digitising the signal patterns from headset-mounted sensors measuring the skull&rsquo;s motion, and extracting features from them, algorithms can be developed to identify normal and a variety of abnormal brain pulse patterns. The BrainPulse sensors passively measure the skull in recording sessions that take approximately three minutes to conduct. The entire device itself is portable and provides analysis immediately once the recording session is complete. Lovoi adds, &ldquo;We see evidence that our technology can contribute to a wide range neurological deficits.&rdquo;</span></p></div> Neuravi introduces collaborative clot research initiative at ESMINT http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuravi-introduces-collaborative-clot-research-initiative-at-esmint 2014-09-08T11:37:00Z 2014-09-08T11:37:00Z <div id="Introduction5" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Neuravi introduced the Neuravi Thromboembolic Initiative (NTI) during a series of workshops on &ldquo;The Science of Clot&rdquo; at the European Society of Minimally Invasive Neurological Therapy (ESMINT) conference in Nice, France. The NTI brings together Neuravi engineers with clinicians and researchers from leading international institutions in an effort to deepen the understanding of the mechanical properties of clot and occlusion dynamics, with the goal of improving the physician&rsquo;s ability to restore flow in acute ischaemic stroke.</strong></span></p> </div><div id="Text15" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The ESMINT conference gathers leaders in minimally invasive neurological therapy from across Europe. &ldquo;One of the goals of ESMINT is to advance the practice of neuro-intervention through the support of research, education and training,&rdquo; observed Laurent Pierot, president of the ESMINT Congress. &ldquo;Currently, there is a growing interest in identifying different clots and in understanding how different clot characteristics may impact treatment in acute ischaemic stroke. The NTI workshops will help in these efforts.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The NTI workshops featured a presentation by Anastasios Mpotsaris, Uniklinik K&ouml;ln, as well as interactive hands-on sessions with engineers exploring clot characterisation, the dynamics of occlusion formation and clot-device interactions and any potential implications for revascularisation.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The NTI represents Neuravi&rsquo;s commitment to advance the treatment of stroke by investing and collaborating in research to unravel the science of stroke occlusion,&rdquo; states Eamon Brady, chief executive officer of Neuravi. &ldquo;We are excited to have this opportunity to both share and learn with the neurointerventional community during these interactive workshops.&rdquo;</span></p></div> Diplomat to distribute Plegridy (peginterferon beta-1a) for treatment of multiple sclerosis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/diplomat-to-distribute-plegridy-peginterferon-beta-1a-for-treatment-of-multiple-sclerosis 2014-09-04T18:39:00Z 2014-09-04T18:39:00Z <div id="ImageMain6" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/diplomat-to-distribute-plegridy-peginterferon-beta-1a-for-treatment-of-multiple-sclerosis"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/Plegridy_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction6" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Diplomat has announced that it will distribute Plegridy (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy was approved on 15 August 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.</strong></span></p> </div><div id="Text16" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The approval of Plegridy comes as a result of the one of the largest pivotal studies of beta interferon conducted, <a href="http://clinicaltrials.gov/ct2/show/NCT00906399?term=advance&amp;rank=13" target="_blank"><strong>ADVANCE</strong></a>, which included more than 1,500 multiple sclerosis patients. ADVANCE was a two-year, phase 3, placebo-controlled study that evaluated the efficacy and safety of Plegridy administered subcutaneously. The ADVANCE study demonstrated a reduction in relapses, disability progression and the number of multiple sclerosis lesions in comparison to the results with placebo.</span></p></div> GeNeuro phase 2a study reinforces novel approach to treat multiple sclerosis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/geneuro-phase-2a-study-reinforces-novel-approach-to-treat-multiple-sclerosis 2014-09-03T18:51:00Z 2014-09-03T18:51:00Z <div id="Introduction7" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>GeNeuro has announced positive results from a one-year, open-label extension of a phase IIa study. GeNeuro tested its monoclonal antibody GNbAC1 in 10 multiple sclerosis patients, nine of which had primary or secondary progressive disease. GNbAC1 targets the MSRV-Env protein expressed by genes of endogenous retroviral origin, which GeNeuro believe plays a critical role in the pathogenesis of multiple sclerosis.</strong></span></p> </div><div id="Text17" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The long-term safety profile of GNbAC1 was confirmed, with excellent tolerability among patients following repeat administration, verifying results of the earlier phase I study. With respect to clinical endpoints, the average Expanded Disability Status Score (EDSS), which measures disease progression, remained stable over one year. MRI analysis revealed that the brain images also remained stable and biomarkers associated with the target showed a consistent decline. These results confirm the safety and tolerability of GNbAC1 and support a positive pharmacodynamic response to the treatment. The positive results of this clinical study represent the successful first step in GeNeuro&rsquo;s phase II programme. A proof-of-concept clinical study to test the efficacy of GNbAC1 in multiple sclerosis will follow in 2015.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Francois Curtin, chief executive officer of GeNeuro states: &ldquo;We are very excited by the potential that GNbAC1 offers as a new avenue to treat multiple sclerosis patients. In addition to confirmation of long-term safety of the monoclonal antibody in patients, we have seen that the cohort of progressive multiple sclerosis patients was stable over one year from both clinical and MRI standpoints. Moreover, there is a clear decrease in the associated biomarkers supporting a positive pharmacodynamic response. This reinforces our conviction that GNbAC1 can completely transform the multiple sclerosis therapeutic landscape.&rdquo; Curtin adds: &ldquo;Preliminary results of this study presented at the American Academy of Neurology earlier this year generated a high level of enthusiasm among clinicians as they see that this treatment could bring new hope to patients as a safe therapy addressing a causal factor of the disease, breaking with the immunosuppressive logic of existing treatments.&rdquo;</span></p></div> National charity unveils big new ambitions for children with brain injury http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/national-charity-unveils-big-new-ambitions-for-children-with-brain-injury 2014-09-01T17:43:00Z 2014-09-01T17:43:00Z <div id="Introduction8" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The UK&rsquo;s leading charity for children with brain injury has launched a new three-year strategy, outlining ambitious plans to reach thousands more children and families across the UK.</strong></span></p> </div><div id="Text18" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">By 2017, The Children&rsquo;s Trust aims to be reaching 2,500 children living with brain injury every year through a major expansion of its community services. The charity will also undertake significant redevelopment work at its national specialist centre in Tadworth, Surrey and has committed to making greater investments in its online information service, research and campaigning.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Children&rsquo;s Trust, which is celebrating its 30th anniversary this year, provides residential and community-based rehabilitation for children with an acquired brain injury as a result of a serious accident or illness. The charity also runs a special school for children with profound and multiple learning difficulties and provides transitional medical care to children with complex health needs.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Over 40,000 children are estimated to be left with an acquired brain injury every year in the UK.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />One of the key objectives of the new strategy is a major increase in the number of charity-funded partnerships between The Children&rsquo;s Trust and the NHS. Through these partnerships, The Children&rsquo;s Trust embeds their qualified brain injury specialists within major trauma hospitals. Here they provide practical support to families as their child makes the often difficult return to home and school following a brain injury.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Brain injury specialists from the charity have been working at Sheffield Children&rsquo;s Hospital since 2011 and Nottingham Children&rsquo;s Hospital since 2013, supporting more than 500 children and families across South Yorkshire and the East Midlands. As part of their new strategy, The Children&rsquo;s Trust aims to have brain injury specialists in 10 major trauma centres across the UK by 2017, providing support to around 250 children and families in each area every year.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Dalton Leong, chief executive of The Children&rsquo;s Trust, says: &ldquo;Our big new ambitions will see us using our skills and expertise to help even more children with brain injury right across the UK. Never before has there been such an opportunity to increase the expert support available to these children and their families, who are amongst the most vulnerable people in our society. Over the last 30 years, our services have become beacons of specialist rehabilitation, education and care. Our new strategy will enhance these services and expand the vital support we provide to families across the country and online, as well as increasing our research and campaigning activities. We will need more donations and support from the public to turn our ambitions into reality. So I am calling on everyone who wants to make a difference to thousands more children with brain injury to get behind us.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Childhood Brain Injury: Our Big Ambitions, a brochure outlining the details of The Children&rsquo;s Trust&rsquo;s new strategy, is now available to download from www.thechildrenstrust.org.uk/strategy.</span></p></div> High accuracy for identification of traumatic intracranial haematomas with BrainScope, study says http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/high-accuracy-for-identification-of-traumatic-intracranial-haematomas-with-brainscope-study-says 2014-09-01T17:24:00Z 2014-09-01T17:24:00Z <div id="Introduction9" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The publication of an independent, prospective validation study has demonstrated the potential clinical utility of the BrainScope technology for the identification of acute traumatic intracranial haematomas in patients who present to hospital emergency departments.</strong></span></p> </div><div id="Text19" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The results of the study, &ldquo;Identification of hematomas in mild traumatic brain injury using an index of quantitative brain electrical activity&rdquo;, appeared online ahead of print in the <a href="http://www.liebertpub.com/overview/journal-of-neurotrauma/39/" target="_blank"><em>Journal of Neurotrauma</em></a>, authored by investigators from New York University School of Medicine and The Johns Hopkins University School of Medicine, USA.</span></p> <p><span style="font-size: 10pt;"><br />The technology records brain electrical activity with a handheld, rapid, easy-to-use, non-invasive and non-radiation emitting device, according to BrainScope. The technology utilises advanced signal processing methods and classification algorithms that quantify and characterise features of brain electrical activity associated with traumatic brain injury.</span></p> <p><span style="font-size: 10pt;"><br />In this prospective validation study, ten minutes of brain electrical activity were recorded in 46 adult patients with traumatic haematomas with measureable blood (CT scan positive, &ge;1cc of blood) and 278 head-injured control patients (CT scan negative). The mild presentation of the entire study population is reflected by 97% (313/324) of the patients in the study having a normal Glasgow Coma Scale score of 15 (on a scale of 3&ndash;15), with a mean value of 14.7 for the population with haematomas, and 14.9 for the control group. The volume of blood and distance from recording electrodes were measured by blinded independent experts. A previously derived classification algorithm developed by BrainScope (the &ldquo;TBI-index&rdquo;) was used to identify the probability of a traumatic CT positive lesion in this clinically important independent population.</span></p> <p><span style="font-size: 10pt;"><br />The study reported a sensitivity of 96% to haematomas, which was independent of type of haematoma, blood volume, or distance of the bleed from the recording electrodes on the forehead. Because of the life-threatening risk associated with undetected haematomas, specificity was permitted to be lower (44%) in exchange for extremely high sensitivity. In this study population (n=324), all subjects had been referred for CT scanning by standard clinical practice, of whom 278 were found to be CT negative. These results replicate previously peer-reviewed published findings (Hanley and colleagues, <em>Journal of Neurotrauma</em>, 2013) using the technology in traumatic haematomas, and again importantly demonstrated that the distance and volume restrictions noted with other commercially available methods for detecting traumatic intracranial haematomas were not limitations of BrainScope&rsquo;s technology. These results lend further strong support to the potential enhanced clinical utility of the BrainScope TBI-Index as an important adjunct to acute assessment and triage of clinically important (potentially life-threatening) brain injuries.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Often patients such as those in this study present with very mild symptoms of traumatic brain injury and therefore pose difficult triage decisions upon clinical evaluation. It is not always clear whether the patient might have a clinically important traumatic brain injury (blood in the brain) requiring further clinical evaluation. The ability to determine the likelihood of presence of such injuries non-invasively and without radiation could result in a paradigm shift in the way emergency medicine for TBI is currently practiced,&rdquo; says Michael Singer, president and chief executive officer of BrainScope. &ldquo;This peer-reviewed publication, which independently validated the prior 2013 publication, provides further compelling evidence about the potential for our technology to help assess the existence of brain injuries shortly after injury. Whether in the military or civilian hospital emergency departments, there is a true need for an objective, adjunctive assessment tool for TBI beyond what currently exists. We are highly encouraged by the independent prospective replication of these results.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />BrainScope devices under development for assessment of traumatically-induced head injury and concussion are for investigational use only.</span></p></div> NICE approves Tecfidera (dimethyl fumarate) http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/nice-approves-tecfidera-dimethyl-fumarate 2014-08-29T17:11:00Z 2014-08-29T17:11:00Z <div id="ImageMain10" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/nice-approves-tecfidera-dimethyl-fumarate"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/Tecfidera_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction10" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Thousands of adults in England and Wales living with the most common type of multiple sclerosis may benefit from a new oral treatment, Tecfidera (dimethyl fumarate), as the National Institute for Health and Care Excellence (NICE) issues the Technology Appraisal Guidance (TAG).</strong> </span>&nbsp;</p> </div><div id="Text110" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">NICE has approved Tecfidera as an option for treating adults with active relapsing remitting multiple sclerosis &ndash; normally defined as two clinically significant relapses in the previous two years &ndash; only if, they do not have highly active or rapidly evolving severe relapsing remitting multiple sclerosis and the manufacturer provides Tecfidera with the discount agreed in the patient access scheme.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The NHS will have a three month period to implement the guidance.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Tecfidera is a new oral treatment, licensed for adult patients with relapsing remitting multiple sclerosis. Tecfidera is taken twice daily with food.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Eli Silber,&nbsp;consultant neurologist at the King&rsquo;s Regional Neurosciences Centre, London, &ldquo;I am pleased that our clinical trials team at King&rsquo;s played a part in confirming the clinical benefits of Tecfidera and I am delighted that NICE has recognised the value of this new oral treatment. Multiple sclerosis is a long-term condition and it is important that patients who are newly diagnosed and starting treatment for the first time have access to new and efficacious treatments. In all multiple sclerosis treatments we are balancing clinically confirmed efficacy with side effects and the studies show that this new drug appears to have a very good risk-benefit profile.&rdquo;<em>&nbsp;</em></span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Ben Turner, consultant neurologist and Honorary Senior Lecturer at Barts and The London NHS Trust says, &ldquo;As the UK chief investigator for Tecfidera&rsquo;s DEFINE study, having seen the obvious benefits of Tecfidera in multiple sclerosis patients I am delighted that people with relapsing-remitting multiple sclerosis will now have access to this new treatment.&nbsp;Tecfidera has been shown to significantly reduce the number of multiple sclerosis relapses and delay disability progression compared to placebo. Also, as shown in the studies, Tecfidera is well tolerated, making it a welcome new treatment option.&rdquo;</span></p></div> Alzheimer’s Prevention Registry reaches recruitment milestone of 40,000 individuals http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/alzheimers-prevention-registry-reaches-recruitment-milestone-of-40000-individuals 2014-08-28T16:56:00Z 2014-08-28T16:56:00Z <div id="Introduction11" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The Alzheimer&rsquo;s Prevention Registry has reached a significant milestone in the fight against Alzheimer&rsquo;s by enrolling the 40,000th volunteer interested in participating in major studies of the disease. Championed by Banner Alzheimer&rsquo;s Institute (BAI) and in collaboration with partnering organisations and leading scientists, the online Registry (www.endALZnow.org) aims to accelerate research by connecting healthy individuals who are committed to preventing Alzheimer&rsquo;s with scientists carrying out the studies.</strong></span></p> </div><div id="Text111" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Every person who joins is helping to further research and is bringing us one step closer to unlocking the mysteries of this devastating disease,&rdquo; says Jessica Langbaum, principal scientist at BAI and associate director of the Alzheimer&rsquo;s Prevention Initiative (API). &ldquo;We are excited about the momentum of current prevention research, as many studies begin to recruit and the Registry plays a crucial role in overcoming recruitment barriers.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Registry is unique in that anyone 18 or older with a passion for combating Alzheimer&rsquo;s can be linked to researchers seeking a cure or a new treatment. It was created as part of the API, an international collaborative launched in 2011 to accelerate the pace of research.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Alzheimer&rsquo;s begins developing in the brain long before any symptoms appear - a critical &ldquo;silent&rdquo; period during which scientists believe the disease could be slowed or even stopped. But researchers say that cutting-edge research can be delayed, sometimes by years, because of the difficulty of finding sufficient numbers of volunteers. Clinical trials sometimes need to screen tens of thousands of individuals in order to find the hundreds of participants who fit the trial criteria.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />As Alzheimer&rsquo;s remains the only disease among the top 10 causes of death that has no cure or treatment, the Registry is urgently pushing to accelerate the pace of much-needed research by recruitment both in the USA and internationally. Registry members also receive regular updates on the latest scientific advances, and news and information on overall brain health, Langbaum says.</span></p></div> Aggressive resection should be considered for paediatric epilepsy http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/aggressive-resection-should-be-considered-for-paediatric-epilepsy 2014-08-28T11:31:00Z 2014-08-28T11:31:00Z <div id="ImageMain12" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/aggressive-resection-should-be-considered-for-paediatric-epilepsy"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/DarioEnglot-web.jpg" border="0" vspace="5" /></a></div><div id="Introduction12" style="clear:both;"> <p><strong><span style="font-size: 11pt;">Physicians from the University of California, San Francisco, USA, report that resection is safe and effective in children with pharmacoresistant focal epilepsy but seizure outcomes could be improved through aggressive resection in select patients. They add that high-resolution neuroimaging and invasive electrographic studies could be beneficial.</span></strong></p> </div><div id="Text112" style="clear:both; text-align:left"><p>According to the study&rsquo;s lead author, Dario J Englot there is differences in epilepsy type and pathological substrates between children and adults. He explains that because young children have greater neural plasticity and potential for neurological recovery than adults, extremely aggressive resection such as hemispherectomy would be devastating in an adult, adding that critical functions such as language and motor abilities are more likely to improve post-operatively in a young child, due to reorganisation of eloquent cortex.<br /><br />However, they say that, although resection is a tried and tested treatment method, some patients continue to experience seizures post-surgery.<br /><br />Englot and colleagues performed a retrospective cohort study of children and adolescents who underwent focal respective surgery to determine the reasons for surgical failure. They also performed quantitative and qualitative analyses of factors associated with persistent post-operative seizures. The results were published in the <a href="http://thejns.org/loi/ped" target="_blank"><em>Journal of Neurosurgery: Pediatrics</em></a>.<br /><br />They reviewed data from 110 patients (115 resections) and found that 76% of patients were free from disabling seizures (Engel Class I outcome) at a mean follow-up of 3.1 years.<br /><br />They say that freedom from seizures was predicted by temporal lobe surgery compared with extratemporal resection, tumour or mesial temporal sclerosis compared with cortical dysplasia or other pathologies and by a lower preoperative seizure frequency.<br /><br />From their findings, it was demonstrated that factors associated with persistent seizures (Engel Class II&ndash;IV outcome) were residual epileptogenic tissue adjacent to the resection cavity (40%), an additional epileptogenic zone distant from the resection cavity (32%), and the presence of a hemispheric epilepsy syndrome (28%).<br /><br />&ldquo;While seizure outcomes in paediatric epilepsy surgery may be improved by the use high-resolution neuroimaging and invasive electrographic studies, a more aggressive resection should be considered in certain patients&rdquo;, Englot <em>et al</em> state.<br /><br />They conclude that aggressive resection should extend to hemispherectomy, if a hemispheric epilepsy syndrome is suspected. Englot told <em>NeuroNews</em>: &ldquo;While it is critical to carefully tailor resections to avoid neurological deficits, it is also true that seizure-freedom is the strongest predictor of quality of life. In our view, an aggressive resection involves maximal removal of tissue that is involved in the epileptogenic zone, while preserving eloquent brain regions to the greatest extent possible. For example, in a child with epilepsy caused by a benign brain tumour (e.g. ganglioglioma), a limited resection might involve lesionectomy alone, while an aggressive resection may include intraoperative interictal electrocorticography to delineate epileptogenic peri-tumoral cortex which should also be removed.&rdquo;<br /><br />They add that the patient should receive counselling on treatment expectations as reoperation may be required in some cases.</p> </div> Highest level evidence indicates better outcomes when using iMRI for brain tumour surgery http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/highest-level-evidence-indicates-better-outcomes-when-using-imri-for-brain-tumour-surgery- 2014-08-26T16:37:00Z 2014-08-26T16:37:00Z <div id="ImageMain13" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/highest-level-evidence-indicates-better-outcomes-when-using-imri-for-brain-tumour-surgery-"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/iMRI-web.jpg" border="0" vspace="5" /></a></div><div id="Introduction13" style="clear:both;"> <p><strong><span style="font-size: 11pt;">In a recently published article in the journal <a href="http://journals.lww.com/neurosurgery/pages/default.aspx" target="_blank"><em>Neurosurgery</em></a> the use of VISIUS intraoperative MRI (iMRI) in brain tumour surgery has been proven to result in complete tumour removal in more patients with glioma tumours.&nbsp;</span></strong></p> </div><div id="Text113" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Led by Jin-song Wu, the neurosurgical team at Huashan Hospital at Fudan University in Shanghai, China, conducted the study.</span><br /><br /><span style="font-size: 10pt;">The prospective, parallel, randomised, triple-blind controlled trial design provides the most objective data and therefore highest level evidence to date of the value of iMRI in treating both low and high-grade gliomas. The early results reinforce that high-field iMRI-guided surgery is more effective in achieving complete resection than conventional neuronavigation-guided surgery. Other published studies on high-field iMRI have been mainly retrospective.</span><br /><br /><span style="font-size: 10pt;">&ldquo;iMRI is a practical and valuable asset to increasing the extent of resection for cerebral gliomas, with a specific significant influence for low grade gliomas,&rdquo; Wu says. &ldquo;With trends to statistical significance, these early results are the highest level of iMRI evidence for glioma surgery now available. This leads to more improved overall survivability and quality of life than using conventional neuronavigation.&rdquo;</span><br /><br /><span style="font-size: 10pt;">The low-grade glioma (LGG) subgroup patients who were treated in a VISIUS Surgical Theatre using iMRI had a statistically significant complete resection rate of 82% compared to 43% for the control group of conventional surgery patients. For the high-grade glioma (HGG) patients, 91% of those treated with iMRI had complete resection compared to 73% for the control group. These results are confirmed by volumetric analysis. The LGG subgroup met the endpoint early and that arm of the study stopped enrolling additional patients. The study continues for HGG patients.</span></p> <p><br /><span style="font-size: 10pt;">Jay D Miller, IMRIS CEO and president, notes: &ldquo;Clearly these studies continue to show the benefit of having the level of MR imaging the IMRIS solution provides inside the operating room without moving the patient. We know certain surgeons will not do these types of procedures without being in our surgical suites. In time, use of VISIUS iMRI will develop into a standard of care in these cases.&rdquo;</span><br /><br /><span style="font-size: 10pt;">More than 1,000 patient procedures have been completed using the Fudan University iMRI since its installation in September 2010, the company reports.</span></p></div> US Army funds phase II trial for treatment of PTSD with NeuroSigma eTNS system http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/us-army-funds-phase-ii-trial-for-treatment-of-ptsd-with-neurosigma-etns-system- 2014-08-26T15:57:00Z 2014-08-26T15:57:00Z <div id="ImageMain14" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/us-army-funds-phase-ii-trial-for-treatment-of-ptsd-with-neurosigma-etns-system-"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/NeuroSigma-web.jpg" border="0" vspace="5" /></a></div><div id="Introduction14" style="clear:both;"> <p><strong><span style="font-size: 11pt;">NeuroSigma has announced that the US Department of the Army, through the US Army Medical Research and Material Command, has funded a phase II clinical trial at the University of California, Los Angeles (UCLA) aimed at examining the use of external trigeminal nerve stimulation (eTNS) as treatment for post-traumatic stress disorder (PTSD).</span></strong></p> </div><div id="Text114" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Andrew Leuchter, professor of Psychiatry and Biobehavioral Sciences at UCLA and a physician at the Greater Los Angeles Veterans Administration (GLAVA) Health Care System, will lead the study. The phase II clinical trial is expected to enrol 74 subjects to evaluate eTNS as adjunctive therapy under double-blind conditions for military combat veterans who remain symptomatic despite trials of conventional treatments through the GLAVA PTSD program. An earlier phase I clinical trial of eTNS for the adjunctive treatment of PTSD, conducted at UCLA and funded by NeuroSigma, found significant improvements in the severity of PTSD symptoms with eight weeks of nightly eTNS therapy.&nbsp; NeuroSigma will supply eTNS Systems to support the trial.</span><br /><br /><span style="font-size: 10pt;">&ldquo;Despite the best pharmaceutical and psychological treatments for PTSD, many patients still experience symptoms after months and months of trying to get well, with impact on not only on their lives, but also on their families and their communities.&nbsp; Leuchter and his team are to be congratulated for securing competitive federal funding for this rigorous double-blind clinical trial,&rdquo; says Ian Cook, NeuroSigma&rsquo;s chief medical officer and senior vice president. &ldquo;The phase I clinical trial found improvement in PTSD symptom severity and also in measures of depression and quality of life.&nbsp; This phase II trial will evaluate the effects of eTNS on PTSD in a larger group and specifically in combat veterans. We owe it to our veterans to develop new treatments to address their unmet medical needs.&nbsp; A safe, non-invasive neuromodulation treatment may be able to help give them back their lives where other treatments have fallen short.&rdquo;</span><br /><br /><span style="font-size: 10pt;">In August 2012, NeuroSigma received CE mark approval to market NeuroSigma&rsquo;s first trigeminal nerve stimulation product (Monarch eTNS system) in the European Union, for the adjunctive treatment of epilepsy and major depressive disorder (MDD) for adults and children nine years and older. In addition, the Monarch system also received a class II medical device license from Health Canada in April of 2013 allowing NeuroSigma to market the system for treatment of drug-resistant epilepsy (DRE) and MDD for adults and children nine years and older. In April of 2014, NeuroSigma received approval from the Australian Therapeutic Goods Administration (TGA) to market the system in Australia for the adjunctive treatment of DRE in adults and children nine years and older. NeuroSigma is currently offering the system to patients in these jurisdictions with a physician&rsquo;s prescription.</span></p></div> Medtronic acquires Sapiens Steering Brain Stimulation http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/medtronic-acquires-sapiens-steering-brain-stimulation 2014-08-26T12:39:00Z 2014-08-26T12:39:00Z <div id="ImageMain15" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/medtronic-acquires-sapiens-steering-brain-stimulation"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/DBS-web.jpg" border="0" vspace="5" /></a></div><div id="Introduction15" style="clear:both;"> <p><strong><span style="font-size: 11pt;">Medtronic has announced that it has acquired Sapiens Steering Brain Stimulation (Sapiens SBS) for approximately US$200 million in an all-cash transaction.</span></strong></p> </div><div id="Text115" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Sapiens SBS, located in Eindhoven, The Netherlands, is developing a deep brain stimulation system that features an advanced lead with 40 individual stimulation points. This advanced system is designed to allow more precise stimulation of the intended target in the brain and may potentially result in reduced procedure time and fewer stimulation-induced side effects.</span><br /><br /><span style="font-size: 10pt;">Employees at the Eindhoven facility will continue to work toward bringing this technology to market. In the future, the site will serve as a global research and development centre for Medtronic&rsquo;s Neuromodulation business.</span><br /><br /><span style="font-size: 10pt;">Medtronic and Sapiens SBS will work to finalise product development and begin clinical research to integrate these technologies into an expanded portfolio of deep brain stimulation products within Medtronic&rsquo;s Neuromodulation business.</span><br /><br /><span style="font-size: 10pt;">&ldquo;This acquisition broadens our neuroscience leadership position with innovative brain modulation technology that, along with our comprehensive portfolio of deep brain stimulation solutions, may one day transform the way physicians are able to treat patients with neurodegenerative diseases like Parkinson&rsquo;s disease and essential tremor,&rdquo; says Lothar Krinke, vice president and general manager of the Brain Modulation business at Medtronic.</span><br /><br /><span style="font-size: 10pt;">&ldquo;Since 2011, Sapiens SBS employees have worked tirelessly to develop an advanced deep brain stimulation system,&rdquo; says Jan Keltjens, chief executive officer at Sapiens SBS. &ldquo;We are excited to join Medtronic, and look forward to collectively working to bring this and other novel technologies and therapies to neuromodulation patients worldwide that could benefit from them.&rdquo;</span><br /><br /><span style="font-size: 10pt;">Medtronic Neuromodulation business currently includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.&nbsp;</span><br /><br /><span style="font-size: 10pt;">More than 115,000 patients worldwide have received Medtronic deep brain stimulation therapy, which is approved in Europe and the USA for the treatment of the disabling symptoms of essential tremor, advanced Parkinson&rsquo;s disease and chronic intractable primary dystonia. The approval in the USA is under a humanitarian device exemption (HDE). In Europe, Canada and Australia, deep brain stimulation therapy is approved for the treatment of refractory epilepsy. It is also approved for the treatment of severe, treatment-resistant obsessive-compulsive disorder in the European Union and Australia, and in the USA under an HDE.</span><br /><br /><span style="font-size: 10pt;">The transaction is expected to meet Medtronic&rsquo;s long-term financial metrics and does not impact fiscal year 2015 earnings guidance.</span></p></div> Covidien acquires Reverse Medical Corporation http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/covidien-acquires-reverse-medical-corporation 2014-08-22T17:38:00Z 2014-08-22T17:38:00Z <div id="Introduction16" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Covidien&nbsp;has announced that it has acquired&nbsp;Reverse Medical&nbsp;Corporation, a privately held medical device company focused on expanding the management of vascular disease. Financial terms of the transaction were not disclosed.</strong></span></p> </div><div id="Text116" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Covidien is focused on technologies that deliver improved patient care through clinically relevant and economically valuable solutions,&rdquo; says Brett Wall, president, Neurovascular, Covidien. &ldquo;The acquisition of Reverse Medical is complementary to our existing portfolio and will allow us to leverage existing vascular technologies to compete in the worldwide vascular embolisation market, which is growing at a double digit rate.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Covidien will report the Reverse Medical business as part of its Neurovascular product line in the Medical Devices segment. Annualised dilution is not expected to be material.</span></p> <p><span style="font-size: 10pt;"><br />Reverse Medical is currently commercialising its vascular embolisation plugs, MVP Micro Vascular Plug System and UNO Neurovascular Embolisation System. MVP and UNO are self-expanding vessel occlusion devices, which close blood vessels for vascular embolisation. A number of clinical applications require occlusion of the vasculature to rapidly, effectively and safely provide blood flow cessation.</span></p> <p><span style="font-size: 10pt;"><br />Other Reverse Medical products include ReVerse&nbsp;Microcatheter for device delivery and Barrel Vascular Reconstruction Device (VRD), a self-expandable bifurcation aneurysm bridging device. All the devices have received CE Mark approval and are commercially available in Europe. Additionally, MVP-3 and MVP-5 are 510(k) cleared in the USA.</span></p></div> Stemedica International announces pre-clinical data of Alzheimer’s study http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/stemedica-international-announces-pre-clinical-data-of-alzheimers-study 2014-08-20T11:00:00Z 2014-08-20T11:00:00Z <div id="Introduction17" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Stemedica International SA, a Stemedica Cell Technologies subsidiary developing stem cell therapies for Alzheimer&rsquo;s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischaemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer&rsquo;s disease. The results demonstrated a greater than 30% decrease in amyloid beta (Abeta) plaques in the brain of transgenic animals treated with Stemedica itMSCs compared to the control group that were treated with lactated Ringer&rsquo;s solution (LRS).</strong></span></p> </div><div id="Text117" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Pre-clinical results show Stemedica International&rsquo;s treatment reduces the amount of plaque as much as the best drug candidates to manage Abeta amyloidosis,&rdquo; says Stemedica International&rsquo;s chief scientist Tristan Bolmont. &ldquo;Most importantly, our itMSC treatment did not result in side effects, such as cerebral amyloid angiopathy and micro-haemorrhages.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />These promising results were achieved during a two-year, intensive, pre-clinical research project supported by a grant from the Swiss Commission for Technology and Innovation (CTI). The research was conducted at the Laboratoire d&rsquo;Optique Biomedicale and headed by professor Theo Lasser at &Eacute;cole Polytechnique F&eacute;d&eacute;rale de Lausanne (EPFL) in Switzerland.</span></p> <p><span style="font-size: 10pt;"><br />The results were presented at the Alzheimer&rsquo;s Association International Conference in Copenhagen, Denmark, on 14 July, 2014. In addition,&nbsp;Bolmont will share the findings during his talk&nbsp;at the Stem Cells Regenerative Medicine Congress 2014 in Boston, Massachusetts, USA.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The combination of safety and efficacy of Stemedica&rsquo;s itMSCs clears the pathway for Stemedica International to file an IND application with the FDA for clinical trials,&rdquo; says Stemedica International&rsquo;s general manager Alexei Lukashev. &ldquo;We hope our stem cell treatment can halt or slow down the progression of Alzheimer&rsquo;s disease and, maybe, have some reverse effect on the damage caused by Alzheimer&rsquo;s disease and other forms of dementia, which the Alzheimer&rsquo;s Disease Institute estimates afflicts more than 44 million people worldwide today.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Only Stemedica International&rsquo;s therapies feature itMSCs that are exclusively licensed from the parent company Stemedica Cell Technologies. Unlike other MSCs &ndash; which are grown under normoxic conditions &ndash; Stemedica&rsquo;s bone-marrow-derived, allogeneic itMSCs are unique because they are grown under hypoxic conditions.&nbsp;<em>In vitro</em>&nbsp;experiments demonstrate cells that are exposed to hypoxic conditions show greater homing and engraftment than cells grown under normoxic conditions. Compared to other MSCs, itMSCs secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.</span></p></div> New dementia research reveals overwhelming demand for “the value of knowing” http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-dementia-research-reveals-overwhelming-demand-for-the-value-of-knowing 2014-08-20T10:50:00Z 2014-08-20T10:50:00Z <div id="Introduction18" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Three out of four people would want to know what kind of neurological disorder they had even if there was no cure, according to new global research from GE Healthcare. An even higher percentage of respondents, 81%, would want to identify an incurable neurological disorder if it affected somebody close to them, with more women (84%) wanting to know than men (76%). The &ldquo;Value of Knowing&rdquo; global survey of 10,000 adults across 10 countries explored perspectives on incurable neurological disorders including Alzheimer&rsquo;s and Parkinson&rsquo;s.</strong></span></p> </div><div id="Text118" style="clear:both; text-align:left"><p><span style="font-size: 10pt;"><strong>Prepared to pay for diagnosis</strong></span></p> <p><span style="font-size: 10pt;"><br />While the overwhelming consensus (94%) is that the government or health insurance providers should cover diagnosis, approximately half (51%) of respondents indicated that they would even be prepared to pay for a diagnosis themselves. This sentiment was particularly prevalent in India and China, where 71% and 83% respectively, said they would be prepared to pay. This was echoed by almost one half of those questioned in Russia and around one-third of respondents in UK, USA and Japan.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;What these statistics tell us is just how strongly people feel about tackling neurological disorders like dementia,&rdquo; says Marc Wortmann, executive director of Alzheimer&rsquo;s disease International. &ldquo;Worldwide, nearly 44 million people have dementia and this number is expected to nearly double in 20 years as the world&rsquo;s population ages. Although there is no cure yet, a timely diagnosis is useful for people with dementia to get access to current treatment, services and support, both medical and non-medical. Governments and healthcare systems need to ensure ready access to the diagnostic tools already available to accurately diagnose disorders such as Alzheimer&rsquo;s and Parkinson&rsquo;s, so that people can manage the symptoms as early as possible.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />When people surveyed were asked why they would want to know, the most common answer (71%) was to start treatment that could help manage the symptoms of the disease. Other reasons included the opportunity to change lifestyle to potentially slow the impact of the illness (66%), and the ability to make informed decisions (62%). Those who would not want to know cited undue worry and the futility of knowing about their disorder without being able to control it.</span></p> <p><span style="font-size: 10pt;"><br />Ben Newton, director of PET Neurology for GE Healthcare, comments, &ldquo;It is understandable that dementia is a frightening topic for people. That said, although there are currently no cures for many neurological disorders, there are symptom-modifying therapies and approaches available if detected early enough. It is interesting to note that the majority of respondents with more experience of a neurological disorder via a loved one for example, said that they would want to know, in spite of there being no cure.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />Recognising the symptoms</strong></span></p> <p><span style="font-size: 10pt;"><br />The research also probed respondents&rsquo; recognition of the possible signs and symptoms of dementia. While a majority recognised memory loss (70%) and disorientation (61%) as signs of dementia, less than half of those surveyed were able to identify other very common symptoms, including language problems, personality, mood and behaviour changes, and loss of initiative.</span></p> <p><span style="font-size: 10pt;"><br />Newton adds, &ldquo;Understanding and knowing all the symptoms of a neurological disorder are critical to helping loved ones who may be showing early signs. Acting early on any concerns may mean patients have access to earlier diagnosis and intervention, which could help to manage and delay the impact of a disorder.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />For decades, GE Healthcare has produced diagnostics scanners, imaging agents and software to help physicians see more clearly inside the brain and aid better patient management. Between 2010 and 2020, GE Healthcare plans to invest over US$500 million in research into neurological disorders. The investment crosses all lines of GE Healthcare and focuses on developing new neurology diagnostic solutions, educating consumers, and expanding research already in progress. Target areas include diagnosing post-traumatic stress disorder, Alzheimer&rsquo;s disease, Parkinson&rsquo;s disease, multiple sclerosis, stroke, concussion and traumatic brain injury.</span></p></div> Utah team invents way to image brains of mice using small needle http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/utah-team-invents-way-to-image-brains-of-mice-using-small-needle 2014-08-20T10:38:00Z 2014-08-20T10:38:00Z <div id="Introduction19" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A University of Utah team discovered a method for turning a small, US$40 needle into a 3D microscope capable of taking images up to 70 times smaller than the width of a human hair. This new method not only produces high-quality images comparable to expensive microscopes, but may be implanted into the brains of living mice for imaging at the cellular level.</strong></span></p> </div><div id="Text119" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The study appears in the 18 August issue of the journal&nbsp;<a href="http://scitation.aip.org/content/aip/journal/apl" target="_blank"><em>Applied Physics Letters</em></a>.</span></p> <p><span style="font-size: 10pt;"><br />Designed by Rajesh Menon, an associate professor of electrical and computer engineering, and graduate student Ganghun Kim, the microscope technique works when an LED light is illuminated and guided through a fiberoptic needle or cannula. Returned pictures are reconstructed into 3D images using algorithms developed by Menon and Kim.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Unlike miniature microscopes, our approach does not use optics,&rdquo; Menon says. &ldquo;It&rsquo;s primarily computational.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />He says this approach will allow researchers not only to take images far smaller than those taken by current miniature microscopes, but do it for a fraction of the cost.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We can get approximately 1-micron-resolution images that only US$250,000 and higher microscopes are capable of generating,&rdquo; Menon says. &ldquo;Miniature microscopes are limited to the few tens of microns.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Menon hopes to extend the technology in the future so it can see details down to submicron resolutions, compared with the current 1.4 microns. (A micron is a millionth of a metre. A human hair is about 100 microns wide.)</span></p> <p><span style="font-size: 10pt;"><br />The microscope was originally designed for the lab of Nobel Prize-winning U human genetics professor, Mario R Capecchi, whose team will use it to observe the brains of living mice to gain insight into how certain proteins in the brain react to various stimuli. Because the microscope can be assembled so inexpensively and easily go into hard-to-reach places, Menon and Kim expect many other uses for the device.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;This microscope will open up new avenues of research,&rdquo; Menon says. &ldquo;Its low-cost, small-size, large field-of-view and implantable features will allow researchers to use this in fields ranging from biochemistry to mining.&rdquo;</span></p></div> New non-invasive technique controls the size of molecules penetrating the blood-brain barrier http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-non-invasive-technique-controls-the-size-of-molecules-penetrating-the-blood-brain-barrier 2014-08-20T10:20:00Z 2014-08-20T10:20:00Z <div id="Introduction20" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A new technique developed by&nbsp;Elisa Konofagou, professor of biomedical engineering and radiology at Columbia Engineering, has demonstrated for the first time that the size of molecules penetrating the blood-brain barrier (BBB) can be controlled using acoustic pressure&mdash;the pressure of an ultrasound beam&mdash;to let specific molecules through. The&nbsp;study&nbsp;was published in the July issue of the&nbsp;<em><a href="http://www.nature.com/jcbfm/index.html" target="_blank">Journal of Cerebral Blood Flow &amp; Metabolism</a>.</em></strong></span></p> </div><div id="Text120" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;This is an important breakthrough in getting drugs delivered to specific parts of the brain precisely, non-invasively, and safely, and may help in the treatment of central nervous system diseases like Parkinson&rsquo;s and Alzheimer&rsquo;s,&rdquo; says Konofagou, whose National Institutes of Health Research Project Grant (R01) funding was just renewed for another four years for an additional US$2.22 million. The award is for research to determine the role of the microbubble in controlling both the efficacy and safety of drug safety through the BBB with a specific application for treating Parkinson&rsquo;s disease.</span></p> <p><span style="font-size: 10pt;"><br />Most small&mdash;and all large&mdash;molecule drugs do not currently penetrate the blood-brain barrier that sits between the vascular bed and the brain tissue. &ldquo;As a result,&rdquo; Konofagou explains, &ldquo;all central nervous system diseases remain undertreated at best. For example, we know that Parkinson&rsquo;s disease would benefit by delivery of therapeutic molecules to the neurons so as to impede their slow death. But because of the virtually impermeable barrier, these drugs can only reach the brain through direct injection and that requires anaesthesia and drilling the skull while also increasing the risk of infection and limiting the number of sites of injection. And transcranial injections rarely work&mdash;only about one in ten is successful.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Focused ultrasound in conjunction with microbubbles&mdash;gas-filled bubbles coated by protein or lipid shells&mdash;continues to be the only technique that can permeate the BBB safely and non-invasively. When microbubbles are hit by an ultrasound beam, they start oscillating and, depending on the magnitude of the pressure, continue oscillating or collapse. While researchers have found that focused ultrasound in combination with microbubble cavitation can be successfully used in the delivery of therapeutic drugs across the BBB, almost all earlier studies have been limited to one specific-sized agent that is commercially available and widely used clinically as ultrasound contrast agents. Konofagou and her team were convinced there was a way to induce a size-controllable BBB opening, enabling a more effective method to improve localised brain drug delivery.</span></p> <p><span style="font-size: 10pt;"><br />Konofagou targeted the hippocampus, the memory centre of the brain, and administered different-sized sugar molecules (Dextran). She found that higher acoustic pressures led to larger molecules accumulating into the hippocampus as confirmed by fluorescence imaging. This demonstrated that the pressure of the ultrasound beam can be adjusted depending on the size of the drug that needs to be delivered to the brain: all molecules of variant sizes were able to penetrate the opened barrier but at distinct pressures, ie., small molecules at lower pressures and larger molecules at higher pressures.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Through this study, we have been able to show, for the first time, that we can control the BBB opening size through the use of acoustic pressure,&rdquo; says Konofagou. &ldquo;We have also learned much more about the physical mechanisms associated with the trans-BBB delivery of different-sized agents, and understanding the BBB mechanisms will help us to develop agent size-specific focused ultrasound treatment protocols.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Konofagou and her&nbsp;Ultrasound Elasticity Imaging Laboratory&nbsp;team plan to continue to work on the treatment of Alzheimer&rsquo;s and Parkinson&rsquo;s in a range of models, and hope to test their technique in clinical trials within the next five years.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;It is frightening to think that in the 21<sup>st</sup>&nbsp;century we still have no idea how to treat most brain diseases,&rdquo; Konofagou adds. &ldquo;But we are really excited because we now have a tool that could potentially change the current dire predictions that come with a neurological disorder diagnosis.&rdquo;</span></p></div> electroCore appoints Piper Jaffray to deal with growing interest from pharma http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/electrocore-appoints-piper-jaffray-to-deal-with-growing-interest-from-pharma 2014-08-19T10:29:00Z 2014-08-19T10:29:00Z <div id="ImageMain21" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/electrocore-appoints-piper-jaffray-to-deal-with-growing-interest-from-pharma"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/gammaCore_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction21" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>electroCore has appointed Piper Jaffray to assist in discussions with pharma companies who are interested in partnering with it on the commercialisation of its breakthrough non-invasive vagus nerve (nVNS) stimulation therapy.</strong></span></p> </div><div id="Text121" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;The interest from pharma, medical devices and even technology companies has grown considerably over the last six months,&rdquo; comments chief executive officer and founder JP Errico. &ldquo;We wanted to explore all the opportunities for our future, from partnership to remaining independent. We therefore had discussions with several banks to help us with this process and chose Piper Jaffray. We are under no pressure to do a deal as we are fully funded until 2016. However, as we move from proving that nVNS is a promising treatment for primary headache, to rolling out a sales organisation we wanted to be mindful of all our options.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />electroCore, a US based company, has developed non-invasive Vagus Nerve Stimulation (nVNS) self-administered therapies, which are self-administered by patients for the treatment of multiple conditions in neurology, psychiatry, respiratory and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in respiratory and gastric motility disorders, depression and anxiety.</span></p> <p><span style="font-size: 10pt;"><br />In Europe, electroCore&rsquo;s nVNS technology has a CE mark for primary headache, bronchoconstriction, epilepsy, gastric motility disorders, and depression and anxiety.&nbsp;It also has regulatory approval for the acute and/or prophylactic treatment of cluster headache, migraine and medication overuse headache in South Africa, India, New Zealand, Australia, Colombia, Brazil and Malaysia, and in Canada for cluster headache. US approval is expected in 2015.</span></p> <p><span style="font-size: 10pt;"><br />electroCore recently reported that its successful funding initiative of US$40 million, announced in April last year, has been oversubscribed by US$10 million by all parties including Merck&rsquo;s Global Health Innovation Fund and private equity groups Easton Capital and Core Ventures. The final tranche of US$15 million of the US$40 million was optional but following discussions between the investors this was not only made compulsory but increased by US$10 million to a total of US$50 million. The company reports having more than US$25 million still at its disposal.</span></p> <p><span style="font-size: 10pt;"><br />electroCore has also recently reported on findings of two of four clinical studies (three against a sham device and one against standard of care), full details of which will be presented at the European headache (EHMTIC) meeting in Copenhagen in mid-September this year on the prevention and treatment of migraine and cluster headache.</span></p> <p><span style="font-size: 10pt;"><br />At the American Headache Society (AHS) in June preliminary results of the US sham controlled pilot study that examined the use of electroCore&rsquo;s non-invasive vagus nerve stimulation therapy (nVNS) in the prevention of chronic migraine were presented showing that the study met its endpoint of safety, and demonstrated a reduction in the number of headache days per month for patients using the active device. The study further suggests that patients who remained on therapy for longer periods of time, may enjoy progressively larger decreases in headache days over the period they are on therapy.</span></p> <p><span style="font-size: 10pt;"><br />Earlier in June electroCore reported preliminary results of a multicentre, randomised, trial across Europe. The trial was found to have met its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care. During weeks three and four following the beginning of therapy, the number of cluster headache attacks per week was reduced by 46.3% in patients treated with nVNS compared with 12.5% (p=0.002) in patients treated with the best available standard of care.</span></p> <p><span style="font-size: 10pt;"><br />Charly Gaul, director of the Migraine and Headache Clinic K&ouml;nigstein, Germany and the principal investigator of this study comments; &ldquo;This study is one of the few well controlled, randomised studies of any preventative treatment for cluster headache. The ability of electroCore&rsquo;s gammaCore therapy to significantly reduce the number of weekly cluster headaches in these chronic patients suggests it offers an important new option for this extremely painful and difficult to manage condition.&rdquo;</span></p></div> Enrolment in NeuroSTAT phase II study continues http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/enrolment-in-neurostat-phase-ii-study-continues 2014-08-18T14:35:00Z 2014-08-18T14:35:00Z <div id="Introduction22" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Enrolment to the ongoing clinical phase IIa study with NeuroVive&rsquo;s drug candidate NeuroSTAT for treating patients with severe traumatic brain injury is continuing, and another two patients have been enrolled. Accordingly, at present, seven of a total of 20 patients have been enrolled in the study.</strong></span></p> </div><div id="Text122" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The enrolment of new patients to the study has taken somewhat longer time than scheduled, but NeuroVive assumes that the ten patients to be treated with a lower dose will have been enrolled by year-end, or during Q1 2015 at the latest. <br /><br />Subsequently, the plan is to conduct interim analysis of data from these first ten patients with the aim of forming an opinion of treatment safety. If there are no safety concerns, the objective is for another ten patients to be enrolled during 2015 with treatment at a higher dose. In addition to planned interim analysis, continuous assessment treatment safety is being conducted. Based on safety assessments of the first patients, treatment with NeuroSTAT at the lower dose is considered to be safe and patient enrolment is continuing as planned.</span></p> <p><span style="font-size: 10pt;"><br />This phase IIa study is an open, non-comparative study involving a total number of 20 patients. Its primary endpoint is to evaluate NeuroSTAT&rsquo;s pharmacokinetics and safety in traumatic brain injury. Secondly, a number of measurements will be conducted, firstly to study NeuroSTAT&rsquo;s efficacy at the mitochondrial level, and to study how biochemical processes are affected by NeuroSTAT post-traumatic brain injury. Traumatic brain injury is a segment subject to a major medical need, where there are no registered pharmaceutical therapies at present.</span></p></div> Plegridy (peginterferon beta-1a) approved in the USA for treatment of multiple sclerosis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/plegridy-peginterferon-beta-1a-approved-in-the-usa-for-treatment-of-multiple-sclerosis 2014-08-18T11:15:00Z 2014-08-18T11:15:00Z <div id="ImageMain23" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/plegridy-peginterferon-beta-1a-approved-in-the-usa-for-treatment-of-multiple-sclerosis"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/Plegridy_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction23" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Biogen Idec&nbsp;has announced that the US Food and Drug Administration (FDA) has approved Plegridy&nbsp;(peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS).&nbsp;Plegridy, the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the Plegridy pen, a new, ready-to-use autoinjector, or a prefilled syringe.</strong></span></p> </div><div id="Text123" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Plegridy offers people with MS robust efficacy, a safety profile consistent with the established interferon class, and significantly fewer injections than other beta interferon treatments,&rdquo; says George A Scangos, chief executive officer of Biogen Idec. &ldquo;Plegridy represents the most significant innovation in the interferon class in over a decade, and is the result of our deep commitment to improving the lives of people with MS and those who care for them.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />The FDA approval of Plegridy is based on results from one of the largest pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients. ADVANCE was a two-year, phase 3, placebo-controlled (in year one) study that evaluated the efficacy and safety of PLEGRIDY administered subcutaneously. The analysis for all primary and secondary efficacy endpoints occurred at the end of year one. After the first year, patients on placebo received Plegridy for the duration of the study.</span></p> <p><span style="font-size: 10pt;"><br />In the first year of the ADVANCE clinical trial, Plegridy dosed once every two weeks significantly reduced annualised relapse rate (ARR) at one year by 36% compared to placebo (p=0.0007). Plegridy reduced the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale, by 38% (p=0.0383) compared to placebo. Plegridy also significantly reduced the number of new gadolinium-enhancing [Gd+] lesions by 86% (p&lt;0.0001) and reduced new or newly enlarging T2-hyperintense lesions by 67% (p&lt;0.0001) compared to placebo.</span></p> <p><span style="font-size: 10pt;"><br />The most common adverse reactions were injection site reaction, flu-like illness, fever, headache, muscle pain, chills, injection site pain, weakness, injection site itching and joint pain. The ADVANCE two-year safety data were consistent with safety results observed in year one.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Plegridy is a compelling new treatment option for people living with MS that offers a proven safety profile, strong efficacy and an every two week dosing schedule administered by an innovative delivery system,&rdquo; says Peter Wade, medical director for neurology at the Mandell Center for Comprehensive Multiple Sclerosis Care and Neuroscience Research in Hartford, USA. <br />&ldquo;As a treating neurologist, I believe these attributes will appeal to MS patients who look for less frequent dosing with proven effectiveness.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Plegridy has been recently approved by the European Commission.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;It is always encouraging to have additional treatment options that may help people with MS manage their disease as we move towards our ultimate goal of ending MS forever,&rdquo; says Timothy Coetzee, chief advocacy, services and research officer at the National MS Society.</span></p></div> Low education, smoking, high blood pressure may lead to increased stroke risk http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/low-education-smoking-high-blood-pressure-may-lead-to-increased-stroke-risk 2014-08-18T10:59:00Z 2014-08-18T10:59:00Z <div id="ImageMain24" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/low-education-smoking-high-blood-pressure-may-lead-to-increased-stroke-risk"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/Nordahl_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction24" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Adult smokers with limited education face a greater risk of stroke than those with a higher education, according to new research in the American Heart Association&rsquo;s journal&nbsp;<em><a href="http://stroke.ahajournals.org/" target="_blank">Stroke</a>.</em></strong></span></p> </div><div id="Text124" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The combination of smoking and high blood pressure increased stroke risk the most, confirming earlier findings in numerous studies.</span></p> <p><span style="font-size: 10pt;"><br />In a multicentre Danish study, researchers defined lower education as grade school or lower secondary school (maximum of 10 years) education.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We found it is worse being a current smoker with lower education than a current smoker with a higher education,&rdquo; says Helene Nordahl, study lead author and researcher at the Department of Public Health at the University of Copenhagen in Denmark. &ldquo;Targeted interventions aimed at reducing smoking and high blood pressure in lower socioeconomic groups would yield a greater reduction in stroke than targeting the same behaviours in higher socioeconomic groups.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Researchers divided 68,643 adults (30-70 years old) into low, medium and high education levels and assessed&nbsp;smoking&nbsp;and&nbsp;high blood pressure&nbsp;levels. They found:</span></p> <ul> <li><span style="font-size: 10pt;">Sixteen per cent of men and 11% of women were at high-risk of stroke due to low education level, smoking and high blood pressure.</span></li> <li><span style="font-size: 10pt;">Men were more at risk of stroke than women, and the risk of stroke increased with age.</span></li> <li><span style="font-size: 10pt;">Ten per cent of the high-risk men and 9% of the high-risk women had an ischaemic stroke&nbsp;during the study&rsquo;s 14-year follow-up.</span></li> <li><span style="font-size: 10pt;">Smokers with low education had a greater risk of stroke than smokers with high education regardless of their blood pressure.</span></li> </ul> <p><span style="font-size: 10pt;"><br />&ldquo;Universal interventions such as legislation or taxation could also have a strong effect on stroke in the most disadvantaged,&rdquo; Nordahl says. &ldquo;We need to challenge disparities in unhealthy behaviours, particularly smoking.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Researchers were not able to consider differences associated with ethnicity because 98% of the participants were Danes.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The distribution of stroke risk factors may vary across various contexts and study populations,&rdquo; Nordahl says. &ldquo;However, since the most disadvantaged groups are often exposed to a wide number of stroke risk factors, it seems plausible that these people are at higher risk of stroke not only in Denmark, but also in other industrialised countries.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Co-authors are Merete Osler; Birgitte Lidegaard Frederiksen; Ingelise Andersen; Eva Prescott; Kim Overvad; Finn Diderichsen; and Naja Hulvej Rod. Author disclosures are on the manuscript.</span></p> <p><span style="font-size: 10pt;"><br />The Danish Cancer Society funded the study.</span></p></div> IMRIS intraoperative imaging moving system and coils patents granted in Japan http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imris-intraoperative-imaging-moving-system-and-coils-patents-granted-in-japan 2014-08-14T09:42:00Z 2014-08-14T09:42:00Z <div id="ImageMain25" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imris-intraoperative-imaging-moving-system-and-coils-patents-granted-in-japan"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/035/IMRIS_VISIUS_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction25" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>IMRIS has announced the granting of three patents by the Japanese patent office related to key technology currently integrated into its intraoperative MRI (iMRI) solution within the VISIUS Surgical Theatre. The patents cover control of effective MR imaging using a movable system; imaging coils where clarity is maintained when used while in position during X-ray use; and other components related to using both MR and X-ray imaging in the same environment.</strong></span></p> </div><div id="Text125" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;These patents validate and protect our unique technologies in the territories where we do business,&rdquo; says Meir Dahan, IMRIS chief technology officer and executive vice president of Research and Development. &ldquo;Our intraoperative imaging solutions overcome great challenges in moving a diagnostic quality magnet into multiple locations and then lining it up to produce high quality images while competitor systems are fixed to the floor in a single position.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The covered technology is utilised in VISIUS Surgical Theatres which are hybrid operating room suites with iMRI where a diagnostic quality scanner moves to the patient using ceiling-mounted rails. VISIUS iMRI hybrid ORs may also include X-ray angiography systems where both types of imaging are desired. The fully integrated suites provide neurosurgeons on-demand access to high resolution images - before, during and after procedures without moving the patient from the OR table for truly intraoperative imaging and improved treatment outcomes.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />During brain tumour procedures, serial scanning gives the surgeon the ability to assess results and perform further resection to remove as much tumour as possible. Clinical studies indicate a link between more complete removal of some types of tumours and longer life expectancy and quality of life. IMRIS also develops and manufactures proprietary intraoperative CT systems, head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;As the leader in image guided therapy solutions, these patents provide us significant coverage and recognition for our intellectual property in these markets for years to come,&rdquo; says Jay D Miller, IMRIS president and chief executive officer. &ldquo;By finding ways to improve the vision and precision the surgeon has available, we are working towards mitigating risks and improving the outcomes for neurosurgical patients and lowering the total cost for the health care system.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />IMRIS currently has one hospital customer with VISIUS iMRI in Japan at the University of Tsukuba in Ibaraki, with a second pending installation at Yaminashi University Hospital, Chuo.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The company also recently received several updated patents from administrations in Canada, the United States and European Union.</span></p> </div> Written emergency stroke care protocols may improve hospital performance http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/written-emergency-stroke-care-protocols-may-improve-hospital-performance 2014-08-06T12:54:00Z 2014-08-06T12:54:00Z <div id="ImageMain26" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/written-emergency-stroke-care-protocols-may-improve-hospital-performance"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/010/Mocco.jpg" border="0" vspace="5" /></a></div><div id="Introduction26" style="clear:both;"> <p><strong><span style="font-size: 11pt;">New data presented at the Society of NeuroInterventional Surgery (SNIS) 11th Annual Meeting in (28 &ndash;31, Colorado Springs, USA) helps prove that written care protocols can significantly improve the overall emergency care pathway for stroke.&nbsp;&nbsp;</span></strong></p> </div><div id="Text126" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The data reported was from a study by Vanderbilt University Medical Center, Tennessee, USA.</span><br /><br /><span style="font-size: 10pt;">Over the last decade, an accumulation of evidence has affirmed that, for stroke, reducing the time that elapses from patient presentation to treatment is critical to procedural success and improved patient outcomes. Accordingly, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), the regulating agency that certifies Primary and Comprehensive Stroke Centres, requires that these institutions establish written care protocols to guide performance in the emergency care of acute ischaemic stroke, a press release from SNIS states.</span><br /><br /><span style="font-size: 10pt;">The study details a 2012 initiative by VUMC, an Advanced Certification Comprehensive Stroke Center, to significantly revise its stroke care protocol. &ldquo;Our ultimate goal was to develop an enhanced protocol that eliminates variability in our process, streamlines care to achieve necessary efficiencies, and improves time delays to improve the potential for better patient outcomes,&rdquo; said J Mocco, associate professor of Neurosurgery, Vanderbilt University Medical Center.</span><br /><br /><span style="font-size: 10pt;">The new protocol specifies three phases of activities involved in patient assessment and treatment decisions, as well as corresponding communication to relevant physicians at every phase. Specific measurements that map to the three phases include: time from patient arrival to CT scanning; time from patient arrival to neurology evaluation of diagnostics; and time from patient arrival to treatment with intravenous tissue plasminogin activator (IV tPA). Data was obtained over four separate three-month time periods pre- and post-protocol for comparison (pre-implementation of protocol: January&ndash;March 2012, and post-implementation of protocol: August&ndash;October, 2012; January&ndash;March, 2013; and September &ndash; November, 2013). &ldquo;These categories had been measured as part of our original protocol," continued Mocco, "however, we saw an opportunity to focus attention on some of the sub-processes within each that typically do not command attention, but, if addressed, could make a meaningful difference in quality improvement and the overall result.&rdquo;</span><br /><br /><span style="font-size: 10pt;">Post-implementation of the protocol, an analysis across all categories showed notable progress, with average time from patient arrival to CT scanning decreasing from 40.4 to 13 minutes; average time from patient arrival to neurology evaluation of diagnostics decreasing from 34.3 to 8.3 minutes; and average time from patient arrival to IV tPA treatment decreasing from 67.6 to 46.5 minutes.&nbsp; The latter means that VUMC has successfully met the JCAHO-stipulated metric of 60 minutes for "patient arrival to IV tPA."</span></p> <p><span style="font-size: 10pt;">"The success of this new protocol can truly be attributed to a multidisciplinary effort on the part of all of our physicians and other clinicians who work within the always complex and dynamic environment of emergency stroke care with ever-changing variables, all for the purpose of providing the best care for our stroke patients," said Scott Zuckerman, a senior neurosurgery resident who helped plan and lead the implementation of the protocol.</span><br /><br /><span style="font-size: 10pt;">Mocco added, &ldquo;First and foremost, it illustrates the value of customised written protocols that consider all of the nuances associated with any one hospital&rsquo;s emergency stroke care process. Ours is certainly not a one-size fits all solution. Every stroke centre has to tailor its protocols to its own culture and resources.&nbsp; But, ultimately, we hope our experience will be of benefit to other stroke centres that are considering or just beginning a written protocol initiative to fulfill their mission of offering the highest standard of stroke care to their patients.&rdquo;</span></p></div> NeuroPace RNS system receives approval from CMS for new Technology Add-On Payments http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuropace-rns-system-receives-approval-from-cms-for-new-technology-add-on-payments 2014-08-06T11:18:00Z 2014-08-06T11:18:00Z <div id="ImageMain27" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuropace-rns-system-receives-approval-from-cms-for-new-technology-add-on-payments"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/NeuroPace_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction27" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>NeuroPace has announced that the Centers for Medicare &amp; Medicaid Services (CMS) has approved New Technology Add-on Payments (NTAP) for the RNS system, the world&rsquo;s only commercially available implantable closed-loop responsive neurostimulator system. The NTAP programme recognises new technologies that provide substantial clinical improvement over existing therapies, and is designed to support timely access to innovative technologies for Medicare beneficiaries.</strong></span></p> </div><div id="Text127" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">NeuroPace received premarket approval (PMA) from the US Food and Drug Administration (FDA) for the RNS system in November 2013. It is approved as a treatment for adults with partial onset seizures with one or two seizure onset zones whose seizures have not been controlled with two or more antiepileptic drugs.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are grateful CMS recognises the substantial benefits the RNS system has provided to patients and the need for patients who suffer from uncontrolled seizures to have access to this therapy,&rdquo; says Frank Fischer, chief executive officer at NeuroPace. &ldquo;Epilepsy centres have moved quickly since PMA approval to make the RNS system available. To date, 35 Comprehensive Epilepsy Centers that meet all the qualifications for the highest level of epilepsy care have completed required training and are able to implant the RNS system.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Approximately 2.3 million adults in the United States have active epilepsy, and one-third live with seizures because existing therapies have not provided seizure control. Many people with uncontrolled seizures have or are eligible for Medicare disability benefits. Approval of the NTAP will significantly improve patient access to this new technology.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />As a closed-loop system, the RNS System monitors the brain&rsquo;s own signals, interprets those signals, provides stimulation when needed, and then assesses the brain&rsquo;s response. The breakthrough aspect of the RNS system is its advanced detection and stimulation capabilities. This is unlike all other existing neurostimulation therapies, which continuously or intermittently stimulate the brain without determining the need for treatment or monitoring the response.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The RNS system has been evaluated in three clinical trials, including a prospective, randomised, double-blinded, sham stimulation controlled pivotal study. Results of the clinical trials demonstrate that the substantial clinical improvements experienced by patients over the short- and long-term are durable over many years of therapy. At this time, some patients have been treated with the RNS system for over ten years, and more than 1,500 patient years of experience with responsive neurostimulation have been accumulated to date.</span></p></div> Accenture and Philips announce proof of concept app for ALS patients http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/accenture-and-philips-announce-proof-of-concept-app-for-als-patients 2014-08-05T11:49:00Z 2014-08-05T11:49:00Z <div id="Introduction28" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Royal Philips and Accenture have announced that they have developed proof of concept software connecting a wearable display to Emotiv Insight Brainware that could ultimately give more independence to patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Affecting more than 400,000 people per year, ALS, also known as Lou Gehrig&rsquo;s disease, impairs brain and spinal cord nerve cells, gradually diminishing voluntary muscle action. Late-stage patients often become totally paralysed while retaining brain functions.</strong></span></p> </div><div id="Text128" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;This proof of concept exemplifies how people, devices, data and technology could be brought together quickly to connect beyond the hospital walls in a way that can potentially help improve the quality of life for patients, wherever they are in their journey,&rdquo; says Jeroen Tas, chief executive officer, Healthcare Informatics Solutions and Services for Philips. &ldquo;Philips will continue to collaborate with innovative technology companies such as Accenture to explore new wearable and sensor solutions that change peoples&rsquo; lives and create a healthier future.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><strong><br />How it works</strong></span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />When a wearable display and the Emotiv Insight Brainware, which scans EEG brainwaves, are connected to a tablet, users can issue brain commands to control Philips products including Philips Lifeline Medical Alert Service, Philips SmartTV (with TP Vision), and Philips Hue personal wireless lighting. The tablet also allows control of these products using eye and voice commands. In both cases, a person could communicate preconfigured messages, request medical assistance, and control TVs and lights. Accenture and Philips developed the software that enables the integration and interaction between these multiple technologies.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The proof of concept application demonstrates how existing technology could be used to transform the quality of life for ALS patients. When patients lose muscle control and eye tracking ability, they can still potentially operate the Philips suite of connected products in their home environment through brain commands. The Emotiv technology uses sensors to tune in to electric signals produced by the wearer&rsquo;s brain to detect, in real-time, their thoughts, feelings and expressions. The wearable display provides visual feedback that allows the wearer to navigate through the application menu.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Accenture Technology Labs in San Jose, California, USA collaborated with the Philips Digital Accelerator Lab in the Netherlands to create the software to interact with the Emotiv Insight Brainware and the wearable display. Fjord, a design consultancy owned by Accenture Interactive, designed the display&rsquo;s user interface.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;This proof of concept shows the potential of wearable technology in a powerful new way &mdash;helping people with serious diseases and mobility issues take back some control of their lives through digital innovation,&rdquo; says Paul Daugherty, Accenture&rsquo;s chief technology officer. &ldquo;It is another demonstration of how Accenture and Philips, collaborating with other technology innovators, seek to improve the lives of people with healthcare challenges.&rdquo;</span></p></div> GE Healthcare’s Signa PET/MR 510(k) pending at FDA http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/ge-healthcares-signa-petmr-510k-pending-at-fda 2014-08-05T11:32:00Z 2014-08-05T11:32:00Z <div id="ImageMain29" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/ge-healthcares-signa-petmr-510k-pending-at-fda"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/GE_Signa_PET_MR_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction29" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>GE Healthcare has announced that the first integrated, simultaneous, time-of-flight (TOF) capable, whole body Signa PET/MR is 510(k) pending at the US Food and Drug Administration. Powered by simultaneous image acquisition from GE&rsquo;s latest 3.0 Tesla magnetic resonance (MR) technology and innovative positron emission tomography (PET) technology, the Signa PET/MR represents a new chapter in helping clinicians achieve improved scan efficiency that may lead to more effective treatment paths for clinicians to offer their patients, particularly for oncology, neurology, and cardiology.</strong></span></p> </div><div id="Text129" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">MR is excellent for imaging soft tissue as well as functional and morphological details. PET enables clinicians to visualise cellular activity and metabolism. When these two powerful tools are combined, clinicians may be able to see early cellular changes that can be accurately mapped onto MR images. With this knowledge, clinicians may be able to shorten the time between diagnosis and treatment, in addition to offering the convenience of simultaneous PET and MR scans for patients. Research systems are installed at Stanford University, University of California San Francisco, and University of Zurich.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are excited about Signa PET/MR because of its clinical and research potential,&rdquo; says Andrei H Iagaru, associate professor of Radiology and co-chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center. &ldquo;We have been using the system for research and we are able to explore novel things in areas like neurology and oncology, as well as in paediatrics in the future. Additionally, it is more convenient for the patient due to simultaneous scanning. We can also initiate innovative, complex research; simultaneity allows us to do functional neuro imaging, cardiac imaging, and musculoskeletal imaging that we haven&rsquo;t been able to do before. Time-of-flight offers improved image quality in PET/MR and with the increased detector sensitivity, it may lead to future improvements in dose reduction.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Signa PET/MR features GE&rsquo;s new, exclusive MR-compatible silicon photomultiplier detector (SiPM) technology. This new digital detector is characterised by its enhanced sensitivity; it is up to three times more sensitive than conventional PET technology. It also features fast coincidence timing resolution enabling TOF reconstruction. With TOF reconstruction, the arrival times of each coincident pair of photons are more precisely detected, and the time difference between them is used to localise the PET signal accurately. TOF leads to improved PET image quality with higher structural detail and improved signal-to-noise ratio. The Signa PET/MR is designed to be fully upgradable from a Discovery MR750w 3.0T.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We have received extremely positive feedback from our installations of the research PET/MR systems,&rdquo; says Richard Hausmann, president and chief executive officer of GE Healthcare MR. &ldquo;Our research partners are very excited by the performance of the system and the potential of this new technology. We are proud to bring the first TOF-capable, simultaneous PET/MR system, pending FDA clearance, to market.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br /><br />Signa PET/MR is 510(k) pending at FDA. Not available for sale in the United States. Not yet CE marked. Not available for sale in all regions.</span></p></div> AcuteCare Telemedicine and Colleton Medical Center partner to improve patient access to specialised neurological care http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/tecare-telemedicine-and-colleton-medical-center-partner-to-improve-patient-access-to-specialised-neurological-care 2014-08-05T10:40:00Z 2014-08-05T10:40:00Z <div id="Introduction30" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>AcuteCare Telemedicine&nbsp;continues to expand its presence in the Southeastern region with the addition of new client hospitals. Following the announcement of its partnership with&nbsp;Emory John&rsquo;s Creek,&nbsp;Colleton Medical Center&nbsp;(CMC) in Walterboro, South Carolina, USA recently introduced AcuteCare Telemedicine&rsquo;s leading specialists to their dedicated staff of medical professionals and patients. AcuteCare Telemedicine in collaboration with the&nbsp;South Atlantic Division of HCA&nbsp;worked to bring teleneurology services to Colleton Medical Center.</strong></span></p> </div><div id="Text130" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Colleton recently debuted a&nbsp;robot named ELVIS, an acronym for &ldquo;Early Neurological Intervention That&rsquo;s Successful.&rdquo; AcuteCare Telemedicine can remotely consult with doctors and patients through ELVIS. While the robot is currently located in the emergency department, &ldquo;It can be used throughout the entire facility,&rdquo; reports Colleton Medical Center Emergency Department director Christy Judy. As a result, AcuteCare Telemedicine is standing by 24 hours a day anywhere they are needed throughout CMC. Connecting hospital-based medical professionals with off-site specialists through the use of new telecommunication technologies is improving access of specialised care for patients in smaller, regional hospitals and medical centres.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Attracting and recruiting medical specialists is an ongoing challenge for smaller, regional hospitals who must balance the needs of their patients with the financial realities of healthcare in this demanding economy,&rdquo; says Matthews Gwynn, director and founder of the Stroke Center of Northside Hospital and AcuteCare Telemedicine chief executive officer. &ldquo;Having the ability to consult with a neurologist remotely for treatment of stroke and other neurological maladies is allowing these hospitals to meet the needs of the patients in the communities they serve. AcuteCare Telemedicine is extremely proud to associate the South Atlantic Division of HCA and the Colleton Medical Center.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Brad Griffin, chief executive officer of Colleton Medical Center, is also very pleased with Colleton&rsquo;s new relationship with AcuteCare Telemedicine. &ldquo;This is our first venture with telemedicine and the experience is proving to be very positive for both the patients and our team of medical professionals at Colleton,&rdquo; he says. Griffin reports that the hospital staff has found their experience with AcuteCare Telemedicine to be very comforting, easy to work with, and very professional. He sees Colleton&rsquo;s first telemedicine venture as just the beginning and is looking forward to expanding the utilisation of telemedicine to other medical specialties.</span></p></div> NeuroDerm announces eligibility for European Union centralised procedure for ND0612H http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuroderm-announces-eligibility-for-european-union-centralised-procedure-for-nd0612h 2014-08-04T11:01:00Z 2014-08-04T11:01:00Z <div id="ImageMain31" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuroderm-announces-eligibility-for-european-union-centralised-procedure-for-nd0612h"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/NeuroDerm_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction31" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>NeuroDerm&nbsp;has announced that the European Medicines Agency (EMA) has deemed ND0612H, its product candidate offering continuous delivery of levodopa/carbidopa (LD/CD) treatment for advanced Parkinson&rsquo;s disease, eligible for a European Union marketing authorisation application procedure (&ldquo;centralised procedure&rdquo;). According to EMA guidelines, the EMA can allow products for which the centralised procedure is not mandatory to use that procedure, if the EMA considers that it constitutes a significant therapeutic, scientific or technical innovation.&nbsp;&nbsp;</strong></span></p> </div><div id="Text131" style="clear:both; text-align:left"><p style="margin: 0cm; margin-bottom: .0001pt; line-height: 16.0pt; background: white;"><span style="font-size: 10pt; font-family: Helvetica, sans-serif; color: #464646;">ND0612H is a high-dose form of liquid LD/CD drug delivered continuously through subcutaneous administration by a belt pump. ND0612H is designed to significantly reduce motor complications in advanced Parkinson&rsquo;s disease patients by maintaining steady, high levodopa plasma levels in a convenient manner, to replace current treatments that require highly invasive surgery associated with serious side effects.</span></p> <p style="margin: 0cm; margin-bottom: .0001pt; line-height: 16.0pt; background: white;"><span style="font-size: 10pt; font-family: Helvetica, sans-serif; color: #464646;"><br /> &ldquo;The eligibility for the centralised procedure in the European Union confirms the innovation underlying ND0612H,&rdquo; says&nbsp;Oded Lieberman, NeuroDerm&rsquo;s chief executive officer. &ldquo;It also means that ND0612H will be able to benefit from the more streamlined access to the EU market inherent in this regulatory route. NeuroDerm wishes to bring ND0612H into the market as quickly as possible and make a dramatic change in the lives of Parkinson&rsquo;s disease patients.&rdquo;</span></p> <p style="margin: 0cm; margin-bottom: .0001pt; line-height: 16.0pt; background: white;"><span style="font-size: 10pt; font-family: Helvetica, sans-serif; color: #464646;"><br /> ND0612L, NeuroDerm&rsquo;s low dose drug form for moderate stage Parkinson&rsquo;s patients, has successfully completed phase I and IIa studies. It is currently undergoing a phase II double-blind, randomised, placebo-controlled study supported by a grant from The Michael J Fox Foundation for Parkinson&rsquo;s Research.</span></p></div> Final patient treated in Neuralstem phase II ALS stem cell trial http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/final-patient-treated-in-neuralstem-phase-ii-als-stem-cell-trial 2014-08-04T10:53:00Z 2014-08-04T10:53:00Z <div id="ImageMain32" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/final-patient-treated-in-neuralstem-phase-ii-als-stem-cell-trial"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/stem_cells_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction32" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Neuralstem has announced that the final patient was treated in its phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig&rsquo;s disease). The multicentre phase II trial treated 15 ambulatory patients in five different dosing cohorts. The first 12 patients received injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function, in escalating doses ranging from five injections of 200,000 cells per injection, to 20 injections of 400,000 cells each. The final three patients in the trial received both cervical and lumbar injections, for a total of 40 injections of 400,000 cells each, or a total of 16 million cells transplanted. In contrast, the final three patients in the phase I trial received the maximum 15 injections of 100,000 cells each, for a total of 1.5 million cells. The trial will continue until six months past the final surgery, at which point the data will be evaluated.</strong></span></p> </div><div id="Text132" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;We are all extremely pleased to have completed the transplantations in this historic phase II trial," says principal investigator, Eva Feldman, director of the A Alfred Taubman Medical Research Institute and director of Research of the ALS Clinic at the University of Michigan Health System. &ldquo;By early next year, we will have six-month follow up data on the last patients who received what we believe will be the maximum safe tolerated-dose for this therapy. We look forward to seeing what the data tell us about safety and efficacy of this approach. It is also worth noting that we will have completed this phase II trial within a year, roughly.&nbsp; I would like to thank Parag Patil,&nbsp; and my collaborators at Emory, John Glass and Nick Boulis, and at Mass General, Merit Cudkowicz and Larry Borges, for helping us reach this goal.&rdquo; Feldman is an unpaid consultant to Neuralstem.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The completion of phase II of this important clinical research programme is a major milestone, demonstrating that patients can tolerate the transplantation of high doses of cells and multiple spinal cord injections,&rdquo; says site principal investigator, Jonathan D Glass, director of the Emory ALS Center. &ldquo;From both a clinical and scientific perspective, I think we are now ready to move forward toward a true therapeutic trial to test the efficacy of this surgical approach for slowing the course of ALS.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We would like to express our thanks to all of the doctors and medical staff who made this possible, as well as the patients and their families. Without their bravery, none of this would have happened,&rdquo; says Karl Johe, Neuralstem&rsquo;s chairman of the Board and chief scientific officer. &ldquo;With this landmark trial, the first to transplant stem cells in this volume and through so many injections along the length of the human spinal cord, we hope to establish the dose that is both safe and which may be optimal for treatment. We are excited about the collection and analysis of the final data and look forward to advancing to our next trial.&rdquo;</span></p></div> SNIS Foundation bestows first grant award for cutting-edge neurointerventional research http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/snis-foundation-bestows-first-grant-award-for-cutting-edge-neurointerventional-research 2014-08-01T15:06:00Z 2014-08-01T15:06:00Z <div id="Introduction33" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The SNIS Foundation recognised its first Seed Grant awardee with US$25,000 to fund a translational research project. The first award since the Foundation&rsquo;s inception in 2011, the gift was presented at the Society of NeuroInterventional Surgery (SNIS) 11th Annual Meeting in Colorado Springs, USA.</strong></span></p> </div><div id="Text133" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Representing physicians who specialise in neurointerventional approaches to neurovascular conditions, SNIS formed the SNIS Foundation, in part, to ensure investment in scientific research and discovery that enables practitioners to provide the highest level of care to patients who can benefit from neurointerventional treatment. The Seed Grant is a one-year gift that enables young investigators to conduct pilot projects that address a specific hypothesis and generate preliminary data in preparation for major grant applications to corporations, foundations and governmental agencies.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The first recipient, Daniel Cooke, assistant professor of Radiology and Biomedical Imaging at the University of California, San Francisco, USA, was awarded the grant for his innovative work in facilitating first-time evaluation of endothelial cells harvested from devices utilised in neurointerventional procedures to treat ruptured and unruptured aneurysms. By obtaining these tissue samples during a standard procedure, and analysing genetic expression at the single cell level, Cooke and his team aim to advance neurointervention by utilising their study of endothelial cells to offer insights into the mechanisms of aneurysm formation, evolution, and in some cases, rupture.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;This is exciting and innovative work worthy of continued exploration and support from the SNIS Foundation,&rdquo; says Lee Jensen, professor of Radiology, Neurology and Neurological Surgery at University of Virginia Health System and chair of the SNIS Foundation. &ldquo;The applications for the first SNIS Foundation Seed Grant were very strong, but Cooke&rsquo;s work stood out as the kind of research that could have meaningful implications for our overall approach to neurointerventional aneurysm treatment.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />All Seed Grant proposals were reviewed and ranked by a multi-disciplinary panel, including interventional neuroradiologists, endovascular neurosurgeons, and interventional neurologists. For this first award, it is noteworthy that the chosen grant was the top choice of all panellists.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Three additional grants are expected to be awarded in the next six months. The SNIS Foundation will fund these and future grants with private donations as well as select fundraisers sponsored by the Foundation.&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;After three years of growing the Foundation, it is exciting to realise our goal of funding meaningful research work that aligns with our overall mission,&rdquo; says Jensen.&nbsp; &ldquo;This is a milestone moment in the life of the SNIS Foundation and SNIS, and instrumental to the growth of our neurointerventional specialty.&rdquo;</span></p> </div> New technology may improve visualisation of the brain during stroke treatment http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-technology-may-improve-visualisation-of-the-brain-during-stroke-treatment 2014-08-01T14:53:00Z 2014-08-01T14:53:00Z <div id="Introduction34" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>New technology in the form of a magnetically-assisted remote-controlled catheter (MARC) which could allow physicians to see and assess brain tissue more clearly while treating a stroke may hold promise, according to study authors who released their findings at the Society of NeuroInterventional Surgery (SNIS) 11th Annual Meeting in Colorado Springs, USA.</strong></span></p> </div><div id="Text134" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The findings stand to advance the field of neurointervention. Neurointerventionists typically accomplish this approach by manually directing the catheter and visualising its progress under standard X-ray guidance.&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />With MARC, study authors sought to understand if a remote-controlled catheter under Magnetic Resonance Imaging (MRI) guidance could more effectively accomplish manoeuvring through complex vessel anatomy, which would ultimately allow improved visualisation of the brain tissue affected during a stroke. &ldquo;Given that MRI is the gold standard by which we determine brain tissue viability, it is exciting that we potentially now have new MRI-compatible technology that enables us, while treating a stroke, to make real-time assessments about whether brain tissue is dead or alive,&rdquo; says Steven Hetts, lead study author and associate professor of Radiology at the University of California, San Francisco, USA. &ldquo;The implications are numerous, including improved medical decision-making, which would naturally result in optimising patient safety and clinical outcomes.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />To assess the performance of MARC, Hetts and his colleagues aimed to determine mean procedure times and success data for a custom, clinical-grade MARC prototype under MRI guidance as compared to a manually-navigated catheter, under both MRI and conventional x-ray guidance - each procedure utilising a cryogel vascular model designed to simulate the main and branch blood vessels in a living human. The MRI-guided procedures were performed at 1.5T (magnetic field strength of a standard clinical MRI scanner) using a balanced steady-state free precession sequence in the type of clinical MRI scanner available in most hospitals.&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Results showed that MARC was clearly visible under MRI guidance and was used to successfully complete 192 (80%) of 240 total turns around blood vessels as compared to the manually- directed catheter under both MRI and x-ray guidance, at 144 (60%) of 240 total turns and 119 (74%) of 160 total turns, respectively. MARC also was faster than the manually directed catheter under MRI, with a mean procedure time of 37 seconds per turn as compared to 55 seconds, but comparable to the manually directed catheter under X-ray guidance which required a mean of 44 seconds for each turn. When assessing the time required to navigate the various angles of branch vessels at turns of 45&deg;, 60&deg;, and 75&deg;, MARC proved to be faster than the manually-directed catheter under MRI guidance.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Given that the success of neurointerventional stroke treatment is directly tied to how fast and accurately physicians can eliminate the impact of a clot and restore blood flow to viable portions of the brain, technology that facilitates this objective stands to be transformative,&rdquo; says Hetts. &ldquo;By proving that MRI-guided neurointervention could be more effective than current standard approaches to stroke treatment, we are taking a significant step forward in the advancement of our field.&rdquo;</span></p></div> Los Angeles medical team performs California’s first auditory brainstem implant surgery on toddler http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/los-angeles-medical-team-performs-californias-first-auditory-brainstem-implant-surgery-on-toddler 2014-08-01T12:39:00Z 2014-08-01T12:39:00Z <div id="ImageMain35" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/los-angeles-medical-team-performs-californias-first-auditory-brainstem-implant-surgery-on-toddler"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/041/Auguste_Majkowski_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction35" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A Los Angeles team of scientists and surgeons from Keck Medicine of the University of Southern California (USC),Children&rsquo;s Hospital Los Angeles&nbsp;(CHLA) and Huntington Medical Research Institutes (HMRI) reported that sound registered in the brain of a deaf Canadian boy for the first time after doctors activated a hearing device that had been surgically implanted in his brainstem.</strong></span></p> </div><div id="Text135" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Auguste Majkowski, 3, is the first child in the United States to undergo an auditory brainstem implant (ABI) surgery in a US Food and Drug Administration (FDA)-approved trial supported by a National Institutes of Health (NIH) clinical trial grant. On 12 June, six weeks after surgery at CHLA, the device was activated with positive results at the Department of Otolaryngology &ndash; Head &amp; Neck Surgery clinic at Keck Medicine of USC.</span></p> <p><span style="font-size: 10pt;"><br />Auguste&rsquo;s surgery, device activation and future behavioural study are part of a five-year clinical trial in which 10 devices will be implanted in deaf children under the age of five and studied over the course of three years. The Los Angeles study, co-led by audiologist Laurie Eisenberg, and surgeon Eric Wilkinson, is the only in the United States to be supported by the NIH.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Our Los Angeles-based team has been at the forefront of ABI technology development since it came into use in the late 1970s for adults, so it is especially gratifying to help break the &lsquo;sound barrier&rsquo; once again; this time, for children who previously could not hear,&rdquo; says Eisenberg, a Keck School of Medicine of USC otolaryngology professor. &ldquo;Surgeons outside the United States have been doing ABI surgeries in children for 10 years, but there has never been a formal safety or feasibility study under regulatory oversight. Our team is writing the manuals for all the procedures for this technology, and we have a top-notch multidisciplinary team in place to carry out the research.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />The surgical team that performed the operation at Children&rsquo;s Hospital included Wilkinson, HMRI research scientist and neurotologist at House Clinic; HMRI research scientist and House Clinic neurosurgeon Marc Schwartz, and paediatric neurosurgeon&nbsp;Mark D Krieger, Billy and Audrey Wilder chair, Division of Neurosurgery&nbsp;at CHLA. Attending the surgery was also Vittorio Colletti, of the University of Verona Hospital, Verona, Italy, who has performed the most ABI surgeries on children overseas and is a collaborator on the study.</span></p> <p><span style="font-size: 10pt;"><br />The study&rsquo;s goal is to establish safety and efficacy protocols for the surgery and subsequent behavioural mapping procedures that doctors in the United States can then later utilise once the surgery is approved for children in the USA.</span></p> <p><span style="font-size: 10pt;">&ldquo;Hundreds of children in the USA can benefit from ABI surgery,&rdquo; says Krieger, who also is associate professor of clinical neurosurgery at the Keck School of Medicine of USC. &ldquo;These children would otherwise never hear or develop verbal speech in their lives.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Auguste was the first child accepted into the Los Angeles study. Thirty-six days after the May 6 surgery at CHLA, his parents watched as audiologists Margaret Winter, and Jamie Glater, from the USC Center for Childhood Communication activated the device implanted in Auguste&rsquo;s brainstem. When Winter delivered tiny pulses of electric current to the electrodes in his brain, the toddler lifted his head indicating he heard a sound.</span></p> <p><span style="font-size: 10pt;"><br />Auguste has been deaf since birth. At 22 months, he underwent a bilateral cochlear implant, which uses electrodes to stimulate auditory nerves, but the device did not help him hear because he does not have a cochlear, or hearing, nerve. Auguste travelled with his parents, Sophie and Christophe, from Montreal to Los Angeles to participate in the clinical trial. The NIH grant covers the costs of the device, procedure and subsequent testing. To qualify for participation, patients must show that standard treatment such as hearing aids and cochlear implants have been ineffective.</span></p> <p><span style="font-size: 10pt;"><br />During the six-hour surgery in May, doctors made an incision by Auguste&rsquo;s right ear and removed his right cochlear implant before implanting the ABI device on his brainstem. The ABI device has external and internal parts. The external parts, which consist of a processor with a microphone and transmitter, transform sound into electrical signals and transmit the signals to an internal receiver that is part of the electrode array. The electrode array is placed on the cochlear nucleus of the brainstem. The procedure is considered revolutionary because it stimulates neurons directly at the human brainstem, bypassing the inner ear entirely.</span></p> <p><span style="font-size: 10pt;"><br />The young children who had ABIs implanted outside the United States now have the potential to understand speech, but, in the United States, the device is FDA-approved for use only in patients 12 years or older with neurofibromatosis type II, an inherited disease that causes a non-malignant brain tumour on the hearing nerve. It has shown limited effectiveness in adults, however, and scientists believe that the device would be more effective in young children, when their brains are more adaptable. The clinical trial will attempt to prove that this surgery is safe in young children and allow researchers to study how the brain develops over time and how it learns to hear sound and develop speech.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The children in this study are under five years of age,&rdquo; says Keck School of Medicine of USC Professor Robert V Shannon, an investigator for the trial and leading scientist in the development of ABI technology since 1989. &ldquo;When a child is born, their ear is hard-wired for sound but the brain has to learn how to perceive sound and speech from the information coming up the hearing pathway. If the ear is not providing sound information to the brain, the hearing part of the brain does not develop properly. The ABI provides sound to these pathways so they grow and develop with the child.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />After the devices are implanted, the Los Angeles-based researchers will study how the brain develops over time as it incorporates sound and speech. If the clinical trial is successful, children across the United States will be able to benefit from surgical and audiology techniques and safety and efficacy protocols developed in the study.</span></p></div> Medtronic completes acquisition of Visualase http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/medtronic-completes-acquisition-of-visualase 2014-07-28T14:54:00Z 2014-07-28T14:54:00Z <div id="Introduction36" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Medtronic has announced that it has completed the acquisition of Visualase, a&nbsp;privately held company based in Houston, USA, that develops and markets an FDA-approved MRI-guided laser and image guided system for minimally invasive neurosurgeries, including surgical thermal ablation.</strong></span></p> </div><div id="Text136" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Medtronic will add Visualase&rsquo;s MRI-guided laser ablation system to its portfolio of therapies for treating neurological conditions within its Surgical Technologies business and will integrate the technology into its broader neuroscience offerings. The acquisition of Visualase is another example of Medtronic&rsquo;s ongoing investment in technology and commitment to innovation across the entire surgical care continuum as the company strives to become the partner of choice for neurosurgeons and neuroscience centres around the world.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are excited about this opportunity to add Visualase&rsquo;s complementary technology and expertise to our neurosurgical solutions portfolio, which includes intra-operative imaging, surgical navigation, powered instruments and cerebrospinal fluid (CSF) management,&rdquo; says Mark Fletcher, senior vice president and president, Medtronic Surgical Technologies. &ldquo;The Visualase laser ablation technology gives neurosurgeons a minimally invasive option to precisely target and treat small areas of tissues. We are the recognised leader in high technology solutions for specialties such as neurosurgery, spinal surgery and orthopaedics. This acquisition broadens our strong and growing portfolio of innovative surgical products and represents entries into new areas such as surgical thermal ablation.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The transaction with Medtronic is critical to ensure more patients have access to our beneficial technology,&rdquo; says William Hoffman, chief executive officer of Visualase. &nbsp;&ldquo;We are proud of the MRI-guided laser ablation technology and other products we have developed and their impact on the well-being of patients. Medtronic is clearly committed to the area of minimally invasive neurosurgery and we look forward to working as a team to innovate in this area.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />The all-cash transaction of up to US$105 million includes an initial payment of US$70 million plus additional payments of up to US$35 million which are contingent upon the achievement of specific milestones.&nbsp;Medtronic had previously invested in Visualase and held an ownership stake in the company prior to completion of the acquisition.&nbsp;Net of this ownership stake, the initial payment is approximately US$64 million.&nbsp;Medtronic expects the net impact from this transaction to be neutral to fiscal year 2015 earnings and accretive thereafter, and for this transaction to be consistent with the company&rsquo;s disciplined focus on long-term returns.&nbsp;</span></p></div> IMRIS receives CE mark for integrating latest generation MR scanners within VISIUS surgical theatre http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imris-receives-ce-mark-for-integrating-latest-generation-mr-scanners-within-visius-surgical-theatre 2014-07-28T12:13:00Z 2014-07-28T12:13:00Z <div id="ImageMain37" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imris-receives-ce-mark-for-integrating-latest-generation-mr-scanners-within-visius-surgical-theatre"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/035/IMRIS_VISIUS_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction37" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>IMRIS has announced that it has obtained regulatory CE mark for integrating the next generation MRI core technology into the VISIUS surgical theatre allowing for sales and marketing in the European Union.</strong></span></p> </div><div id="Text137" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">This newest imaging technology, based on the Siemens Aera 1.5T(tesla) and Skyra 3.0T MRI scanners, helps IMRIS deliver even better image quality, faster 3D image acquisition, and improved ease-of-use and workflow during surgical procedures using intraoperative MRI (iMRI). The company received United States Food and Drug Administration (FDA) approval for these advancements in February 2014.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;These high-field intraoperative scanner options will give a hospital&rsquo;s clinical team state-of-the-art applications and image quality that increase productivity,&rdquo; says IMRIS president and chief executive officer Jay D Miller. &ldquo;We bring the latest and unequaled imaging technology into the operating room where it can make the most difference - during the surgery. More and more neurosurgical centres are using image guidance with VISIUS iMRI for an expanding list of conditions and procedures and adjunctive interventions beyond brain tumour resections, such as laser ablation for tumours and epilepsy using stereotactic tools, deep brain stimulation (DBS) and other minimally-invasive techniques that are designed to improve patient outcomes.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Inside a VISIUS surgical theatre equipped with high-field iMRI, surgeons have on-demand access to real-time data and state-of-the-art imaging during the procedure as the scanner uniquely moves on ceiling-mounted rails.</span></p></div> NeuroPace RNS system will play key role in DARPA’s RAM programme http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuropace-rns-system-will-play-key-role-in-darpas-ram-programme1 2014-07-24T12:33:00Z 2014-07-24T12:33:00Z <div id="ImageMain38" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuropace-rns-system-will-play-key-role-in-darpas-ram-programme1"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/NeuroPace_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction38" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>NeuroPace has announced its partnership with the Defense Advanced Research Projects Agency (DARPA) Restoring Active Memory (RAM) teams at the University of Pennsylvania and the University of California, Los Angeles (UCLA), USA to develop new treatments for memory deficits using neurostimulation.</strong></span></p> </div><div id="Text138" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The RNS system is the world&rsquo;s only commercially available implantable closed-loop responsive neurostimulator system. NeuroPace received premarket approval (PMA) from the US Food and Drug Administration (FDA) for the RNS System in November 2013. It is approved as a treatment for adults with partial onset seizures with one or two seizure onset zones whose seizures have not been controlled with two or more antiepileptic drugs.</span></p> <p><br /><span style="font-size: 10pt;">Through the DARPA RAM research, NeuroPace and other collaborators will gain fundamental knowledge regarding the restoration of memory. The company believes this research may expand the clinical applications of the RNS system beyond the treatment of epilepsy, as well as provide the understanding necessary to inform the development of future devices that expand the capabilities of responsive neurostimulation. This collaborative effort will advance the field of brain research and closed-loop neurostimulation applications. A portion of the DARPA project will involve epilepsy patients implanted with the RNS system at seven Comprehensive Epilepsy Centers and will be led by Barbara Jobst, professor of Neurology at Dartmouth, and Martha Morrell, chief medical officer at NeuroPace and clinical professor of Neurology at Stanford University. A separate part of the project will begin with epilepsy patients implanted with the RNS system at UCLA with Itzhak Fried serving as the principal investigator.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Using the RNS system, we will be able to immediately explore ways in which brain stimulation can restore memory function in patients with epilepsy. Insights derived from these early studies will help to guide future research in patients with other neurological disorders that result in memory loss,&rdquo; says Michael Kahana, principal investigator at the University of Pennsylvania.</span></p> <p><br /><span style="font-size: 10pt;">As a closed-loop system, the RNS system monitors the brain&rsquo;s own signals, interprets those signals, provides stimulation when needed, and then assesses the brain&rsquo;s response. The breakthrough aspect of the RNS system is its advanced detection and stimulation capabilities. This is unlike all other existing neurostimulation therapies, which continuously or intermittently stimulate the brain without determining the need for treatment or monitoring the response.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The RNS system is the only commercially available product that continuously monitors the brain&rsquo;s electrical signals, delivers stimulation only when needed and then monitors the response,&rdquo; says Frank Fischer, chief executive officer at NeuroPace. &ldquo;This capability is critical to the research phase of projects like the DARPA RAM programme. Restoring active memory could improve the lives of so many. We are thrilled to be a part of this programme and hope to be part of similar brain research and product development projects in the future.&rdquo;</span></p></div> Plegridy (peginterferon beta-1a) approved in the EU for treatment of multiple sclerosis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/plegridy-peginterferon-beta-1a-approved-in-the-eu-for-treatment-of-multiple-sclerosis 2014-07-23T12:51:00Z 2014-07-23T12:51:00Z <div id="Introduction39" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Biogen Idec&nbsp;has announced that the European Commission has granted marketing authorisation for Plegridy&nbsp;(peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Plegridy is dosed once every two weeks and is administered subcutaneously with the Plegridy pen, a new ready-to-use autoinjector, or a prefilled syringe.</strong></span></p> </div><div id="Text139" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Plegridy, the only pegylated interferon approved for use in relapsing-remitting multiple sclerosis, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression.</span></p> <p><br /><span style="font-size: 10pt;">The European Commission approval of Plegridy is based on results from one of the largest pivotal studies of a beta interferon conducted, <a href="http://clinicaltrials.gov/ct2/show/NCT00906399?term=advance&amp;rank=13" target="_blank"><strong>ADVANCE</strong></a>, which involved more than 1,500 patients with relapsing forms of multiple sclerosis.</span></p> <p><br /><span style="font-size: 10pt;">In the ADVANCE clinical trial, Plegridy, dosed once every two weeks, significantly reduced annualised relapse rate (ARR) at one year by 36% compared to placebo (p=0.0007).</span></p> <p><br /><span style="font-size: 10pt;">Plegridy reduced the risk of sustained disability progression confirmed at 12 weeks by 38% (p=0.0383) and at 24 weeks by 54% (p=0.0069, post-hoc analysis). In addition, the number of gadolinium-enhancing [Gd+] lesions was significantly reduced by 86% (p&lt;0.0001) compared to placebo.</span></p> <p><span style="font-size: 10pt;"><br />Results over two years of ADVANCE confirm that its robust efficacy was maintained beyond the placebo-controlled first year of the study.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The safety and efficacy that Plegridy has demonstrated, combined with its less frequent dosing schedule offers multiple sclerosis patients an option to put their treatment in the background for longer stretches of time,&rdquo; says Bernd C Kieseier, Heinrich-Heine&nbsp;Universit&auml;t, Dusseldorf.</span></p> <p><br /><span style="font-size: 10pt;">The safety and tolerability profile of peginterferon beta-1a observed in ADVANCE&nbsp;was consistent with that of established multiple sclerosis interferon therapies. The most commonly reported adverse drug reactions with peginterferon beta-1a treatment (incidence &ge;10% and at least 2% more frequent on peginterferon beta-1a than on placebo) were injection site reaction, flu-like illness, fever, headache, muscle pain, chills, injection site pain, weakness, injection site itching, and joint pain.</span></p> <p><br /><span style="font-size: 10pt;">Plegridy is the fifth therapy to be offered by Biogen Idec to people living with multiple sclerosis.</span></p></div> US$1 million Career Development Award grant for glioblastoma research with ThermoDox and HIFU http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/us1-million-career-development-award-grant-for-glioblastoma-research-with-thermodox-and-hifu 2014-07-22T10:14:00Z 2014-07-22T10:14:00Z <div id="Introduction40" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Celsion Corporation has announced that its ongoing collaboration with Costas Arvanitis of Brigham and Women&rsquo;s Hospital, a teaching affiliate of&nbsp;Harvard Medical School, has been expanded through the recent award of a&nbsp;US$1 million&nbsp;Career Development Award from the National Institutes of Health&rsquo;s Center for Biomedical Imaging and Bioengineering (NIBIB).</strong></span></p> </div><div id="Text140" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The grant will support preclinical studies evaluating ThermoDox, the company&rsquo;s heat-activated liposomal encapsulation of doxorubicin, in combination with High Intensity Focused Ultrasound (HIFU), for the treatment of brain tumours. The grant, titled &ldquo;Controlled Delivery and Release of Chemotherapy in Brain Tumours with FUS&rdquo; provides on average of&nbsp;US$200,000&nbsp;in annual funding for five years, and will be used to advance preclinical development of ThermoDox for the treatment of brain cancers, including glioblastoma multiforme, under the company&rsquo;s&nbsp;January 2014&nbsp;collaboration with Brigham and Women&rsquo;s Hospital, Harvard Medical School.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;This peer-reviewed grant award builds upon our ongoing collaborative work to explore treatments for brain tumours,&rdquo; says Costas D Arvanitis, Brigham and Women&rsquo;s Hospital,&nbsp;Harvard Medical School. &ldquo;Delivering chemotherapeutic agents across the blood-brain barrier is particularly challenging, but in recent years we have discovered that this could be achieved using focused ultrasound, including enhanced delivery of liposomal doxorubicin.&nbsp;We are hopeful that this grant will allow us to determine the potential utility of a promising therapeutic application for one of the most insidious cancers - glioblastoma.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Glioblastoma is a highly aggressive and deadly form of brain cancer for which there are few treatment options,&rdquo; says&nbsp;Michael H Tardugno, Celsion&rsquo;s president and chief executive officer.&nbsp;&ldquo;Working with a prominent cancer research group like Dr Arvanitis and his team, combined with the financial support of the NIH, will help accelerate the research required to elucidate the potential of ThermoDox combined with HIFU in this difficult to treat cancer, and provide a path forward for larger, more comprehensive phase II studies.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">If promising results are obtained from these phase I studies, a phase II grant application will be submitted to include more comprehensive studies of ThermoDox and HIFU for the treatment of glioblastoma multiforme brain tumours.</span></p></div> Study links enzyme to Alzheimer’s disease http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/study-links-enzyme-to-alzheimers-disease 2014-07-21T15:54:00Z 2014-07-21T15:54:00Z <div id="ImageMain41" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/study-links-enzyme-to-alzheimers-disease"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Alzheimers_enzyme_study_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction41" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Unclogging the body&rsquo;s protein disposal system may improve memory in patients with Alzheimer&rsquo;s disease, according to a study from scientists at Kyungpook National University in Korea published in&nbsp;<a href="http://jem.rupress.org/" target="_blank"><em>The Journal of Experimental Medicine</em></a>.</strong></span></p> </div><div id="Text141" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">In Alzheimer&rsquo;s disease, various biochemical functions of brain cells go awry, leading to progressive neuronal damage and eventual memory loss. One example is the cellular disposal system, called autophagy, which is disrupted in patients with Alzheimer&rsquo;s disease, causing the accumulation of toxic protein plaques characteristic of the disease. Jae-sung Bae and colleagues had earlier noted that the brains of Alzheimer&rsquo;s disease patients have elevated levels of an enzyme called acid sphingomyelinase (ASM), which breaks down cell membrane lipids prevalent in the myelin sheath that coats nerve endings. But whether increased acid sphingomyelinase directly contributes to Alzheimer&rsquo;s disease (and if so, how) was unclear.</span></p> <p><span style="font-size: 10pt;"><br />The group now finds that these two defects are linked. In mice with Alzheimer&rsquo;s disease-like disease, elevated acid sphingomyelinase activity clogged up the autophagy machinery resulting in the accumulation of undigested cellular waste. Reducing levels of acid sphingomyelinase restored autophagy, lessened brain pathology, and improved learning and memory in the mice. Provided these results hold true in humans, interfering with acid sphingomyelinase activity might prove to be an effective way to slow&mdash;and possibly reverse&mdash;neurodegeneration in patients with Alzheimer&rsquo;s disease.</span></p></div> Scientists find new clues to brain’s wiring http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/scientists-find-new-clues-to-brains-wiring 2014-07-21T15:40:00Z 2014-07-21T15:40:00Z <div id="ImageMain42" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/scientists-find-new-clues-to-brains-wiring"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/Brain_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction42" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>New research provides an intriguing glimpse into the processes that establish connections between nerve cells in the brain. These connections, or synapses, allow nerve cells to transmit and process information involved in thinking and moving the body.</strong></span></p> </div><div id="Text142" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Reporting online in&nbsp;<a href="http://www.cell.com/neuron/home" target="_blank"><em>Neuron</em></a>, researchers at Washington University School of Medicine in St Louis have identified a group of proteins that programme a common type of brain nerve cell to connect with another type of nerve cell in the brain.</span></p> <p><span style="font-size: 10pt;"><br />The finding is an important step forward in efforts to learn how the developing brain is built, an area of research essential to understanding the causes of intellectual disability and autism.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We now are looking at how loss of this wiring affects brain function in mice,&rdquo; says senior author Azad Bonni, the Edison Professor of Neurobiology and head of the Department of Anatomy and Neurobiology at the School of Medicine.</span></p> <p><span style="font-size: 10pt;"><br />Bonni and his colleagues are studying synapses in the cerebellum, a region of the brain that sits in the back of the head. The cerebellum plays a central role in controlling the coordination of movement and is essential for what researchers call procedural motor learning, which makes it possible to move our muscles at an unconscious level, such as when we ride a bicycle or play the piano.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The cerebellum also regulates mental functions,&rdquo; Bonni says. &ldquo;So, impairment of the wiring of nerve cells in the cerebellum may contribute to movement disorders as well as cognitive problems including autism spectrum disorders.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />His new results show that a complex of proteins known as NuRD (nucleosome remodelling and deacetylase) plays a fairly high supervisory role in some aspects of the cerebellum&rsquo;s construction. When the researchers blocked the NuRD complex, cells in the cerebellum called granule cells failed to form connections with other nerve cells, the Purkinje neurons. These circuits are important for the cerebellum&rsquo;s control of movement coordination and learning.</span></p> <p><span style="font-size: 10pt;"><br />Bonni and his colleagues showed that NuRD exerts influence at the epigenetic level, which means it controls factors other than DNA that affect gene activity. For example, NuRD affects the configurations of molecules that store DNA and that can open and close the coils of DNA like an accordion, making genes less or more accessible. Changing the accessibility of genes changes their activity levels. For instance, cells cannot frequently make proteins from genes in a tightly packed coil of DNA.</span></p> <p><span style="font-size: 10pt;"><br />NuRD also alters tags on the proteins that store DNA, decreasing the chances that the gene will be used. Among the genes deactivated by NuRD are two that control the activity of other genes involved in the wiring of the cerebellum.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;This tells us that the NuRD complex is very influential&mdash;not only does it affect the activity of genes directly, it also controls other regulators of multiple genes,&rdquo; Bonni says.</span></p></div> Making a mental match: Pairing a mechanical device with stroke patients http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/making-a-mental-match-pairing-a-mechanical-device-with-stroke-patients 2014-07-18T12:24:00Z 2014-07-18T12:24:00Z <div id="ImageMain43" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/making-a-mental-match-pairing-a-mechanical-device-with-stroke-patients"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Georgia-Tech-stroke-device_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction43" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The repetitive facilitation exercise is one of the most common rehabilitation tactics for stroke patients attempting to regain wrist movement. Stroke hemiparesis individuals are not able to move that part of their body because they cannot create a strong enough neural signal that travels from the brain to the wrist.</strong></span></p> </div><div id="Text143" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">With repetitive facilitation exercise, however, patients get a mental boost. They are asked to think about moving. At the same time, a practitioner flexes the wrist. The goal is to send a long latency response from the stretch that arrives in the brain at the exact time the thought happens, creating a neural signal. The result is a strong, combined response that zips back to the forearm muscles and moves the wrist.</span></p> <p><span style="font-size: 10pt;">It all happens in a span of approximately 40 to 60 milliseconds.&nbsp;</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;Timing is everything. When the window is that small, it is not easy for two people to match each other,&rdquo; says Georgia Institute of Technology master&rsquo;s graduate Lauren Lacey.</span></p> <p><br /><span style="font-size: 10pt;">That&rsquo;s why Lacey and a team of fellow Georgia Tech researchers created&nbsp;a mechanical device that takes people out of the process, replacing them with accurate computers. Their functional MRI-compatible hemiparesis rehab device creates a long latency stretch reflex at the exact time as a brain signal.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;It&rsquo;s kind of like trying to fill a bucket with water,&rdquo; explains Minoru Shinohara, an associate professor in Georgia Tech&rsquo;s Human Neuromuscular Physiology Lab. &ldquo;Stroke individuals can only mentally fill it halfway. The machine pours in the rest to make it full.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">So far, the research team has worked only with healthy individuals in their study. Study participants lie on a bed with the arm extended beneath a pneumatic actuator tendon hammer. In order to simulate the weak signal created by hemiparesis individuals to move their wrist, a transcranial magnetic stimulator (TMS) is placed on the heads of these healthy individuals at a 45-degree angle. Milliseconds after the hammer taps the wrist&rsquo;s tendon, the TMS creates a weak signal in the motor cortex. The responses overlap, produce and send a strong signal back to the arm, and the wrist moves.</span></p> <p><br /><span style="font-size: 10pt;">The team has successfully varied the timing of the transcranial magnetic stimulator signal and speed of the hammer to strike faster or slower depending on how much of a boost is needed to complement the brain signal. Now that the researchers have proven the viability of the transcranial magnetic stimulator-actuator system, they will next work with stroke individuals.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The device is designed to adapt to people whether they are hyper, normo or hyporeflexive,&rdquo; says Lacey, who graduated in spring with a master&rsquo;s degree from the George Woodruff School of Mechanical Engineering.</span></p> <p><br /><span style="font-size: 10pt;">Also, because the machine is MRI-compatible, it will allow the team to study what is happening in the brain during rehab, opening the door for robotics.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Once we fully understand what is happening mentally and physiologically, we should be able to create a robot that can reproduce successful rehabilitative exercises such as repetitive facilitation exercise,&rdquo; says Jun Ueda, an associate professor in the School of Mechanical Engineering. &ldquo;It appears that the timing is the critical piece of this exercise. Robots are great at timing, so the results are very promising for robotics.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">The Georgia Tech team was assisted by researchers at Japan&rsquo;s Kagoshima University, Kazumi Kawahira, Megumi Shimodozono and Yong Yu, who originally performed clinical studies of conventional repetitive facilitation exercise. The device was presented at the&nbsp;Design of Medical Devices Conference&nbsp;in Minneapolis, Minnesota, USA this spring.</span></p> <p><br /><span style="font-size: 10pt;">This research was partially supported by the National Science Foundation (NSF) under sub-award EEC 0540834. Any conclusions expressed are those of the principal investigator and may not necessarily represent the official views of the NSF.</span></p></div> JAMA study: Stroke risk and death rates fall over past two decades http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/jama-study-stroke-risk-and-death-rates-fall-over-past-two-decades 2014-07-18T11:57:00Z 2014-07-18T11:57:00Z <div id="ImageMain44" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/jama-study-stroke-risk-and-death-rates-fall-over-past-two-decades"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/019/Stroke_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction44" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Fewer Americans are having strokes and those who do have a lower risk of dying from them finds a new study led by Johns Hopkins Bloomberg School of Public Health researchers.</strong></span></p> </div><div id="Text144" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The study found a 24% overall decline in first-time strokes in each of the last two decades and a 20% overall drop per decade in deaths after stroke. However, the decline in stroke risk was concentrated mainly in the over-65 set, with little progress in reducing the risk of strokes among young people. In contrast, the drop in stroke-related deaths each decade was primarily found among those under age 65, with mortality rates holding firm in older people.</span><br /> <br /><span style="font-size: 10pt;"> A report on the results is published in the July 16 issue of the&nbsp;<a href="http://jama.jamanetwork.com/journal.aspx" target="_blank"><em>Journal of the American Medical Association</em>&nbsp;(<em>JAMA</em>)</a>.</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;We can congratulate ourselves that we are doing well, but stroke is still the number four cause of death in the United States,&rdquo; says study co-author Josef Coresh, a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health. &ldquo;This research points out the areas that need improvement. It also reminds us that there are many forces threatening to push stroke rates back up and if we do not address them head-on, our gains may be lost.&rdquo;</span><br /> <br /><span style="font-size: 10pt;"> Coresh says he worries what the future of stroke will look like as the obesity epidemic, which began in the 90s, matures. As millions more are diagnosed with hypertension and diabetes &ndash; which often go hand-in-hand with obesity -- they will face increased risk for stroke.</span><br /> <br /><span style="font-size: 10pt;"> For their analysis, researchers used results from the Atherosclerosis Risk in Communities (ARIC) study, a prospective study of 15,792 residents of four US communities who were between the ages of 45 and 64 when the study began in the late 1980s. In this analysis, they followed 14,357 participants who were free of stroke in 1987, looking specifically for all stroke hospitalisations and deaths between then and the end of 2011.</span><br /> <br /><span style="font-size: 10pt;"> Seven per cent of the study sample (1,051) had a stroke over that period. Of those, 10% died within 30 days, and 21%, 40% and 58% died within one year, five years and by the end of the study in 2011. Each decade, the number of deaths occurring within 10 years of a stroke was reduced by roughly eight deaths per 100 cases. The decrease was not across the board. Instead it was primarily the result of stroke victims under the age of 65 surviving longer. While they varied by age, the results were similar across race and gender, a finding that researchers were heartened to discover since a previous study suggested African-American stroke rates were not improving.</span><br /> <br /><span style="font-size: 10pt;"> The researchers found that the decrease in stroke incidence and mortality is partly due to more successful control of risk factors such as blood pressure, smoking cessation and the wide use of statin medications for controlling cholesterol. However, an increase in diabetes likely acted in the opposite direction, pushing up stroke rates, though to a lesser extent. Stroke severity and improvements in treatment likely also impacted the data, though the study could not measure the exact role they played.</span><br /> <br /><span style="font-size: 10pt;"> The age disparities in outcomes suggest areas where physicians and researchers may want to focus in the future to prevent strokes in those under 65 and reduce deaths in those over 65.</span><br /> <br /><span style="font-size: 10pt;"> Nearly 800,000 Americans suffer strokes each year; of those, about 600,000 are first-time strokes. &ldquo;Stroke is not only one of the main causes of death, but a leading cause of long-term disability in adults. Therefore, prevention is the best strategy,&rdquo; says study leader Silvia Koton, a visiting faculty member at the Bloomberg School and incoming nursing department chair at Tel Aviv University.</span><br /> <br /><span style="font-size: 10pt;"> National data show that the number of death certificates listing stroke as the underlying cause of death has decreased for a long time. However, only research studies such as this one can distinguish whether the decline is due to a reduction in the number of strokes or whether people are just living longer after having them, researchers say. In this study, researchers also confirmed the occurrence of each stroke by reviewing each medical chart using uniform criteria. Researchers focused on deaths from all causes because following a stroke, many patients die from other causes including heart disease and pneumonia.</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;Since rates are not equally falling across the board, physicians and policymakers need to pay closer attention to specific subgroups,&rdquo; Koton says. &ldquo;These data are also helpful in monitoring the results of how we care for people of all ages, hopefully helping them even before they have a stroke.&rdquo;</span><br /> <br /><span style="font-size: 10pt;"> The ARIC study is supported by contracts with the National Institutes of Health&rsquo;s National Heart, Lung, and Blood Institute as well as NHLBI grants.</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;Stroke Incidence and Mortality Trends in US Communities, 1987 to 2011,&rdquo; was written by Silvia Koton; Andrea L.C. Schneider; Wayne Rosamond; Eyal Shahar; Tingying Sang; Rebecca Gottesman; and Josef Coresh.</span></p></div> ROADSTER trial studying new path to carotid revascularisation completes patient enrolment http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/roadster-trial-studying-new-path-to-carotid-revascularisation-completes-patient-enrolment- 2014-07-18T11:02:00Z 2014-07-18T11:02:00Z <div id="ImageMain45" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/roadster-trial-studying-new-path-to-carotid-revascularisation-completes-patient-enrolment-"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Carotid-artery-disease_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction45" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Silk Road Medical has announced the completion of enrolment in its pivotal <a href="http://clinicaltrials.gov/ct2/show/NCT01685567?term=ROADSTER&amp;rank=1" target="_blank"><span style="color: #000080;">ROADSTER</span></a> study. The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally invasive procedure. The device under study is the company&rsquo;s Enroute transcarotid neuroprotection system which incorporates proven surgical principles to protect the brain from a stroke during carotid angioplasty and stenting, and features a mechanism to divert dangerous debris away from the brain by temporarily reversing blood flow. Data from the trial will be used to support 510(k) clearance of the Enroute transcarotid neuroprotection system as well as pre-market approval of the Enroute transcarotid stent system.</strong></span></p> </div><div id="Text145" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;The Enroute transcarotid neuroprotection system was designed to reduce the excess stroke risk of a carotid stent procedure, while at the same time minimising the surgical risks of an open carotid artery surgery known as carotid endarterectomy,&rdquo; says Sumaira Macdonald an expert in the field of carotid artery disease and Silk Road Medical&rsquo;s chief medical officer. &ldquo;Until now, carotid stents were typically placed via the femoral artery approach, which is about three feet from the culprit carotid stenosis, and requires navigation of catheters and other instruments through often hostile territory, increasing the risk of stroke during or immediately after the procedure,&rdquo; she says. &ldquo;We know that carotid stents are effective in preventing strokes in the long term, but we need a safer way to deliver them. The Silk Road procedure moves the access point to within inches of the stenosis to avoid at-risk steps and provides a surgically-inspired method of protecting the brain throughout the simplified procedure.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">By contrast, the gold standard carotid endarterectomy procedure requires a large incision in the neck and a surgery that carries some risk of nerve damage, bleeding, scarring and infection. The Silk Road procedure is designed to reduce these surgical risks as well. &ldquo;Historically, there has not been a safe and effective minimally invasive procedure that could hold up to the clinical outcomes established by carotid endarterectomy. This new procedure may be it,&rdquo; says Richard Cambria, chief, Division of Vascular and Endovascular Surgery at Massachusetts General Hospital and The Robert R Linton MD Professor of Vascular and Endovascular Surgery at the Harvard Medical School. &ldquo;The results from our centre will be announced at the VEITH Symposium.&rdquo; Cambria serves as the National co-principal investigator for the ROADSTER trial.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The ROADSTER trial included an elite, multi-disciplinary group of physicians across the US and Europe with vast experience in treating carotid disease,&rdquo; says Christopher Kwolek, director of the Vascular and Endovascular training programme at Massachusetts General Hospital, chief of Vascular Surgery at Newton Wellesley Hospital, and National co-principal investigator for the ROADSTER trial. &ldquo;Similar to important endovascular innovations in aortic aneurysms and peripheral arterial disease, this new minimally invasive procedure will be an important step forward in the treatment of carotid artery disease for the vascular specialist.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Erica Rogers, chief executive officer for Silk Road Medical, comments, &ldquo;We believe the ROADSTER data will support clearance and approval of our planned marketing applications with the FDA. We are grateful for the collaboration of our investigators who allowed this study to complete enrolment on time. We are quite eager to present the full results of the study in the near future.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Both the Enroute transcarotid neuroprotection system and stent system have been granted CE mark approval. The Enroute transcarotid neuroprotection system is limited by United States law to investigational use. The Enroute transcarotid stent system is not currently available in the United States.</span></p></div> Stroke inpatient rehabilitation facilities yield better neurological outcomes than skilled nursing facilities http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/stroke-inpatient-rehabilitation-facilities-yield-better-neurological-outcomes-than-skilled-nursing-facilities 2014-07-17T09:38:00Z 2014-07-17T09:38:00Z <div id="ImageMain46" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/stroke-inpatient-rehabilitation-facilities-yield-better-neurological-outcomes-than-skilled-nursing-facilities"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Hospital-Stay-Main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction46" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A demographic analysis has revealed that an association exists between discharge disposition and National Institutes of Health Stroke Scores (NIHSS) at 90-day follow-up. Patients discharged to an inpatient rehabilitation facility were found to have more favourable outcomes compared with those sent home or to a skilled nursing facility. According to the authors, this study is the first to examine the role of discharge disposition in an acute stroke treatment trial in the modern era.</strong></span></p> </div><div id="Text146" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Rishi Gupta (Wellstar Neurosurgery, Marietta, USA) and others evaluated the demographic data from the SENTIS (The safety and efficacy of NeuroFlo technology in ischemic stroke) trial to determine the impact of stroke severity and discharge disposition on 90-day outcomes in US patients&mdash;the results were published in the <a href="http://jnis.bmj.com/" target="_blank"><em>Journal of NeuroInterventional Surgery</em></a>.</span></p> <p><br /><span style="font-size: 10pt;">The <a href="http://clinicaltrials.gov/ct2/show/NCT00119717?term=SENTIS&amp;rank=1" target="_blank"><strong>SENTIS</strong></a> trial, originally published in the <a href="http://www.ajnr.org/" target="_blank"><em>American Journal of Neuroradiology</em></a> in 2013, was a multicentre, prospective, randomised controlled trial that evaluated the safety and effectiveness of the NeuroFlo catheter (CoAxia) in stroke patients compared to standard medical therapy. In the trial, it was found that there were consistent reductions in all-cause and stroke-related mortality in the NeuroFlo-treated patients. Although the results showed that treatment with NeuroFlo was safe, it was also demonstrated that there was not a benefit of doing so when compared to standard medical therapy. Therefore, Gupta and colleagues analysed NIHSS from days one and four, discharge disposition and 90-day modified Rankin Score to investigate whether discharge disposition to home or acute rehabilitation is associated with a clinical favourable outcome from the SENTIS data.</span></p> <p><br /><span style="font-size: 10pt;">Of the 292 patients, 153 (52.1%) were discharged to an inpatient rehabilitation facility, 11 (38%) to home and 28 (9.6%) to a skilled nursing facility.</span></p> <p><br /><span style="font-size: 10pt;">Two out of the 28 patients discharged to a skilled nursing facility achieved a 90-day modified Rankin Score of &le;2 compared with the 60/153 patients in the inpatients rehabilitation facility (OR 8.39, 95% CI 1.92 to 36.64, p=0.0047).&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />According to Gupta <em>et al,</em> these results show that an association between outcomes and discharge disposition remains after adjustments for age and admission NIHSS.</span></p> <p><br /><span style="font-size: 10pt;">They add that three of the 50 patients with NIHSS of &ge;14 at four days achieved modified Rankin Scored of 0&ndash;2 at 90 days.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;This analysis shows that discharge to an inpatient rehabilitation facility is associated with better neurological outcomes than discharge to a skilled nursing facility. Additionally, patients with NHISS of &ge;14 at day four are unlikely to achieve independent function.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Co-author Samir R Belagaje, assistant professor, Neurology and Rehabilitation Medicine, Emory University School of Medicine, USA, spoke to <em>NeuroNews</em> and shed light on the implications of the findings of the study for the future.</span></p> <p><span style="font-size: 10pt;"><strong><br />How could these findings be applied to patient care after stroke in the future?</strong></span></p> <p><br /><span style="font-size: 10pt;">Our results reinforce the concept that care of patients with stroke must be optimised in all phases of their care and not just the acute phase. In the real world, neurologists and other healthcare practitioners should try to get their patients to their acute rehabilitation (inpatient rehabilitation) whenever possible and when their patients are unable to go home immediately. In the research world, our research helps with the design of future clinical trials of acute stroke intervention by pointing out the importance of the discharge disposition and possibly standardised. Our data may also point to further examination of the decision process in determining which patients go to inpatient rehabilitation facility vs. skilled nursing facility and help get more patients to an inpatient rehabilitation facility to improve their overall outcome.</span></p> <p><span style="font-size: 10pt;"><strong><br />Would discharging all patients to an inpatient rehabilitation facility be cost-effective?</strong></span></p> <p><br /><span style="font-size: 10pt;">We do not have any data at this point to clearly say one way or another. It is probably not cost-effective as there are some patients who, because of their stroke severity, simply do not make the improvements to justify the resources in terms of therapists and the intensity of therapy. They would do the same with less intensity as provided in a skilled nursing facility.&nbsp;</span></p> <p><br /><span style="font-size: 10pt;">Furthermore, there are some patients because of their age, stroke severity, or other medical comorbidities are unable to tolerate the intensity of the inpatient facility rehabilitation and could actually do worse. This would result in more acute hospitalisations, longer stays in facilities, and worsened outcomes all of which would add further costs making this strategy less cost-effective.</span></p></div> Banner Alzheimer’s Institute partners with Novartis in new study of Alzheimer’s prevention treatments http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/banner-alzheimers-institute-partners-with-novartis-in-new-study-of-alzheimers-prevention-treatments 2014-07-16T15:19:00Z 2014-07-16T15:19:00Z <div id="Introduction47" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Researchers from the Banner Alzheimer&rsquo;s Institute (BAI) have announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs&mdash;an active immunotherapy and an oral medication&mdash;can prevent or delay the emergence of symptoms of Alzheimer&rsquo;s in people at particularly high risk for developing the disease at older ages.</strong></span></p> </div><div id="Text147" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The five-year APOE4 trial will involve more than 1,300 cognitively healthy older adults, ages 60&nbsp;to 75<em>,&nbsp;</em>at high risk of developing symptoms of&nbsp;Alzheimer&rsquo;s because they inherited two copies of the apolipoprotein E (APOE4) gene&mdash;one from each parent. About 2% of the world&rsquo;s population carries two copies of this gene and one in four people carry one copy of the APOE4 gene, which is strongly linked to late-onset Alzheimer&rsquo;s.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;We are taking clinical trials to a critical new stage,&rdquo; says Pierre N Tariot, study director for BAI, an arm of Banner Health, one of the largest non-profit healthcare systems in&nbsp;the United States. &ldquo;This approach shifts the research paradigm from trying to reverse disease damage to attacking and preventing its cause, years before symptoms could surface.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">The trial&mdash;subject to regulatory authority approval&mdash;will begin in 2015 at approximately 60 sites in&nbsp;Europe&nbsp;and North America, including BAI&rsquo;s headquarters in&nbsp;Phoenix, Arizona, USA.</span></p> <p><br /><span style="font-size: 10pt;">The active immunotherapy is aimed at triggering the body&rsquo;s immune system to produce antibodies that attack different forms of the amyloid protein, which many researchers have suggested plays a critical role in the development of Alzheimer&rsquo;s. The oral medication is a BACE (beta-secretase1) inhibitor, designed to prevent the production of different forms of the amyloid protein.</span></p> <p><br /><span style="font-size: 10pt;">The two drugs, which will be tested separately, are intended to stop the accumulation of amyloid. The drugs are being introduced even before amyloid accumulates in some of the participants&rsquo; brains. The trial will increase the chance of finding treatments that will prevent, slow or delay the loss of memory and other cognitive abilities associated with Alzheimer&rsquo;s.</span></p> <p><br /><span style="font-size: 10pt;">Study participants will be recruited via multiple venues, including the Alzheimer&rsquo;s Prevention Registry website created by BAI in 2012. The registry currently has more than 37,000 potential volunteers and is aiming to recruit more than 250,000.</span></p> <p><br /><span style="font-size: 10pt;">Volunteers who meet the study criteria will be asked to mail a sample of their genetic material (such as a cheek swab) to a laboratory. The volunteers will learn the results of that test in the context of possibly enrolling in the trial.</span></p> <p><br /><span style="font-size: 10pt;">Volunteers who are selected for the API APOE4 study will receive genetic counselling. &ldquo;We are keenly aware of the extreme sensitivity and emotional impact of disclosing genetic information,&rdquo; Langbaum says.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;There are no guarantees that any of these investigational treatments will prevent the clinical onset of Alzheimer&rsquo;s disease,&rdquo; says Eric M Reiman, one of the study directors for BAI. &ldquo;But we are grateful for these opportunities to find out.&rdquo;</span></p></div> Worldwide Alzheimer’s and dementia epidemic grows http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/worldwide-alzheimers-and-dementia-epidemic-grows 2014-07-15T15:41:00Z 2014-07-15T15:41:00Z <div id="ImageMain48" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/worldwide-alzheimers-and-dementia-epidemic-grows"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/World_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction48" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>While the global epidemic of Alzheimer&rsquo;s disease continues to grow, new data on lower incidence in the &ldquo;youngest old&rdquo; from developed countries in Europe&nbsp;and&nbsp;the United States&nbsp;suggest the possibility of reducing risk and/or preventing the disease, according to the results of several research studies announced at the Alzheimer&rsquo;s Association International Conference2014 (AAIC&nbsp;2014) in&nbsp;Copenhagen, Denmark. Scientists suggest higher education levels and more aggressive treatment of cardiovascular disease may be key.</strong></span></p> </div><div id="Text148" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Pointing in the other direction, researchers reported at AAIC 2014 that incidence and prevalence of Alzheimer&rsquo;s in developing countries such as&nbsp;Colombia, and large regions of&nbsp;Asia&nbsp;and&nbsp;Africa, may be severely underreported. They also raise questions about the effects of the growing incidence of obesity and diabetes in developed countries, both of which are associated with increased risk of cognitive decline and dementia.</span></p> <p><span style="font-size: 10pt;">For clarity following are the definitions of prevalence and incidence:</span></p> <ul> <li><span style="font-size: 10pt;">Prevalence &ndash; the number or proportion of cases of a disease in a population. (ie., How many people have Alzheimer&rsquo;s disease in the USA right now?)</span></li> <li><span style="font-size: 10pt;">Incidence &ndash; the number of new cases of a disease in a population over a given time. (ie., How many new cases of Alzheimer&rsquo;s are there this year in&nbsp;Denmark?)</span></li> </ul> <p><span style="font-size: 10pt;">&ldquo;The good news is that recent trends in developed countries in&nbsp;Europe&nbsp;and the USA suggest that reduction and possibly even prevention of Alzheimer&rsquo;s disease might be possible &ndash; but, at the same time, we must acknowledge the growing worldwide epidemic,&rdquo; says&nbsp;Maria Carrillo, Alzheimer&rsquo;s Association vice president of Medical and Scientific Relations. &ldquo;We must continue efforts to halt this terrible scourge that devastates families and economies.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;According to new data reported at AAIC 2014, Alzheimer&rsquo;s and dementia incidence and prevalence in developing countries may be much higher than previously thought, and rising rates of obesity and diabetes pose an unknown but potentially serious threat to cognitive health throughout the world. Many questions remain, and the only way we can get the answers is through more research,&rdquo; Carrillo says.</span></p> <p><br /><span style="font-size: 10pt;">There are hints in the literature that engaging in more challenging mental activities, such as higher levels of education or intellectually demanding occupations, may increase cognitive reserve and thereby reduce the risk of developing Alzheimer&rsquo;s or another dementia.</span></p> <p><span style="font-size: 10pt;"><strong><br />Review of recent data suggests fewer new cases of Alzheimer&rsquo;s in&nbsp;the United States&nbsp;and&nbsp;Europe<br /> <br /> </strong>Worldwide prevalence of Alzheimer&rsquo;s disease is projected to increase in the decades ahead as the planet&rsquo;s population ages, but recently published studies from&nbsp;the United States,&nbsp;the Netherlands,&nbsp;Sweden, and&nbsp;England suggest a decline in incidence or prevalence of dementia (or both) in those countries, according to a review of recent research conducted by&nbsp;Kenneth Langa of the&nbsp;University of Michigan&nbsp;and the VA Ann Arbor Center for Clinical Management Research, and reported at a plenary session at AAIC 2014.</span></p> <p><span style="font-size: 10pt;"><br />Langa observed from the studies that a number of factors, especially rising levels of education and more aggressive treatment of cardiovascular risk factors such as hypertension and high cholesterol, may be leading to improved brain health and consequent decline of numbers of new cases of Alzheimer&rsquo;s disease and dementia in certain countries or regions of the world.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Whether this trend will continue in the face of rising levels of obesity and diabetes, and whether it is also true in low- and middle-income countries, are key unanswered questions,&rdquo; says Langa. &ldquo;The answers will have enormous implications for the extent of the future worldwide impact of Alzheimer&rsquo;s disease and dementia in the decades ahead.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />Extent of dementia in&nbsp;Asia&nbsp;and Sub-Saharan Africa may be severely underestimated<br /> <br /> </strong>In 2009, Alzheimer&rsquo;s Disease International (ADI) published data on global prevalence of dementia based on a review of 154 worldwide studies and United Nations (UN) population projections. Alzheimer&rsquo;s Disease International carried out an update on that data for the&nbsp;December 2013&nbsp;G8 Dementia Summit in&nbsp;London, focusing primarily on new evidence from&nbsp;Asia and Sub-Saharan Africa, and presented the results at AAIC 2014.</span></p> <p><span style="font-size: 10pt;"><br />Based on a meta-analysis of Chinese and Sub-Saharan African studies combined with the latest UN population projections, Alzheimer&rsquo;s Disease International concluded that the 2009 estimates of worldwide Alzheimer&rsquo;s disease were too low. Alzheimer&rsquo;s Disease International now estimates that 44.35 million people in the world were living with dementia in 2013, significantly up from the earlier estimate of 36 million people living with dementia in 2010. They project that the number will rise to 75.62 million in 2030 &mdash; 15% higher than the 2009 estimate &mdash; and 135.46 million in 2050, which is 17% higher than the 2009 Alzheimer&rsquo;s Disease International estimate.</span></p> <p><br /><span style="font-size: 10pt;">Specifically in the two focus regions, the researchers found that dementia prevalence increased for&nbsp;East Asia from about 5% to about 7%, and in Sub-Saharan African regions from a range of roughly 2 to 4% to 4.76%.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Dementia, including Alzheimer&rsquo;s disease, is one of the biggest global health challenges facing our generation,&rdquo; says&nbsp;Marc Wortmann, executive director, Alzheimer&rsquo;s Disease International. &ldquo;As more and better data becomes available, the effect we&rsquo;ve seen is a reduction in the variation of prevalence between world regions.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;In addition, newly available data suggests that the current burden and future impact of the global dementia epidemic has been underestimated, particularly for the&nbsp;Asia&nbsp;and Sub-Saharan Africa. Especially in light of these revised estimates, there is an urgent need to develop policies to face this disease in all countries of the world, and to enhance our efforts in finding a cure or treatment that can delay the onset of dementia,&rdquo; Wortmann adds.</span></p> <p><span style="font-size: 10pt;"><strong><br />New sases of dementia decline over three decades in the Framingham Heart Study<br /> <br /> </strong>At AAIC 2014,&nbsp;Claudia L Satizabal of&nbsp;Boston University School of Medicine&nbsp;and colleagues reported on the results of a study of dementia trends among participants in the Framingham Heart Study, an ongoing, long-term (since 1948), multi-generational cardiovascular health study of residents of&nbsp;Framingham, Massachusetts, USA, to which dementia tracking has been added since 1975.</span></p> <p><span style="font-size: 10pt;"><br />Framingham Study participants undergo comprehensive assessments for cardiovascular risk factors every two to four years, and remain under intensive surveillance for dementia and stroke. Study researchers defined four non-overlapping five-year time windows (epochs) across the past three decades, each beginning with a baseline examination, and studied new cases of dementia among all dementia-free participants age 60 and older.</span></p> <p><br /><span style="font-size: 10pt;">After adjusting for age at entry and gender, the researchers found that compared with the first epoch, the second epoch had a 22% reduction in new cases of dementia, the third had a 38% reduction, and the fourth had a 44% reduction. The reduction was strongest in participants between age 60 and 69.</span></p> <p><br /><span style="font-size: 10pt;">The researchers found the decrease in dementia incidence was greatest in women across all epochs, while men showed a more gradual decrease over time. The decreasing trend in dementia incidence was true for individuals with a higher educational level, defined as having a high school diploma, whereas individuals without a high school diploma did not appear to benefit from this reduction.</span></p> <p><br /><span style="font-size: 10pt;">During that 30-year time period, the researchers observed among the participants a substantial improvement in educational achievement, better management of blood pressure, higher levels of HDL cholesterol, and a considerable decline in smoking, heart disease and stroke across the same epochs. However, an increasing trend in obesity and diabetes was seen in this population.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;These reductions in age-specific rates of new cases of dementia in the Framingham Study participants might be partly explained by the beneficial trends we observed in educational attainment and heart health risk factors,&rdquo; says Satizabal. &ldquo;This leads us to cautious optimism that some cases of dementia may be preventable. However, one of the limitations of this work is that the&nbsp;Framingham&nbsp;sample is largely of European descent. Additional studies are needed in populations of different racial and ethnic backgrounds.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />In&nbsp;Colombia, dementia and Alzheimer&rsquo;s disease might be underestimated by up to 50%<br /> <br /> </strong>To date,&nbsp;Colombia&nbsp;has had only one study, known as EPINEURO, which attempted to estimate the country&rsquo;s dementia prevalence from representative samples of the population 20 years ago. Using updated population estimates and prevalence estimates published in the international literature,&nbsp;Yuri Takeuchi of Universidad Icesi (Colombia) and colleagues estimated the number of people with dementia, and especially Alzheimer&rsquo;s disease, in&nbsp;Colombia&nbsp;by stage of the disease. The results were reported at AAIC 2014.</span></p> <p><br /><span style="font-size: 10pt;">The researchers created three models for Alzheimer&rsquo;s prevalence in the country, each using different projections for the proportion of people with mild, moderate, and severe disease, and different theoretical assumptions on the transitions between stages. They found that the number of people with Alzheimer&rsquo;s in Colombia&nbsp;could be as much as 220,000 in 2015, and 260,000 in 2020. The scientists calculate that current estimates for Alzheimer&rsquo;s disease and other dementias in&nbsp;Colombia&nbsp;might be too low by as much as 50%. (The prevalence estimate of dementia for&nbsp;Colombia&nbsp;in people over 65 used in the study was 6%, according to Takeuchi.)</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;To our knowledge, this is the first attempt to model and estimate dementia prevalence by stage of disease in the developing world; it is certainly the first attempt in&nbsp;Colombia,&rdquo; says Takeuchi. &ldquo;The fastest growth in ageing is happening in developing countries such as&nbsp;Colombia. This has profound implications not only for older people themselves, but for their households, social and community infrastructure, and social policy. These estimations by stage of disease are key information for policymakers because both the social burden and social costs are substantially different depending on the stage of disease.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />Dementia in&nbsp;Germany&nbsp;declined between 2007 and 2009<br /> <br /> </strong>Gabriele Doblhammer of the German Center for Neurodegenerative Diseases (DZNE) and colleagues conducted a study exploring short-term dementia trends in&nbsp;Germany, and reported the results at AAIC 2014.</span></p> <p><br /><span style="font-size: 10pt;">The research is based on claims data from the largest public health insurance company in&nbsp;Germany&nbsp;which covers about one-third of the total population aged 50+ and more than half of the oldest-old. The data include complete records of the inpatient and outpatient services, including dementia diagnosis. The complete insured population of roughly five million people at risk of dementia and about 600,000 dementia cases was used to study the prevalence; a 2.5% sample was the basis for the incidence study.</span></p> <p><br /><span style="font-size: 10pt;">The researchers found that between 2007 and 2009, the total number of people with dementia decreased significantly among German women age 74 to 85. Dementia prevalence in 2009 was 3.6% lower than in 2007 and 1.8% lower than in 2008. Over that period, new cases of dementia decreased significantly for both men and women.</span></p> <p><br /><span style="font-size: 10pt;">According to the researchers, over the last decade there was reduction in new cases of cerebrovascular disease in&nbsp;Germany&nbsp;and a &ldquo;better treatment of vascular risk factors such as high blood pressure, hypercholesterolemia, and diabetes mellitus.&rdquo; Among the elderly, increasing levels of education and wealth also were observed.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;This was the first study to explore dementia trends in&nbsp;Germany,&rdquo; says Doblhammer. &ldquo;The ageing of the babyboomers and the increasing life expectancy will lead to more dementia cases in old age. It is necessary to explore the modifiable risk factors of dementia in order to prevent the occurrence of the disease. In addition, more research is needed whether the increasing obesity epidemic and related diseases, such as the metabolic syndrome, may counterbalance the positive trends we are observing today,&rdquo; the researchers add.</span></p></div> C2N expands partnership with Washington University School of Medicine http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/c2n-expands-partnership-with-washington-university-school-of-medicine 2014-07-15T15:11:00Z 2014-07-15T15:11:00Z <div id="ImageMain49" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/c2n-expands-partnership-with-washington-university-school-of-medicine"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/blood_tests_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction49" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>C<sub>2</sub>N Diagnostics has announced that it has expanded its partnership with Washington University School of Medicine (WUSM) in St Louis, USA. The objective of this collaboration is to commercialise a clinical blood test for detecting the earliest stages of Alzheimer&rsquo;s disease as well as mild cognitive impairment. Under terms of the agreement, C<sub>2</sub>N has acquired the exclusive worldwide commercial license rights to a suite of technologies developed in the laboratories of professors Randall Bateman and David Holtzman in the Department of Neurology at WUSM.</strong></span></p> </div><div id="Text149" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The licensed technologies build upon the Stable Isotope Labelling Kinetics (SILK) platform pioneered at WUSM and already marketed by C<sub>2</sub>N. The new technologies enable a novel approach to measure the metabolism of brain-derived proteins implicated in Alzheimer&rsquo;s disease and mild cognitive impairment. For the first time, instead of analysing Alzheimer&rsquo;s disease proteins in cerebrospinal fluid, it is now possible to detect the same metabolic markers in patients&rsquo; blood samples.</span></p> <p><br /><span style="font-size: 10pt;">This capability has implications for the advancement of new treatments, early prevention, and personal wellness. Alzheimer&rsquo;s is now one of the major global healthcare concerns. Approximately 44 million people currently have clinical Alzheimer&rsquo;s disease. Millions more have mild cognitive impairment that places them at high risk for progression to clinical Alzheimer&rsquo;s disease. The number of cases of Alzheimer&rsquo;s disease and mild cognitive impairment are expected to increase sharply in the years ahead due to the aging baby boomer population.</span></p> <p><br /><span style="font-size: 10pt;">Pharmaceutical companies developing new drugs targeting Alzheimer&rsquo;s disease increasingly recognise that early intervention provides the greatest chance of halting or reversing disease progression. Biomarkers are needed to detect this early pathology, which can begin at least 15 years before the onset of any clinical symptoms. At the same time, dynamic biomarkers, like those offered by the SILK platform, may also track treatment responses during the pre-symptomatic stages of disease.</span></p> <p><br /><span style="font-size: 10pt;">Since 2008, C<sub>2</sub>N has applied the SILK-A&beta;&nbsp;test to measure the kinetics of beta-amyloid in cerebrospinal fluid. The test has served as a primary endpoint in clinical drug studies to demonstrate target engagement and guide dose selection. The SILK-A&beta;&nbsp;isoforms test is also highly sensitive to identifying people with brain amyloidosis (one of the earliest indicators of Alzheimer&rsquo;s disease), even before amyloid deposits are seen with brain imaging. Still, the more invasive nature of cerebrospinal fluid sampling has impeded the full potential of the SILK-A&beta;&nbsp;method.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;With a simplified SILK-A&beta;&nbsp;test available through blood sampling, we now have an opportunity to validate a unique therapeutic and diagnostic marker,&rdquo; states Joel B Braunstein, chief executive officer of C<sub>2</sub>N. &ldquo;We plan to achieve this validation by collaborating with pharmaceutical companies that are testing their compounds in phase 2 and phase 3 clinical studies, as well as by participating in natural history studies tracking the progression of Alzheimer&rsquo;s disease. If successful, we expect to be able to offer a reliable and informative screening test that is also convenient for patients.&rdquo;</span></p></div> St Jude Medical announces definitive agreement to acquire NeuroTherm http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/st-jude-medical-announces-definitive-agreement-to-acquire-neurotherm 2014-07-14T16:48:00Z 2014-07-14T16:48:00Z <div id="Introduction50" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>St Jude Medical has announced that it has signed a definitive agreement to acquire privately held&nbsp;NeuroTherm, a manufacturer of interventional pain management therapies, for approximately&nbsp;US$200 million&nbsp;in cash.</strong></span></p> </div><div id="Text150" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">NeuroTherm is a global leader in the treatment of spinal pain using radiofrequency ablation (RFA), a segment of the chronic pain market in which&nbsp;St Jude Medical does not currently participate. The company expects to complete this transaction by the end of the third quarter, subject to customary closing conditions. NeuroTherm is expected to add approximately&nbsp;US$10 million to US$15 million&nbsp;to St Jude Medical&rsquo;s 2014 sales. Excluding acquisition-related expenses, this transaction will be neutral to St Jude Medical&rsquo;s consolidated earnings per share in 2014 and accretive thereafter on a GAAP basis.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;NeuroTherm&rsquo;s radiofrequency ablation products are an ideal complement to St Jude Medical&rsquo;s chronic pain portfolio, providing our global sales force with additional interventional pain therapies that offer potential relief to patients earlier in the chronic pain continuum,&rdquo; says&nbsp;Michael T Rousseau, chief operating officer of&nbsp;St Jude Medical. &ldquo;As the only medical device manufacturer with both RFA and spinal cord stimulation, this acquisition will enable us to offer more treatment options to patients worldwide who suffer from the debilitating effects of chronic pain.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />NeuroTherm&rsquo;s flagship technology is a multi-lesion radiofrequency generator that allows real-time temperature monitoring and enables continuous delivery of energy to each site designed to ensure complete treatment of each targeted spinal nerve. The company&rsquo;s products are available in over 65 countries.</span></p> <p><br /><span style="font-size: 10pt;">Christopher R von Jako, president and chief executive officer of NeuroTherm says, &ldquo;St Jude Medical&rsquo;s global leadership in chronic pain represents an excellent opportunity to bring NeuroTherm&rsquo;s radiofrequency ablation technologies to more pain specialists and patients. We are proud of the business that NeuroTherm has built and thank our employees and shareholders for their commitment to developing innovative interventional pain management therapies. We see a promising future with&nbsp;St Jude Medical&nbsp;that combines our products with a leading pain franchise and further develops the underpenetrated global market for chronic pain.&rdquo;</span></p></div> Looking back on 40 years of the Glasgow Coma Scale http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/looking-back-on-40-years-of-the-glasgow-coma-scale 2014-07-14T15:58:00Z 2014-07-14T15:58:00Z <div id="ImageMain51" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/looking-back-on-40-years-of-the-glasgow-coma-scale"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Graham_Teasdale_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction51" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A group of leading brain injury specialists look back on 40 years of the Glasgow Coma Scale and outline the continuing role of the scale in research and clinical practice, in a new <a href="http://press.thelancet.com/glasgowcomascale.pdf" target="_blank">Personal View</a> published in <em><a href="http://www.thelancet.com/journals/laneur/issue/current" target="_blank">The Lancet Neurology</a>.</em>&nbsp;&nbsp;&nbsp;</strong></span></p> </div><div id="Text151" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The Personal View is published on the 40<sup>th</sup> anniversary of the Glasgow Coma Scale&rsquo;s introduction in a 1974 <em>Lancet</em> article.&nbsp;Since this seminal publication, the Glasgow Coma Scale has provided a practical method for bedside assessment of impairment of conscious level, the clinical hallmark of acute brain injury. The scale was designed to be easy to use in clinical practice in general and specialist units and to replace previous ill-defined and inconsistent methods. Forty years later, the Glasgow Coma Scale has become an integral part of clinical practice and research worldwide.</span></p> <p><br /><span style="font-size: 10pt;">The paper&rsquo;s lead author is Professor Graham Teasdale, of the University of Glasgow, UK, one of the authors of the original paper introducing the scale.&nbsp;Teasdale and colleagues examine the extent to which the original aspirations of the authors have been fulfilled, address some myths and misapprehensions about the scale, examine criticisms, and outline the continuing role of the scale in research and clinical practice.</span></p> <p><span style="font-size: 10pt;">A <em>Lancet Neurology </em>podcast interview with Professor Teasdale is available <a href="http://download.thelancet.com/flatcontentassets/audio/laneur/2014/laneur_august.mp3" target="_blank"><span style="color: #800000;"><strong>here</strong></span></a>.</span></p></div> Potential Alzheimer’s disease risk factors and risk reduction strategies become clearer http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/potential-alzheimers-disease-risk-factors-and-risk-reduction-strategies-become-clearer 2014-07-14T10:48:00Z 2014-07-14T10:48:00Z <div id="Introduction52" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Participation in activities that promote mental activity, and moderate physical activity in middle age, may help protect against the development of Alzheimer&rsquo;s disease and dementia in later life, according to new research reported at the Alzheimer&rsquo;s Association International Conference&nbsp;2014 (AAIC&nbsp;2014) in&nbsp;Copenhagen, Denmark.</strong></span></p> </div><div id="Text152" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Research reported at AAIC 2014 also showed that sleep problems &ndash; especially when combined with post-traumatic stress disorder (PTSD) &ndash; may increase dementia risk in veterans. Additionally, in a population of people age 90 and older, high blood pressure was seen to help protect against cognitive decline. This is counter intuitive as heart health risk factors, including hypertension, are generally considered to elevate risk of Alzheimer&rsquo;s and other dementias.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Determining more specifically the factors that raise and lower risk of Alzheimer&rsquo;s disease and other dementias is an essential component in our battle against the Alzheimer&rsquo;s epidemic,&rdquo; says&nbsp;Heather Snyder, Alzheimer&rsquo;s Association director of Medical and Scientific Operations. &ldquo;We are now getting a more clear idea of the opportunities for risk reduction through behaviour changes and other health factors. We are learning that Alzheimer&rsquo;s risk and protective factors may change over the course of our lives.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;These studies from AAIC 2014 underscore the need to fund larger, longer-term studies in different and diverse populations to enable us to develop helpful &rsquo;prescriptions&rsquo; for lifestyle change &ndash; for example, which foods to eat and avoid, how much physical activity and what types &ndash; and to learn more specifically about how Alzheimer&rsquo;s and dementia risk factors change as we age,&rdquo; Snyder adds.</span><br /><br /></p> <p><span style="font-size: 10pt;"><strong>Cognitively stimulating activities are associated with greater brain volumes and higher cognitive test scores</strong></span></p> <p><br /><span style="font-size: 10pt;">Prior studies have suggested that participation in activities that stimulate thought, new ideas, new memories, and that challenge us mentally may encourage brain health as we age and possibly reduce risk of cognitive impairment and dementia. The mechanisms underlying this possible effect are not currently well understood.</span></p> <p><br /><span style="font-size: 10pt;">At AAIC 2014,&nbsp;Stephanie Schultz, and colleagues at the Wisconsin Alzheimer&rsquo;s Institute and the Wisconsin Alzheimer&rsquo;s Disease Research Center reported on the results of a study of 329 cognitively normal middle-aged adults (mean age=60.3 years, 69% women) enrolled in the Wisconsin Registry for Alzheimer&rsquo;s Prevention. Forty per cent of the participants were positive for the APOe4 gene and 74% had a parental family history of Alzheimer&rsquo;s, both of which are known to increase the risk for developing Alzheimer&rsquo;s.</span></p> <p><br /><span style="font-size: 10pt;">These at-risk adults reported their current engagement in cognitively-stimulating activities using the Cognitive Activity Scale (CAS), underwent MRI brain imaging, and completed a comprehensive battery of neurocognitive tests. The CAS consists of 10 items that ask individuals how often they participate in various cognitive activities, such as reading books and going to museums. The scientists focused on CAS-Games, which is a single item on the scale that asks participants how often they play games such as cards, checkers, crosswords or other puzzles.</span></p> <p><br /><span style="font-size: 10pt;">After controlling for factors known to influence brain volume and cognitive test scores, such as age and gender, the researchers found that a higher self-reported frequency of game playing was significantly associated with greater brain volume in several regions involved in Alzheimer&rsquo;s disease (such as the hippocampus) and with higher cognitive test scores on memory and executive function.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Our findings suggest that, for some individuals, engagement in cognitively stimulating activities, especially those involving games such as puzzles and cards, might be a useful approach for preserving brain structures and cognitive functions that are vulnerable to Alzheimer&rsquo;s disease,&rdquo; says Schultz. &ldquo;More detailed studies of specific cognitive activities, including games, would help further our understanding of how an active, healthy lifestyle may help delay the development of Alzheimer&rsquo;s.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />Moderate exercise in middle age is associated with decreased risk of dementia</strong></span></p> <p><br /><span style="font-size: 10pt;">Of the growing body of research concerning lifestyle and brain health, and also the possibility of reduced risk of Alzheimer&rsquo;s and other dementias, perhaps the strongest and most consistent evidence exists for regular physical activity.</span></p> <p><br /><span style="font-size: 10pt;">Yonas E Geda, and colleagues at the Mayo Clinic investigated the relationship between timing of exercise (mid-life/50-65 vs late-life/70 and above) and risk of new cases of dementia in 280 older adults (median age=81) with mild cognitive impairment from the Mayo Clinic Study of Aging, and reported on their findings at AAIC 2014.</span></p> <p><br /><span style="font-size: 10pt;">A person with mild cognitive impairment has a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills. These changes are serious enough to be noticed by the individuals experiencing them or to other people, but they are not severe enough to interfere with daily life or independent function. People with mild cognitive impairment are at an increased risk of developing Alzheimer&rsquo;s disease.</span></p> <p><br /><span style="font-size: 10pt;">Study participants completed a questionnaire on the frequency and intensity of exercise during their lifetime. After following the participants for about three years, the researchers found that a history of moderate physical exercise in middle age was associated with a significantly decreased risk of mild cognitive impairment progressing to dementia. (The association did not hold for either light or vigorous exercise in middle age, or for any level of physical activity in late life.)</span></p> <p><br /><span style="font-size: 10pt;">In a second study reported at AAIC, the researchers looked at the timing of physical exercise and the risk of new cases of mild cognitive impairment. The study participants were 1,830 older adults with normal cognition from the Mayo Clinic Study of Aging. Participants underwent neurological evaluations, cognitive tests, and a self-reported questionnaire about physical exercise habits in mid-life and late-life, and were followed for an average of 3.2 years. The scientists observed that light physical exercise in mid-life and late-life were associated with decreased risk of incident mild cognitive impairment. Additionally, vigorous mid-life as well as moderate late-life physical exercise were associated with decreased risk of incident mild cognitive impairment.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;In our studies, we found that physical exercise at various levels, especially in mid-life, is beneficial for cognitive function,&rdquo; Geda says. &ldquo;These are intriguing results, but they are not yet conclusive. More research is needed to determine the extent and nature of physical activity in protecting against MCI and dementia.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />Poor sleep is associated with higher dementia risk in veterans; PTSD more than doubles that risk</strong></span></p> <p><br /><span style="font-size: 10pt;">It is known that sleep disturbance is a risk factor for cognitive decline and dementia, but this association has not been carefully investigated in older veterans. At AAIC 2014,&nbsp;Kristine Yaffe of the&nbsp;University of California, San Francisco&nbsp;and colleagues reported on the results of a retrospective study of sleep disturbance and dementia among 200,000 veterans age 55 and older, 96.5% of whom were male.</span></p> <p><br /><span style="font-size: 10pt;">The researchers examined eight years of the veterans&rsquo; medical records. After controlling for variables such as gender, income, education, and health status, they found that veterans who had a diagnosis of non-specific sleep disturbance, apnoea, or insomnia at baseline had a 30% increased risk of dementia compared with veterans with no diagnosed sleep problems. They also found that veterans with both PTSD and sleep disturbance had an 80% increased risk of dementia.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;This is the first investigation into the link between sleep disturbance and dementia in a large cohort of older, mostly male veterans,&rdquo; says Yaffe. &ldquo;Further research is needed to clarify the role of sleep disturbance as either a risk factor for, or an early symptom of, dementia among veterans, and in other populations as well.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />In people 90 and older, late onset hypertension may protect against dementia</strong></span></p> <p><br /><span style="font-size: 10pt;">While hypertension during midlife is considered to increase risk for Alzheimer&rsquo;s and other dementia, there is emerging research evidence suggesting that its role in dementia risk may change over time, and may instead help protect against dementia in people age 90 and over, known as the &ldquo;oldest old.&rdquo;&nbsp;Maria Corrada of the&nbsp;University of California, Irvine&nbsp;and colleagues investigated the relationship between risk of dementia, age of the onset of hypertension, and blood pressure measurements in the oldest old, and reported the results at AAIC 2014.</span></p> <p><br /><span style="font-size: 10pt;">The researchers followed 625 participants every six months for up to ten years in The 90+ Study, an ongoing longitudinal study of people age 90 and older. At enrolment, participants did not have dementia and were 93 years old on average; 69% were female. The researchers found that participants with a hypertension onset age of 80 to 89 years had a significantly lower risk of developing dementia compared with participants with no history of hypertension. Participants with onset at age 90 or older had an even lower dementia risk.</span></p> <p><br /><span style="font-size: 10pt;">The investigators also found that people with blood pressure levels in the hypertensive range had a significantly lower risk of developing dementia compared to people with blood pressure in the normal range.&nbsp; The association was independent of whether participants were taking medications that treat hypertension.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;In our study, high blood pressure is not a risk factor for dementia in the oldest old, but just the opposite,&rdquo; says Corrada. &ldquo;Developing hypertension at older ages may be beneficial for maintaining intact cognition through mechanisms related to cerebral perfusion or to vascular or other pathologies. It is important to understand these mechanisms, because recommendations for healthy blood pressure in the oldest old may turn out to differ from those in younger people.&rdquo;</span></p></div> Cataract surgery improves not only vision but cognition and quality of life in dementia patients http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/cataract-surgery-improves-not-only-vision-but-cognition-and-quality-of-life-in-dementia-patients 2014-07-14T10:25:00Z 2014-07-14T10:25:00Z <div id="Introduction53" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Cataract surgery for people with Alzheimer&rsquo;s disease and other dementias not only improves vision but can slow decline in cognition and improve quality of life for both people with the disease and their caregivers, according to clinical trial results reported at the Alzheimer&rsquo;s Association International Conference&nbsp;2014 (AAIC) in&nbsp;Copenhagen, Denmark.</strong></span></p> </div><div id="Text153" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;This study supports the Alzheimer&rsquo;s Association view that people with dementia retain, and benefit from, full healthcare treatment,&rdquo; says&nbsp;Maria Carrillo, Alzheimer&rsquo;s Association vice president of Medical and Scientific Relations. &ldquo;Too common attitudes such as, &lsquo;There&rsquo;s no need for extra care&rsquo; or &lsquo;Why put them through all of that&rsquo; are not justified and are bad medical practice.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Appropriate thoughtfulness and restraint are necessary when considering surgery or other procedures for people with Alzheimer&rsquo;s or another dementia. However, we should not assume that medical procedures cannot be pursued or are too risky. As these new results show, improving sensory abilities, for example, can provide benefits in a variety of ways &ndash; for people with Alzheimer&rsquo;s and also for their caregivers from whom unnecessary burden can be lifted,&rdquo; Carrillo says.</span></p> <p><br /><span style="font-size: 10pt;">At AAIC 2014,&nbsp;Alan J Lerner, of&nbsp;Case Western Reserve University&nbsp;and University Hospitals Case Medical Center, and colleagues reported interim results from an ongoing clinical trial to determine the effects of cataract removal on several measures of visual ability, cognitive measures, and quality of life in people with dementia. Study participants are recruited from dementia and ophthalmology clinics at University Hospitals Case Medical Center and MetroHealth Medical Center in&nbsp;Cleveland, Ohio, USA, and are divided into two groups: (1) immediate surgery following recruitment and (2) delayed or refused surgery. Vision and cognitive status, mood, and capability to complete daily activities are evaluated at baseline and six months after recruitment, or six months after surgery.</span></p> <p><br /><span style="font-size: 10pt;">Preliminary analysis of results from 20 surgical and eight non-surgical participants showed that the surgical group had significantly improved visual acuity and quality of life, reduced decline in memory and executive functioning, and improvements in behavioural measures compared with the non-surgical group. Levels of perceived burden for caregivers of people in the surgical group also showed improvement.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;These preliminary results indicate that improved vision can have a variety of benefits for people with dementia and their loved ones, both visual and non-visual,&rdquo; says Lerner. &ldquo;Our findings need to be verified in a larger study, but they suggest the need to aggressively address dementia co-morbidities such as vision-impairing cataracts, while balancing safety and medical risks.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;If the results hold up, it will significantly affect how we treat cataracts in individuals with dementia. Other interventions to offset sensory loss &ndash; including vision and hearing &ndash; may help improve quality of life for people with dementia and their caregivers,&rdquo; Lerner adds.</span></p></div> New data shows combination therapy is more effective than monotherapy in removing beta-amyloid plaques from the brains of mice http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-data-shows-combination-therapy-is-more-effective-than-monotherapy-in-removing-beta-amyloid-plaques-from-the-brains-of-mice 2014-07-14T09:59:00Z 2014-07-14T09:59:00Z <div id="Introduction54" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Eli Lilly and Company has announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data results found that combination therapy was more effective in removing clumps of amyloid-beta protein in the brain &ndash; a component that is thought to lead to Alzheimer&rsquo;s disease &ndash; than use of one therapy. These data were presented at the Alzheimer&rsquo;s Association International Conference 2014 (AAIC 2014) in&nbsp;Copenhagen, Denmark&nbsp;by&nbsp;Ron DeMattos, research fellow in the Neuroscience Division at Eli Lilly and Company.&nbsp;</strong></span></p> </div><div id="Text154" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;This non-clinical study demonstrates that by simultaneously targeting two different steps in the beta-amyloid disease process, researchers can slow the progression of Alzheimer&rsquo;s disease pathology in genetically engineered mice,&rdquo; says DeMattos. &ldquo;These results may have a significant impact on the future of Alzheimer&rsquo;s disease therapies as they support the clinical rationale for using future testing of combination therapy against the a-beta protein in the clinical practice.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Alzheimer&rsquo;s disease, the most common form of dementia, causes progressive decline in memory and other aspects of cognition. A number of new investigational mechanisms for the treatment of Alzheimer&rsquo;s disease are currently in development. One type of investigational mechanism, called beta-secretase inhibitors, aims to block the body&rsquo;s ability to produce beta-amyloid protein, a possible component that leads to Alzheimer&rsquo;s disease. The other type of investigational drug is called a beta-amyloid antibody, which targets the removal of the beta-amyloid protein. </span><span style="font-size: 10pt;">Compounds that are thought to work through these mechanisms have been studied in clinical trials on their own; however, most of the trials have not shown significant treatment effects. Therefore, many believe that multiple steps of the beta-amyloid deposition process need to be simultaneously targeted in order to remove significant quantities of the beta-amyloid pathology.</span></p> <p><br /><span style="font-size: 10pt;">The non-clinical study results showed that when used on their own (as monotherapies), the beta-secretase inhibitor and the N3pG beta-amyloid antibody removed approximately 50% of the clumps of amyloid-beta protein, whereas the combination therapy resulted in an even more substantial 86% removal. Additionally, combination therapy significantly lowered deposited A&beta;1-42 75 percent relative to the time zero controls. Histological analyses indicated that the BACE inhibitor monotherapy resulted in removal of diffuse deposits of beta-amyloid, the antibody monotherapy resulted in removal of cored plaques, and the combination therapy removed both the diffuse deposits and cored plaques. Multiple different types of biochemical analyses confirmed that the combination treatment was superior to the monotherapy treatments.&nbsp;</span></p> <p><span style="font-size: 10pt;"><strong><br />Study Methods<br /> <br /></strong>Aged PDAPP transgenic mice (17-19 months) were randomised into the following five cohorts: 1) time zero control, 2) large and small molecule compound controls, 3) plaque-specific A&beta; antibody (anti-A&beta;p3-x), 4) BACE inhibitor, and 5) A&beta; antibody + BACE inhibitor. The aged mice were treated for four months with either a beta-secretase inhibitor or the N3pG beta-amyloid antibody, or the combination of the two drugs. Effectiveness of the treatments was determined by measuring the amount of beta-amyloid protein remaining in the brains of the mice.</span></p></div> Post-concussion ‘return to play’ decision for footballers should be made solely by doctors, says new editorial http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/post-concussion-return-to-play-decision-for-footballers-should-be-made-solely-by-doctors-says-new-editorial 2014-07-14T09:47:00Z 2014-07-14T09:47:00Z <div id="Introduction55" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>An editorial published in <em><a href="http://www.thelancet.com/journals/laneur/issue/current" target="_blank">The Lancet Neurology</a>&nbsp;</em>calls for sports authorities to take into consideration the long-term neurological problems that repeated concussions can cause.</strong></span></p> </div><div id="Text155" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Cerebral concussion is the most common form of sports-related traumatic brain injury, and the long-term effects of repeated concussions may include dementia, amyotrophic lateral sclerosis, and other neurological disorders, say the journal editors.</span></p> <p><br /><span style="font-size: 10pt;">However, what is perhaps more concerning, is that even when the symptoms of concussion are delayed, or if they come and go quickly, neurological damage can remain without detection. This can lead to footballers, such as Uruguayan defender &Aacute;lvaro Pereira during the 2014 FIFA World Cup, overruling doctors&rsquo; advice to be substituted and returning to play after sustaining a head injury.</span></p> <p><br /><span style="font-size: 10pt;">The journal editors argue that the decision for players to return to a game after sustaining a concussion should be made only by healthcare professionals, and &ldquo;should surely be taken out of the hands of those with a vested interest in the player&rsquo;s performance.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">According to the journal editors, &ldquo;Many sporting organisations now acknowledge the potentially serious consequences of mild traumatic brain injury and have drawn up new protocols to protect athletes who sustain a head injury. However FIFPro, the world players&rsquo; union, has called for an investigation of concussion protocols and return-to-play standards following Pereira&rsquo;s injury.&rdquo;</span></p></div> Cinnamon may be used to halt the progression of Parkinson’s disease http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/cinnamon-may-be-used-to-halt-the-progression-of-parkinsons-disease 2014-07-11T16:50:00Z 2014-07-11T16:50:00Z <div id="Introduction56" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Neurological scientists at Rush University Medical Center have found that using cinnamon, a common food spice and flavouring material, can reverse the biomechanical, cellular and anatomical changes that occur in the brains of mice with Parkinson&rsquo;s disease. The results of the study were recently published in the June 20 issue of the&nbsp;<a href="http://www.springer.com/biomed/neuroscience/journal/11481" target="_blank"><em>Journal of Neuroimmune Pharmacology</em></a>.</strong></span></p> </div><div id="Text156" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Cinnamon has been used widely as a spice throughout the world for centuries,&rdquo; says Kalipada Pahan, study lead researcher and the Floyd A Davis professor of neurology at Rush. &ldquo;This could potentially be one of the safest approaches to halt disease progression in Parkinson&rsquo;s patients.&rdquo;</span></p> <p><span style="font-size: 10pt;">&ldquo;Cinnamon is metabolised in the liver to sodium benzoate, which is an FDA-approved drug used in the treatment for hepatic metabolic defects associated with hyperammonemia,&rdquo; says Pahan. It is also widely used as a food preservative due to its microbiocidal effect.</span></p> <p><br /><span style="font-size: 10pt;">Chinese cinnamon (Cinnamonum cassia) and original Ceylon cinnamon (Cinnamonum verum) are two major types of cinnamon that are available in the USA.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Although both types of cinnamon are metabolised into sodium benzoate, by mass spectrometric analysis, we have seen that Ceylon cinnamon is much more pure than Chinese cinnamon as the latter contains coumarin, a hepatotoxic molecule,&rdquo; says Pahan.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Parkinson&rsquo;s disease,&rdquo; says Pahan. &ldquo;It is known that some important proteins like Parkin and DJ-1 decrease in the brain of Parkinson&rsquo;s disease patients.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />The study found that after oral feeding, ground cinnamon is metabolised into sodium benzoate, which then enters into the brain, stops the loss of Parkin and DJ-1, protects neurons, normalises neurotransmitter levels, and improves motor functions in mice with Parkinson&rsquo;s disease.</span></p> <p><br /><span style="font-size: 10pt;">This research was supported by grants from National Institutes of Health.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Now we need to translate this finding to the clinic and test ground cinnamon in patients with Parkinson&rsquo;s disease. If these results are replicated in Parkinson&rsquo;s disease patients, it would be a remarkable advance in the treatment of this devastating neurodegenerative disease,&rdquo; says Pahan.</span></p></div> Northwestern Medicine enrols first participant in study of device to treat brain aneurysms http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/northwestern-medicine-enrols-first-participant-in-study-of-device-to-treat-brain-aneurysms 2014-07-11T16:22:00Z 2014-07-11T16:22:00Z <div id="ImageMain57" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/northwestern-medicine-enrols-first-participant-in-study-of-device-to-treat-brain-aneurysms"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/010/Bernard--R-Bendok.jpg" border="0" vspace="5" /></a></div><div id="Introduction57" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Northwestern Medicine&nbsp;is participating in a multicentre US clinical trial to evaluate the safety and effectiveness of the Microvention FRED flow diversion system (Flow Re-Direction Endoluminal Device) for the treatment of wide-necked intracranial aneurysms.&nbsp;The trial involves inserting a&nbsp;small, metallic mesh tube via a micro-catheter into the blood vessel across the entrance to the aneurysm. The device contains the flow of blood within the tube to keep it away from the aneurysm. This causes the aneurysm to clot and minimises the chance of rupture.</strong></span></p> </div><div id="Text157" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Bernard R Bendok, a neurological surgeon at Northwestern Memorial, performed&nbsp;the first surgery on 12 March. The patient was released from the hospital three days later and continues to recover.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Historically, large aneurysms are particularly difficult to treat,&rdquo; says Bendok, who is also a professor of neurological surgery, radiology and otolaryngology at&nbsp;Northwestern University Feinberg School of Medicine.&nbsp;&ldquo;This new device system may offer additional benefits over first generation flow diversion devices because it can be partially deployed, retrieved and accurately repositioned or redeployed to ensure the most precise placement.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The results of this national trial could change the way large aneurysms are treated in a way that is a huge benefit to the patient,&rdquo; Bendok adds. &ldquo;Not only is this safer, it is less invasive, which drastically cuts recovery time. We&nbsp;are thrilled to offer participation in this study to our patients.&rdquo;</span></p></div> NIH funds phase II trial for treatment of ADHD with Monarch eTNS system http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/nih-funds-phase-ii-trial-for-treatment-of-adhd-with-monarch-etns-system 2014-07-11T16:08:00Z 2014-07-11T16:08:00Z <div id="Introduction58" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>NeuroSigma has announced that the US National Institutes of Health (NIH) has awarded&nbsp;UCLA&nbsp;a grant that funds a phase II 90-subject paediatric clinical trial at the&nbsp;University of California, Los Angeles&nbsp;(UCLA) focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma&rsquo;s Monarch external trigeminal nerve stimulation (eTNS) system.</strong></span></p> </div><div id="Text158" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">James McGough, professor of Psychiatry and Biobehavioral Sciences at&nbsp;UCLA, will lead the study as principal investigator, with&nbsp;Sandra Loo, associate professor, as co-principal investigator. Their earlier phase I trial of eTNS for the treatment of ADHD, funded by NeuroSigma, found significant improvements in the severity of ADHD symptoms with eight weeks of nightly eTNS therapy.&nbsp;This phase II clinical trial will evaluate eTNS as monotherapy, under double-blind conditions, in up to 90 children, ages eight to 12, in a four week randomised clinical trial conducted at UCLA.&nbsp;NeuroSigma will provide eTNS systems to&nbsp;UCLA&nbsp;in support of the trial.&nbsp;Neither McGough nor Loo has any affiliation with NeuroSigma.</span></p> <p><span style="font-size: 10pt;"><br />ADHD usually arises in childhood.&nbsp;The US Center for Disease Control and Prevention (CDC) has reported national survey findings that approximately 11% of children ages four to 17 have been diagnosed with the disorder, and that about one in five high school boys will receive this diagnosis during childhood.&nbsp;Symptoms include difficulty paying attention in school, at play, or in the home, a reluctance to take on tasks that require sustained mental effort, being easily distracted, exhibiting physical hyperactivity, and engaging in impulsive behaviours.&nbsp;These symptoms may interfere with social, school, or work functioning.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;I am very pleased that the NIH has funded this extremely important phase II clinical trial in ADHD.&nbsp;Millions of parents seek alternatives to drug treatment for their children with ADHD that are safe and non-invasive,&rdquo; says Leon Ekchian, NeuroSigma&rsquo;s president and chief executive officer.&nbsp;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;McGough and Loo are to be congratulated for receiving this grant, particularly at a time when the NIH budget is under pressure to fund only the most promising lines of investigation. NIH awards represent one of the most stringent forms of peer review in biomedical science,&rdquo; notes&nbsp;Ian Cook, NeuroSigma&rsquo;s chief medical officer and senior vice president.&nbsp;&ldquo;Besides showing safety of eTNS in children, their phase I study found a significant impact on the clinical symptoms of ADHD, and substantial improvements on sleep as well as several objective computer-based measures of cognitive performance.&nbsp;We look forward to confirming these results in this phase II clinical trial under double-blind controlled conditions. A neuromodulation treatment option for ADHD could avoid concerns about the exposure of children to the psychostimulant medications that are the current first-line treatments.&rdquo;&nbsp;</span></p></div> New US patent for Barrel vascular reconstruction device http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-us-patent-for-barrel-vascular-reconstruction-device 2014-07-11T15:32:00Z 2014-07-11T15:32:00Z <div id="Introduction59" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Reverse Medical Corporation has announced that the United States Patent Office has notified the company that a new patent has issued entitled &ldquo;Protuberant Aneurysm Bridging Device and Method of Use&rdquo;. This new patent grants six claims surrounding the use of the company&rsquo;s Barrel vascular reconstruction device technology platform.</strong></span></p> </div><div id="Text159" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The Reverse Medical Barrel vascular reconstruction device represents a proprietary technology designed specifically for treating complex intracranial bifurcation artery anatomy. The Barrel design is unique, essentially reducing the neck size of wide-neck bifurcation aneurysms, enabling traditional coil embolisation, a craft already mastered by the neuro interventionalist, while maintaining patency of all involved vasculature.</span></p> <p><br /><span style="font-size: 10pt;">Commenting on this new patent, Reverse Medical chief technology officer Brian Strauss says, &ldquo;This patent solidifies our intellectual property foundation of unique means for treating wide-neck bifurcation aneurysms, and along with our other issued patents and pending applications, provides us with broad protection for our innovative device portfolio for treating a variety of neuro and peripheral vascular conditions.&rdquo;</span></p></div> High stress, hostility, depression linked with increased stroke risk http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/high-stress-hostility-depression-linked-with-increased-stroke-risk 2014-07-11T09:50:00Z 2014-07-11T09:50:00Z <div id="ImageMain60" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/high-stress-hostility-depression-linked-with-increased-stroke-risk"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Clot_in_the_brain_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction60" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Higher levels of stress, hostility and depressive symptoms are associated with significantly increased risk of&nbsp;stroke&nbsp;or transient ischaemic attack in middle-age and older adults, according to new research in the American Heart Association journal&nbsp;<em><a href="http://stroke.ahajournals.org/" target="_blank">Stroke</a>.</em></strong></span></p> </div><div id="Text160" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">A transient ischaemic attack is a stroke caused by a temporary blockage of blood flow to the brain.</span></p> <p><br /><span style="font-size: 10pt;">Researchers investigated how psychological factors might influence risk for chronic disease, using data from the Multi-Ethnic Study of Atherosclerosis (MESA), an ongoing study on cardiovascular disease risk factors in participants living in six US cities.</span></p> <p><br /><span style="font-size: 10pt;">More than 6,700 adults (ages 45-84; 53% women) completed questionnaires assessing chronic stress, depressive symptoms, anger and hostility over two years. Participants were 38.5% white, 27.8% African-American, 11.8% Chinese and 21.9% Hispanic. All were free of cardiovascular disease at the start of the study.</span></p> <p><br /><span style="font-size: 10pt;">In follow-up for an additional 8.5 to 11 years, 147 strokes and 48 transient ischaemic attacks occurred.</span></p> <p><br /><span style="font-size: 10pt;">Compared to people with the lowest psychological scores, those with highest scores were:</span></p> <ul> <li><span style="font-size: 10pt;">86% more likely to have a stroke or transient ischaemic attack for high depressive symptoms.</span></li> <li><span style="font-size: 10pt;">59% more likely to have a stroke or transient ischaemic attack for the highest chronic stress scores.</span></li> <li><span style="font-size: 10pt;">More than twice as likely to have a stroke or transient ischaemic attack for the highest hostility scores.</span></li> </ul> <p><span style="font-size: 10pt;">No significant increased risk was linked to anger.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;There is such a focus on traditional risk factors &mdash; cholesterol levels, blood pressure, smoking and so forth &mdash; and those are all very important, but studies like this one show that psychological characteristics are equally important,&rdquo; says Susan Everson-Rose, study lead author and associate professor of medicine at the University of Minnesota in Minneapolis, USA.</span></p> <p><br /><span style="font-size: 10pt;">These associations noted in the study were significant even when researchers accounted for age, race, sex, health behaviours and other known risk factors of stroke.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Given our ageing population, it is important to consider these other factors that might play a role in disease risk. Stroke is a disease of the elderly predominantly, and so learning more about things that can influence risk for stroke as people age is important.&rdquo;</span></p> <p><span style="font-size: 10pt;">Researchers measured chronic stress in five domains: personal health problems, health problems of others close to the participant, job or ability to work, relationships and finances.</span></p> <p><br /><span style="font-size: 10pt;">They assessed depressive symptoms with a 20-question scale and analysed anger with a 10-item scale that captured the extent and frequency of experiencing that emotion. Hostility, which is a negative way of viewing the world, was measured by assessing a person&rsquo;s cynical expectations of other people&rsquo;s motives.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;One thing we did not assess is coping strategies,&rdquo; Everson-Rose says. &ldquo;If someone is experiencing depressive symptoms or feeling a lot of stress or hostility, we don&rsquo;t know how they manage those, so it&rsquo;s possible that positive coping strategies could ameliorate some of these associations or effects,&rdquo; she says. &ldquo;We did not inquire about coping. I would say that is one of the tasks for future studies.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Researchers did not identify potential racial and ethnic differences or sex differences in the observed associations, but were not able to fully examine such differences due to the smaller numbers of strokes in some groups.</span></p> <p><br /><span style="font-size: 10pt;">Co-authors are Nicholas Roetker; Pamela Lutsey; Kiarri Kershaw; W T Longstreth Jr; Ralph Sacco; Ana Diez Roux; Alvaro Alonso. Author disclosures are on the manuscript.</span></p> <p><br /><span style="font-size: 10pt;">The National Heart, Lung, and Blood Institute funded the study.</span></p></div> Less-invasive technique repairs life-threatening condition http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/less-invasive-technique-repairs-life-threatening-condition 2014-07-10T10:14:00Z 2014-07-10T10:14:00Z <div id="Introduction61" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A patient who underwent a less-invasive technique to repair an arteriovenous fistula was able to return to work just two weeks after surgery.</strong></span></p> </div><div id="Text161" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">What enabled the patient, Bill Abt to recover so quickly and painlessly was a less-invasive surgical technique performed by Loyola University Medical Center neurosurgeon William W Ashley, Jr.</span></p> <p><br /><span style="font-size: 10pt;">The less-invasive technique Ashley performed was an endovascular treatment. He inserted a catheter in an artery in the groin, then guided the catheter up past the heart and through the carotid artery into the brain. Once the catheter reached the fistula, Ashley injected a liquid polymer that immediately solidified. This effectively sealed off the fistula to prevent a possible rupture.</span></p> <p><br /><span style="font-size: 10pt;">The case began when Abt consulted a physician about tinnitus (chronic ringing in his ear). The physician ordered a scan, which detected the arteriovenous fistula.</span></p> <p><br /><span style="font-size: 10pt;">Normally, arteries and veins are separate, with arteries transporting high-pressure blood from the heart to the body&rsquo;s organs, and veins carrying low-pressure blood back to the heart. But in Abt&rsquo;s case, an artery in his brain was directly connected to a vein. Consequently, high-pressure blood was shooting into the vein -- like a fire hose connected to a garden hose. The thin-walled vein, not designed to withstand such pressure, ballooned outward and was at risk of rupturing. Blood leaking from such a rupture could have caused a debilitating or fatal stroke.</span></p> <p><br /><span style="font-size: 10pt;">Christopher Loftus, chair of the Department of Neurological Surgery presented the case to a multidisciplinary cerebrovascular conference. Loftus led the discussion as physicians carefully examined the risks and benefits of all options, including traditional open surgery, the less-invasive endovascular treatment or no treatment at all. Loftus decided to bring Ashley in on the case.</span></p> <p><br /><span style="font-size: 10pt;">Abt underwent the less-invasive endovascular treatment on a Friday. He went home the next day, and began working from home the following week. The second week, he returned to work as senior vice president for administration and business at Carthage College in Kenosha, USA.</span></p></div> Treating oxygen-deprived newborns with hypothermia improves survival without brain damage in later childhood http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/treating-oxygen-deprived-newborns-with-hypothermia-improves-survival-without-brain-damage-in-later-childhood 2014-07-10T09:34:00Z 2014-07-10T09:34:00Z <div id="ImageMain62" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/treating-oxygen-deprived-newborns-with-hypothermia-improves-survival-without-brain-damage-in-later-childhood"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/028/baby_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction62" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The cooling of newborn babies suffering from perinatal asphyxia &ndash; a lack of oxygen at the time of birth &ndash; significantly increases their chance of survival without brain damage to later childhood (age six to seven years), according to a Medical Research Council (MRC) funded clinical trial.</strong></span></p> </div><div id="Text162" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The study, published in the&nbsp;<a href="http://www.nejm.org/" target="_blank"><em>New England Journal of Medicine</em></a>, found that 51.7% of infants treated with hypothermia survived with an IQ of 85 or above, which is considered to be within the normal range, compared to 39.4% of those treated with standard care. Cooling significantly reduced the chance of oxygen-deprived children suffering from cerebral palsy and other moderate/severe disabilities. The children also showed improved motor functioning. However, the authors observed that there was no difference in mortality rate &ndash; reported to be around 30% of children enrolled in the trial &ndash; between the standard care and hypothermia-treated groups.</span></p> <p><span style="font-size: 10pt;"><br />The trial, led jointly by the National Perinatal Epidemiology Unit (NPEU) at the University of Oxford and Imperial College London, is the largest study of its kind and the first study to show improved brain function in children treated using this method in later life<strong>. </strong>Before this trial, there was limited information on the beneficial effect of cooling after asphyxia beyond the age of 18 months. This work is important because it demonstrates that the improvements observed in brain function are not just temporary.</span></p> <p><span style="font-size: 10pt;"><br />The <a href="https://www.npeu.ox.ac.uk/toby" target="_blank"><strong>MRC TOBY</strong></a> trial (Total body hypothermia) involved newborn babies of at least 36 weeks gestation that suffered from a lack of oxygen at birth. The children were randomly assigned into two groups within six hours of delivery, and either treated with standard care or standard care plus hypothermia, when their body temperature was reduced to 33.5˚C for 72 hours. After that time, they were slowly returned to a normal body temperature of 37˚C.</span></p> <p><span style="font-size: 10pt;"><br />The current research is part of the follow up <a href="https://www.npeu.ox.ac.uk/tobycs" target="_blank"><strong>TOBY Children Study</strong></a> that aimed to find out if there were any differences in the health of the children, treated with or without cooling, in later life. The scientists tested the children&rsquo;s mental abilities and performance at school, looked at parent and teacher reports on behaviour and investigated the presence and severity of any disabilities that resulted from oxygen deprivation.</span></p> <p><span style="font-size: 10pt;"><br />Following oxygen deprivation a number of processes are set off in the brain, which lead to brain cell death and permanent neurological damage. Hypothermia interrupts these processes to reduce brain injury and has consistently been shown to improve outcomes at 18 months. This study now confirms treatment with cooling is safe and effective, and that the benefits persist in the long term. The treatment has been endorsed by the National Institute for Health and Care Excellence (NICE) and adopted into clinical practice in the NHS; it has the advantage of being relatively simple and inexpensive to carry out.&nbsp;These new findings support its general use in neonatal clinical practice.</span></p> <p><span style="font-size: 10pt;"><br />Denis Azzopardi, of King&rsquo;s College London and lead author of the study, says: &ldquo;This study is important as it confirms improved brain function persisting into middle childhood with cooling treatment and it is a proof of the concept that treatment following oxygen deprivation at birth can be effective.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Brenda Strohm, research nurse and TOBY trial coordinator at the NPEU, University of Oxford, says: &ldquo;We are indebted to all the families who took part in the TOBY Trial and then the TOBY Children Study; their contribution to these two important studies has made a real difference to neonatal care.&rdquo;&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;While corresponding with the families over the years, I have shared many happy stories of achievement and success as well as moments of sadness and loss; this is a privilege which adds a special dimension to my role of study co-ordinator. Thanks to our latest research, now when a baby is treated with cooling, families can be more fully informed about what might lie ahead, not only in the coming months but in the next few years too.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Hugh Perry, chair of the MRC Neurosciences and Mental Health Board, says: &ldquo;This study is a great example of how research can change people&rsquo;s lives. Although major advances have been made in how childbirth is managed, approximately two out of every 1,000 newborn infants suffer from a lack of oxygen around the time of birth. Prior to the introduction of cooling therapy there were no approved, specific treatments that reduced the risk of brain injury long-term following asphyxia.<strong>&rdquo;</strong></span></p></div> Advances in trigeminal nerve stimulation featured at European congress on epileptology http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/advances-in-trigeminal-nerve-stimulation-featured-at-european-congress-on-epileptology 2014-07-09T14:49:00Z 2014-07-09T14:49:00Z <div id="Introduction63" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>NeuroSigma has announced top-line summaries of presentations made at the 11th European Congress on Epileptology in&nbsp;Stockholm, Sweden, related to the use of external trigeminal nerve stimulation (eTNS) in epilepsy.</strong></span></p> </div><div id="Text163" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Sean Slaght reported an update of observational findings in on-going adjunctive treatment with eTNS of adults at&nbsp;Kings College&nbsp;London, UK.&nbsp;In a group of 13 real-world, care-seeking patients with drug resistant epilepsy, who completed at least 12 weeks of nightly use of the Monarch eTNS system, they observed a median reduction in seizure frequency of 38%. The Kings College London researchers additionally reported on significant improvement in quality of life, mood, and sleep metrics.</span></p> <p><br /><span style="font-size: 10pt;">In the first-ever use of eTNS in paediatric patients with drug resistant epilepsy, Slaght reported preliminary findings on seven children, age 10 to 17, treated with this non-invasive, adjunctive therapy. Three children (43% of the group) reported a 50% or more reduction of their seizure frequency after 18 weeks.</span></p> <p><br /><span style="font-size: 10pt;">Observational findings were also presented by Jos&eacute; Serratosa, from the Fundaci&oacute;n Jim&eacute;nez D&iacute;az University Hospital,&nbsp;Madrid, Spain.&nbsp;In a group of eight adult patients treated with eTNS, 25% experienced a decrease in seizures of over 90%.</span></p> <p><br /><span style="font-size: 10pt;">Consistent with earlier phase I and II trials conducted in&nbsp;the United States, the European groups reported an absence of serious adverse events.</span></p> <p><span style="font-size: 10pt;"><br />Other investigators from Kings College London reported data on measures of cortical excitability in five adult drug resistant epilepsy patients undergoing eTNS treatment for 18 weeks. Brief magnetic pulses were used to assess cortical function before and after a course of treatment, in an effort to evaluate the mechanism of action of eTNS.&nbsp;&nbsp;Adam Pawley presented work conducted with Mark Richardson&nbsp;at Kings College London.&nbsp;Measures of cortical excitability consistently decreased with use of eTNS, implicating potential effects on signalling in both GABA<sub>A</sub>- and GABA<sub>B</sub>-mediated circuits. Other antiepileptic therapies have previously been shown to reduce measures of cortical excitability.</span></p> <p><br /><span style="font-size: 10pt;">Christianne Heck from the&nbsp;University of Southern California&nbsp;(USC),&nbsp;Los Angeles, chaired a satellite symposium, &ldquo;Trigeminal Nerve Stimulation (TNS): Neuromodulation for the 21st Century.&rdquo; This session introduced TNS to a large number of epileptologists attending the Congress and provided them with both background neurobiological data and clinical results.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The experience at these leading European epilepsy centres bears out the safety profile we have seen in the USA for eTNS, and provides confirmatory evidence of the effects of eTNS on seizures, mood, sleep, and quality of life,&rdquo; says&nbsp;Christopher DeGiorgio, NeuroSigma&rsquo;s vice president of Neurology and the professor of Neurology who first investigated eTNS for drug resistant epilepsy at the&nbsp;University of California, Los Angeles&nbsp;(UCLA).&nbsp;&ldquo;Millions of people living with epilepsy are still having seizures despite the best medication treatment available, often facing cognitive side effects from multiple antiepileptic drugs and the disease itself.&nbsp;eTNS may become an important tool to address this unmet medical need.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;While these studies were of modest size, the researchers conducting these independent effectiveness evaluations are in the vanguard in providing important data that complement the findings from controlled clinical trials. These findings provide us with confidence in the design of the pivotal trial in drug resistant epilepsy that we are preparing to commence. &nbsp;Further, the work with cortical excitability elucidates another biological mechanism by which eTNS may achieve its anticonvulsant effect, and builds on the data showing acute changes in regional brain activity observed with PET scanning at&nbsp;UCLA,&rdquo; adds&nbsp;Ian Cook, chief medical officer and senior vice president at NeuroSigma.&nbsp;</span></p> <p><br /><span style="font-size: 10pt;">NeuroSigma provided eTNS Systems to the investigators&rsquo; institutions, but was otherwise uninvolved in the conduct of the research at either Kings College London or the Fundaci&oacute;n Jim&eacute;nez D&iacute;az University Hospital.</span></p></div> Brainlab announces launch of Right.Brain Foundation http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/brainlab-announces-launch-of-rightbrain-foundation 2014-07-09T14:26:00Z 2014-07-09T14:26:00Z <div id="ImageMain64" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/brainlab-announces-launch-of-rightbrain-foundation"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Brainlab_Kick_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction64" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Brainlab has announced the launch of the Right.Brain Foundation, which will provide medical technology and education to selected hospitals and public institutions in Southeast Asia, Africa, Central and South America.</strong></span></p> </div><div id="Text164" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Countries were reviewed carefully and selected based on several criteria including: per capita income, reliable energy supply, adequately trained healthcare professionals; keeping in mind the distribution of wealth, political stability and safety of the country as well as where patients may be able to benefit the most from providing treatment.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;We understand and acknowledge the World Health Organisation&rsquo;s principles for a good medical equipment donation,&rdquo; says Stefan Vilsmeier, president and chief executive officer, Brainlab. &ldquo;The Right.Brain Foundation, which provides the equipment and trained personnel to the hospitals in need, also includes personnel training at the local hospital level. This helps further their education, provide hope for their country, and raise the bar in academic achievements for residents and studying physicians.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">The Right.Brain Foundation purpose, &ldquo;Together we provide medical technology to create opportunities for a better world,&rdquo; dovetails perfectly with the Brainlab vision to increase access to and consistency of treatment for patients everywhere. Brainlab is committed to supporting Right.Brain by providing on-point, frugal technologies that will make the most impact in the countries to be served. The technology that will be loaned to the hospitals is Kick Purely Navigation, a robust, reliable and minimalist image guided surgery system that is compact and can be easily shipped. Engineered with focused functionality, Kick is small but powerful and supports and advances neurosurgery efforts in developing countries.</span></p> <p><br /><span style="font-size: 10pt;">Right.Brain will partner with hospitals and physicians in North America and Europe, building an exchange programme to help teach the physicians in developing countries how to use the technology effectively. Furthermore, Brainlab employees will volunteer their vacation time to Right.Brain to provide additional on-site training and support to the local hospitals.</span></p> <p><br /><span style="font-size: 10pt;">Beyond time donations, Brainlab employees are also encouraged to give to Right.Brain via a variety of opportunities such as frequent flyer-mile donations, monetary donations at the Brainlab Open House on Friday, 11 July, 2014 in Feldkirchen, Germany and merchandise available at brainlab.com/rightbrain where 20% of the proceeds will be donated to the Right.Brain Foundation. In the near future, Brainlab will extend support opportunities to current business partners to further the mission of Right.Brain with additional technologies, training and education.</span></p> <p><br /><span style="font-size: 10pt;">The inaugural Right.Brain project will take place at the Calmette Hospital in Phnom Pehn, Cambodia. For this operation, Right.Brain will cooperate closely with La Cha&icirc;ne de l&rsquo;Espoire, a French foundation which is locally based and will ensure a smooth integration of Brainlab technology and help ensure the mission&rsquo;s success.</span></p> <p><br /><span style="font-size: 10pt;">This announcement is the culmination of a passionate idea long held by Brainlab Founder and chief executive officer, Stefan Vilsmeier and just the beginning of the company&rsquo;s social impact journey. This year, as the company celebrates 25 years of medical technology innovation, Brainlab expands its reach beyond the 80 countries currently served to include developing countries in need of the right medical technology to make a difference.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;This mission has been 25 years in the making; it extends beyond the walls of our corporate offices and the hospitals we traditionally serve.&rdquo; Vilsmeier adds. &ldquo;This project is unlike any other effort in which Brainlab has participated. Right.Brain will bring technology into underserved areas, connect experienced surgeons and staff with those in need of training and support and most importantly, help patients in need. In five years, we hope to have 80% of the countries using some type of surgical navigation and more patients benefiting from neurosurgical care.&rdquo;</span></p></div> InspireMD announces completion of CGuard CARENET trial http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/inspiremd-announces-completion-of-cguard-carenet-trial 2014-07-09T10:13:00Z 2014-07-09T10:13:00Z <div id="ImageMain65" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/inspiremd-announces-completion-of-cguard-carenet-trial"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/CGuard_carotid_embolic_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction65" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>InspireMD has announced that it has concluded enrolment in its CARENET (Carotid embolic protection study using MicroNet) clinical trial. The multi-specialty trial is assessing the peri-procedural safety and efficacy of CGuard systems in the treatment of carotid lesions. The acute procedural performance of the CGuard device was 100% successful for all of the 30 patients enrolled in the trial.</strong></span></p> </div><div id="Text165" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Thirty patients were enrolled at four sites across Europe and will be followed up using traditional assessments post-procedure and at 30 days to include MACE (death, stroke, MI), and ipsilateral stroke (31 days to one year).&nbsp; In addition, DW-MRI (Diffusion Weighted Magnetic Resonance Imaging) is being done pre and post procedure and at 30 days, as well as ultrasound examination at 30 days and one year on every patient.&nbsp;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The proprietary CGuard carotid embolic protection system uses the same MicroNet technology featured on the MGuard and MGuard Prime coronary embolic protection systems. The MicroNet technology is a single fibre knitted mesh wrapped on an open cell stent platform designed to trap debris that can dislodge and travel downstream after a patient is treated with traditional stenting methods. This technology seeks to protect patients from plaque debris and blood clots breaking off and which can lead to life threatening strokes. The size, or aperture, of the MicroNet &rsquo;pore&rsquo; is only 150-180 microns in order to maximise protection against the potentially dangerous plaque and thrombus within the carotid artery.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;I am excited that enrolment in the CGuard CARENET study has just been completed. I have treated many patients with carotid artery disease over the years and the unique CGuard embolic protection system with MicroNet has changed the way I think about treating these challenging patients,&rdquo; states Joachim Schofer, from the Hamburg University Cardiovascular Center, in Hamburg, Germany. &ldquo;The experience that we have gained using the CGuard device has given us a sense of confidence in regards to new technology options when treating these patients. The small pore size of the MicroNet technology allows excellent blood flow while trapping potentially harmful plaque debris and thrombus. The CGuard technology provides an elegantly simple solution for embolic protection that has not been available in the past. I look forward to reviewing and analysing all of the CARENET data over the next several weeks and sharing the results soon afterward.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The completion of the CGuard CARENET trial on schedule with 100% procedural success rate is an important milestone for InspireMD,&rdquo; states Alan Milinazzo, president and chief executive officer of InspireMD, &ldquo;Our investigators have done a wonderful job throughout this trial, and their feedback on the CGuard has been very positive and informative. The initial results support our belief that the MicroNet technology may deliver life-saving benefits to patients with carotid artery disease and revolutionise the way the carotid stenting procedures are performed. We are looking forward to analysing the data from the CARENET trial and sharing the results in mid-September at the upcoming TCT conference.&rdquo;</span></p></div> SMC says yes to Lemtrada 12mg IV for adults with active relapsing-remitting multiple sclerosis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/smc-says-yes-to-lemtrada-12mg-iv-for-adults-with-active-relapsing-remitting-multiple-sclerosis 2014-07-08T10:56:00Z 2014-07-08T10:56:00Z <div id="ImageMain66" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/smc-says-yes-to-lemtrada-12mg-iv-for-adults-with-active-relapsing-remitting-multiple-sclerosis"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/038/Lemtrada_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction66" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The Scottish Medicines Consortium (SMC) has published its advice that Lemtrada has been accepted for use within NHS Scotland for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical or imaging features.</strong></span></p> </div><div id="Text166" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;RRMS accounts for 85% of all initial diagnoses in multiple sclerosis. We are pleased that after many years in development, Lemtrada is now available to patients in Scotland. This provides people with multiple sclerosis with an important and innovative treatment option to consider in partnership with their multiple sclerosis specialists.&rdquo; says Amy Bowen, director of Service Development at the MS Trust. </span><br /><br /><span style="font-size: 10pt;">There are approximately 10,000 people living with multiple sclerosis in Scotland. The majority of people with RRMS experience approximately one or two relapses per year. Around half of all relapses may leave people with lingering problems and disability may accumulate over time. </span><br /><br /><span style="font-size: 10pt;">Lemtrada is the second of Genzyme&rsquo;s treatments for multiple sclerosis to receive approval for use from the SMC and become available for use within NHS Scotland. Lemtrada has also been approved by NICE and is available for NHS patients in England &amp; Wales.</span></p> </div> UK researchers take new steps towards Alzheimer’s blood test http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/uk-researchers-take-new-steps-towards-alzheimers-blood-test 2014-07-08T10:39:00Z 2014-07-08T10:39:00Z <div id="Introduction67" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Researchers at King&rsquo;s College London and co-funded by Alzheimer&rsquo;s Research UK have announced a panel of 10 proteins that could form a blood test to predict those most likely to develop Alzheimer&rsquo;s. The research is the result of an international collaboration involving Proteome Sciences and funded by Alzheimer&rsquo;s Research UK, the MRC and NIHR Maudsley Biomedical Research Centre. The study is published on 8 July in the journal <a href="http://www.alzheimersanddementia.org/" target="_blank"><em>Alzheimer&rsquo;s and Dementia</em></a>.</strong></span></p> </div><div id="Text167" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">There is currently a large focus in the research community on developing simple and accurate tests that could detect Alzheimer&rsquo;s early or predict who may go on to develop the disease. Alzheimer&rsquo;s changes are known to start in the brain 10 to 15 years before symptoms show and so detecting the disease early could give new treatments the best chance of success.</span></p> <p><br /><span style="font-size: 10pt;">Simon Lovestone, now at Oxford University, and his team studied blood samples from 1,148 volunteers. Of the participants, 452 did not have dementia, 476 had Alzheimer&rsquo;s and 220 had mild cognitive impairment (MCI). Mild cognitive impairment is a term used to describe early memory and thinking problems, which do not necessarily lead onto Alzheimer&rsquo;s, but can put people at a higher risk of the disease. Some of the volunteers also had brain scans to look for tell-tale signs of Alzheimer&rsquo;s in the brain.</span></p> <p><br /><span style="font-size: 10pt;">The researchers analysed blood samples from the volunteers for 26 proteins previously linked to Alzheimer&rsquo;s disease. They found that several of these proteins associated with brain shrinkage on brain scans in people with mild cognitive impairment and Alzheimer&rsquo;s. Taking their research a step further, the team investigated whether any of the proteins could predict the progression from mild cognitive impairment to Alzheimer&rsquo;s. They discovered a panel of 10 proteins that were able to predict which volunteers with mild cognitive impairment would go on to develop Alzheimer&rsquo;s within a year.</span></p> <p><br /><span style="font-size: 10pt;">Abdul Hye, lead author of the study from the Institute of Psychiatry at King&rsquo;s College London, says: &ldquo;Memory problems are very common, but the challenge is identifying who is likely to develop dementia. There are thousands of proteins in the blood, and this study is the culmination of many years&rsquo; work identifying which ones are clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment, will develop Alzheimer&rsquo;s disease within a year, with a high level of accuracy.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Simon Lovestone, senior author of the study from the University of Oxford, who led the work whilst at King&rsquo;s, says: &ldquo;Alzheimer&rsquo;s begins to affect the brain many years before patients are diagnosed with the disease. Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected. A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease. Our next step will be to test our findings in even larger sample sets, to further improve accuracy and reduce the risk of misdiagnosis, before we can develop a reliable test suitable to be used by doctors.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Eric Karran, director of Research at Alzheimer&rsquo;s Research UK, the UK&rsquo;s leading dementia research charity, says:</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;As the onset of Alzheimer&rsquo;s is often slow and subtle, a blood test to identify those at high risk of the disease at an early stage would be of real value. Detecting the first signs of Alzheimer&rsquo;s could improve clinical trials for new treatments and help those already concerned about their memory, but we are not currently in a position to use such a test to screen the general population.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;It is promising to see research taking us closer to mapping the first changes in Alzheimer&rsquo;s, and the team has pooled data from different studies worldwide to bolster their findings. Many people with mild cognitive impairment will not go on to develop Alzheimer&rsquo;s, but the proteins identified in this panel could help researchers to understand the biology driving the disease in those who do. However, with the risk of misdiagnosis from this panel still high, we would need to see such a test well validated and repeated before it could be used in the clinic.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;With an ageing population, and age the biggest risk factor for Alzheimer&rsquo;s, we are expecting rising numbers of people to be affected over the coming years. It is important to develop new ways to intervene early in the disease to help people maintain their quality of life for as long as possible.&rdquo;</span></p></div> New surgical tool provides hope for patients with inoperable deep bleeding in the brain http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-surgical-tool-provides-hope-for-patients-with-inoperable-deep-bleeding-in-the-brain 2014-07-07T10:15:00Z 2014-07-07T10:15:00Z <div id="ImageMain68" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-surgical-tool-provides-hope-for-patients-with-inoperable-deep-bleeding-in-the-brain"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/040/Apollo_system_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction68" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The Apollo system, manufactured by Penumbra, has been widely launched following first-in-man clinical use at leading US hospitals.</strong></span></p> </div><div id="Text168" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">According to Penumbra, Apollo is an innovative new surgical tool that enables minimally invasive removal of deeply seated tissue and fluids in the brain during a single, efficient operation. With combined use of an endoscope and image guidance, the Apollo system allows decompression and removal of otherwise inoperable blood clots deep in the brain, among other uses.</span><br /> <br /><span style="font-size: 10pt;"> Alexander Khalessi, assistant professor of surgery and neurosciences at UC San Diego Medical Center and surgical director of Neurocritical Care, successfully treated the first patient in the world using the Apollo device. Khalessi explains: &ldquo;Our first patient was a 41-year-old male who suffered a spontaneous bleeding deep in his brain that completely shifted his ventricular system, interrupted fluid circulation and compressed his midbrain. Despite standard measures including a ventricular catheter to drain fluid, the overall pressure in his brain was not well controlled. Of greater urgency, the patient was essentially comatose with a fixed downward gaze consistent with a Parinaud&rsquo;s syndrome. With evidence of midbrain compression and this clinical sign, we knew this gentleman was at risk for time-sensitive, irreversible damage to the connection between his brain and body.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Large, decompressive open surgeries for this condition are not supported in the published data. Ongoing research efforts include a trial exploring minimally invasive approaches that involve the implantation of a small catheter with gradual removal of the clot over many days. For my patient, I was concerned his need was more urgent, and that the Apollo system would facilitate the same surgical result in minutes, rather than days.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Following successful clot removal with the Apollo system, our patient&rsquo;s gaze improved and we were able to remove brain pressure monitors and breathing support within 48 hours. As opposed to facing several weeks comatose in the intensive care unit, our patient was transferred to the hospital floor, was able to talk to his family, and has since transitioned to a rehabilitation facility.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;This initial success led to our use of Apollo in a second, 51-year-old patient with a massive haemorrhage; Apollo facilitated complete removal through a small incision in the eyebrow. He left the intensive care unit within 24 hours and like our first patient, went from a near fatal situation in the hospital, to quickly beginning his recovery in a rehabilitation facility.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;I remain hopeful we are finally making progress in an all too common and horribly disabling and fatal disease,&rdquo; Khalessi concludes.</span></p> <p><span style="font-size: 10pt;"><br />Demetrius Lopes, section chief of Cerebrovascular Neurosurgery at Rush University Medical Center in Chicago, USA, is also an early user. &ldquo;I think the arrival of the Apollo system is very timely. We have had great initial experience in removing intraventricular blood. Use of the Apollo system has resulted in faster patient recovery and a shortened stay in the intensive care unit,&rdquo; explains Lopes.</span></p> <p><br /><span style="font-size: 10pt;">David Fiorella, professor of Clinical Neurological Surgery and Radiology at Stony Brook University Medical Center, discussed his view on the value of the Apollo system and compared it to alternative techniques. &ldquo;Our team at Stony Brook has had tremendous success thus far using the Apollo system, in conjunction with neuroendoscopy and image guidance, for the removal of haemorrhages in the brain. This technique has the potential to be a truly important advance for our field, since no other treatment has convincingly been shown to help patients with this lethal disease. Usually patients with this type of haemorrhagic stroke have very poor outcomes and extremely long hospital stays. Just hours after treatment, our patients began showing improvement, and they continued to improve rapidly during their hospital stays.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;While we were very pleasantly surprised by our patients&rsquo; impressive clinical responses, some data indicates that these types of outcomes might be expected. The investigators in the Minimally invasive surgery and tPA in ICH evacuation (MISTIE II) trial found that when they achieved near complete removal of blood clots (to less than 10 millilitres remaining), they observed higher rates of good clinical outcomes. However, this degree of clot reduction was not achieved in most patients. In addition, with the MISTIE technique, clot reduction required several days of drainage through a small catheter left in place after surgery. With the new Apollo system, it seems that we may be able to achieve the desired level of clot reduction immediately and safely in most patients. Therefore, it is possible that we will continue to observe clinical benefits that surpass our former expectations.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;While these early results are certainly impressive and give us enthusiasm going forward,&nbsp;it is important to recognise that we are very early on in our experience with this procedure. Much more data will be required before we know exactly how effective it is and which patients will benefit most,&rdquo; Fiorella comments.</span></p> <p><br /><span style="font-size: 10pt;">The Apollo system is the result of decades of research and development work in the field of advanced aspiration and vibrational energy technology by researchers at Penumbra. Advanced aspiration technology was first developed and perfected in the field of acute ischaemic stroke where blood clots inside the arteries of the brain are starving brain tissue of vital oxygen and nutrients. The Apollo system adds internal energy generation to a specialised advanced aspiration tool to surgically address deep bleeding in the brain, a particularly devastating form of acute haemorrhagic stroke.</span></p></div> New results show personalised brain tumour vaccine helps patients live longer http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-results-show-personalised-brain-tumour-vaccine-helps-patients-live-longer 2014-07-07T09:53:00Z 2014-07-07T09:53:00Z <div id="Introduction69" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient&rsquo;s own tumour in addition to standard of care lived longer compared to those who received standard of care alone, according to new results from a study involving Northwestern Medicine researchers and released on 1&nbsp;July.</strong></span></p> </div><div id="Text169" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Glioblastomas are fast growing tumours that invade normal brain tissue. The disease is often resistant to treatments such as chemotherapy and radiation and median survival is approximately 15 months from the point of first diagnosis.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Improving the survival for GBM patients is an important goal for many of us here at&nbsp;Northwestern,&rdquo; says the study&rsquo;s principal investigator&nbsp;Andrew Parsa, who is chair of neurological surgery at&nbsp;Northwestern Memorial Hospital&nbsp;and the Michael J Marchese professor and chair of the&nbsp;department of neurological surgery&nbsp;at&nbsp;Northwestern University Feinberg School of Medicine. &ldquo;This brain cancer does not discriminate. It affects all ages, genders and races and less than 5% of glioblastoma patients survive five years. With new research and studies like this, we hope to one day write a different ending to the story by turning this into a chronic disease &ndash; one that can be treated with medication.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Typically, patients newly diagnosed with a glioblastoma undergo surgery to remove their tumour followed by radiation and temozolomide, an oral chemotherapy drug. This phase 2 single-arm trial consisted of 46 patients and added a vaccine made from their tumour to their treatment. The vaccine is unique to each patient and is engineered to trigger an immune system response to kill tumour cells that may remain following surgery. &nbsp;&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Results showed the patients who added the vaccine to their treatment lived longer. More specifically, 50% of the patients enrolled in the trial lived for two years, an encouraging result for a cancer that often kills patients within one year. The patients enrolled in this trial were treated at eight centres across the USA including Northwestern Memorial.</span></p> <p><br /><span style="font-size: 10pt;">Median overall survival for patients enrolled in the trial is 23.8 months. For the standard of care alone, median overall survival rate is 14.6 months. The trial also monitored each patient&rsquo;s progression-free survival, which is the length of time a patient lives with the tumour controlled. Vaccine treated patients had a median progression-free survival of nearly 18 months, approximately two- to three-times longer than patients treated with radiation and temozolomide alone.<sup>&nbsp;&nbsp;</sup>In addition, 22% of patients enrolled in the trial were alive at 24 months and continue to be monitored. &nbsp;</span></p> <p><br /><span style="font-size: 10pt;">Based on the positive phase 2 trial results, Agenus Inc, the biopharmaceutical company&nbsp;developing the vaccine, is exploring partnerships for a randomised, phase 3 trial. A successful trial could lead to the vaccine potentially being approved to treat brain tumours, making it one of only a few approved therapeutic cancer vaccines and treatments for GBM patients.&nbsp;&nbsp; &nbsp;</span></p> <p><br /><span style="font-size: 10pt;">While new findings such as this one continue to extend the lives of patients with glioblastoma, for the moment, it remains one of the most dreaded diagnoses, which is why Parsa, co-leader of the Translational Research in Solid Tumours Programme at the&nbsp;Robert H Lurie Comprehensive Cancer Center of Northwestern University, and other Northwestern Medicine researchers are also studying&nbsp;the vaccine for GMB patients whose tumour returns. &nbsp;The phase 2 recurrent and newly diagnosed trials are being led by Parsa and primarily have been supported through funding from the American Brain Tumor Association, Accelerated Brain Cancer Cure, National Brain Tumor Society and National Cancer Institute Special Programs of Research Excellence.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;A glioblastoma is the most common primary malignant brain tumour and affects up to 17,000 Americans annually,&rdquo; says&nbsp;Jeffrey Raizer, co-director of the Northwestern Brain Tumor Institute, director of medical neuro-oncology at the Lurie Cancer Center and the principal investigator for the study at Northwestern Memorial. &ldquo;Vaccine therapy has the potential to offer a safer and less toxic cancer treatment to patients. While conventional therapies sometimes cause debilitating side effects, this treatment is simply a series of injections that is increasing the survival of patients in early trials.&nbsp;Importantly, it can be combined with other therapies allowing us to attack these tumours from different approaches.&rdquo;</span></p></div> Mazor Robotics receives first order for Renaissance system with brain module http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/mazor-robotics-receives-first-order-for-renaissance-system-with-brain-module 2014-07-07T09:37:00Z 2014-07-07T09:37:00Z <div id="ImageMain70" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/mazor-robotics-receives-first-order-for-renaissance-system-with-brain-module"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/008/Renaissance_Mazor-Robotics_Main.gif" border="0" vspace="5" /></a></div><div id="Introduction70" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Mazor Robotics has announced that it has received the first order for its Renaissance system since the commercial launch of the brain surgery module.</strong></span></p> </div><div id="Text170" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The system was sold to Bryan Medical Center in Lincoln, Nebraska, USA and will be utilised for spine and brain procedures. Bryan Medical Center is a 640-bed, not-for-profit, locally owned and governed health care organisation serving patients from throughout Nebraska, as well as parts of Kansas, Iowa, South Dakota and other states in the region.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The first order for Renaissance with our brain surgery module is a new milestone for Mazor Robotics. The value proposition offered to our customers enabled our team to achieve the first system placement in the USA, less than three months after we commercially launched the brain application,&rdquo; comments Ori Hadomi, chief executive officer. &ldquo;The versatility of the Renaissance system enables surgeons and hospital administrators to deploy a single proven system for both brain and spine procedures.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">The company commercially launched the brain application at the American Association of Neurological Surgeons (AANS) annual meeting in April 2014. Renaissance&rsquo;s brain module is primarily used to assist with deep brain stimulation procedures to treat movement disorders, such as Parkinson&rsquo;s disease. Three other hospitals, including Littleton Adventist (Littleton, Colorado), were utilising the brain application during a pre-launch testing period and continue to use the system for brain surgeries.</span></p></div> Successful combined approach to extensive cerebral venous sinus thrombosis with Penumbra aspiration and Solitaire FR http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/successful-combined-approach-to-extensive-cerebral-venous-sinus-thrombosis-with-penumbra-aspiration-and-solitaire-fr 2014-07-02T14:08:00Z 2014-07-02T14:08:00Z <div id="ImageMain71" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/successful-combined-approach-to-extensive-cerebral-venous-sinus-thrombosis-with-penumbra-aspiration-and-solitaire-fr"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Solitaire-FR-2-web_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction71" style="clear:both;"> <p><strong><span style="font-size: 11pt;">A combined approach with the Penumbra aspiration system (Penumbra) and the Solitaire FR retrieval device (ev3, Covidien) has been successfully used in a patient with extensive superior sagittal sinus thrombosis and cortical venous thrombosis, according to a case report.&nbsp;</span></strong></p> </div><div id="Text171" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Radoslav Raychev, Division of Interventional Neuroradiology, Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, USA and colleagues, report the successful treatment in the <a href="http://jnis.bmj.com/" target="_blank"><em>Journal of NeuroInterventional Surgery</em></a>.</span><br /><br /><span style="font-size: 10pt;">The novel technique was performed in a young woman with rapid, progressive neurologic decline due to malignant cerebral oedema caused by a cerebral venous sinus thrombosis.</span><br /><br /><span style="font-size: 10pt;">&ldquo;Complete revascularisation of the occluded sinus was achieved using suction thrombectomy with the 5Max Penumbra catheter in combination with the Solitaire retrieval device,&rdquo; describes Raychev <em>et al</em>.</span><br /><br /><span style="font-size: 10pt;">&ldquo;To our knowledge, this is the first reported case describing such a combined mechanical approach to cerebral venous sinus thrombosis. The clot retrieval properties of the Solitaire device combined with direct aspiration via the newest generation Penumbra catheters may allow more rapid, safe and efficient revascularisation than all previously reported endovascular treatments for this potentially devastating condition,&rdquo; they say.</span></p></div> New brain-training app Brain+ launches in the UK http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-brain-training-app-brain-launches-in-the-uk 2014-07-02T12:29:00Z 2014-07-02T12:29:00Z <div id="Introduction72" style="clear:both;"> <p><strong><span style="font-size: 11pt;">Brain+, a brain-training programme that outpaces existing apps in engagement, effectiveness and economy for users, is being launched in a brand new version on the 1 July. Free to download, Brain+ is available to iPhone and iPad users through the Apple App Store.</span> </strong></p> </div><div id="Text172" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Brain+ contains a number of scientifically designed, yet fun and motivating mind-training games that improve key mental capabilities in the areas of attention, memory, problem solving and planning. The Brain+ exercises are developed in collaboration with leading brain scientists from Copenhagen University and are suitable for people of all ages.</span><br /> <br /><span style="font-size: 10pt;"> Launched in Denmark in 2013, Brain+ offers a uniquely differentiated and unmatched value proposition in the digital brain-training space by being the first to create and combine a solid scientific foundation with brain-training exercises delivered as games of higher quality and longer-term motivation compared with the simpler exercises in pricier apps already in market.&nbsp;</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;Not many people are fully aware of all the possibilities for their brains, but it&rsquo;s very important how you train your brain,&rdquo; says Brain+ chief executive officer Kim Baden-Kristensen. &ldquo;The capacity you build over the years prolongs your mental life and prevents ageing. We built Brain+ in the belief that people want to keep developing and challenging their mental capacity.&rdquo;</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;We believe that to achieve the right amount of brain-training intensity and duration, you need to be engaged and immersed,&rdquo; he adds. &ldquo;We achieve this by designing our exercises more like traditional mobile games and less like clinical exercises, whereas our competition utilise a more traditional exercise approach.&rdquo;</span></p> <p><span style="font-size: 10pt;"><strong><br />Improve your mental abilities</strong></span><br /> <br /><span style="font-size: 10pt;"> Built on cutting-edge neuroscientific insights, methods and training principles that have been validated scientifically, the Brain+ platform&rsquo;s exercises deliver effective training for improving and protecting the brain&rsquo;s abilities, performance and health in children, young adults, older adults and people in need of rehabilitation and recovery from brain injury, disease and deficit recovery.</span><br /> <br /><span style="font-size: 10pt;"> For children, Brain+ takes advantage of their strong drive to play, learn and build abilities toward the development of a high-performing brain. With young adults, Brain+ boosts their day-to-day abilities and mental health to increase quality of life and performance at school or on the job.&nbsp; For older adults, Brain+ increases abilities in core cognitive functions to maintain mental health and forestall age-related deterioration. And for people with brain injury, disease or in need of deficit recovery and maintenance, Brain+ prioritises cognitive abilities to assist in either returning to a normal life or stabilising or even improving a range of deficits.</span><br /> <br /><span style="font-size: 10pt;"> According to a company release, Brain+ is designed to deliver better performance results than other entrants in the brain-training market, which lack strength in scientific foundation and effect, and are locked into sterile, non-motivating models of test exercises. Specifically, Baden-Kristensen says, earlier entrants in the space fail to motivate users over the long term by properly engaging and captivating them due to a lack of gamification best practices, which Brain+ employs in its games.</span><br /> <br /><span style="font-size: 10pt;"> Because Brain+ develops exercises that closely resemble state-of-the art mobile games, the production value, art quality and design requirements are all high, thereby paving the way for unique training experiences, mimicking the entertainment provided by traditional mobile games while maintaining an emphasis on strengthening brain functions.</span><br /> <br /><span style="font-size: 10pt;"> Baden-Kristensen said Brain+ has feedback from many users who say they can feel the app makes a demonstrable difference in their lives because it&rsquo;s fun, engaging, less of a chore to give their brains a workout and drives a desire to share the challenge of their brain exercises with friends and family members.&nbsp;</span></p> <p><span style="font-size: 10pt;">Brain+&nbsp;has invested heavily in the development of a science-based, machine-learning algorithm and technology that challenges the user dynamically and with high precision according to the skills of the individual. </span><br /> <br /><span style="font-size: 10pt;"> <strong>Recommended by Benjamin Sadock</strong></span><br /> <br /><span style="font-size: 10pt;"> &ldquo;The Brain+ project provides a unique and well-proven approach to improve brain function,&rdquo; says Benjamin Sadock, the Menas S Gregory professor of Psychiatry at the New York University School of Medicine. &ldquo;The programme combines new scientific knowledge about how the brain works with the latest advances in gaming techniques to train the brain to operate at its maximum capacity.</span><br /> <br /><span style="font-size: 10pt;"> &ldquo;The use of characters, action, movement, music and immediate feedback allows brain fitness to occur in an environment that is both playful and entertaining. Brain+ will be of use to both healthy adults and those with memory problems who wish to improve their cognitive skills,&rdquo; Sadock says.&nbsp; &ldquo;This is an exciting programme that will continually motivate and stimulate the user to gain new skills and greater confidence in his or her intellectual life. I recommend it most highly.&rdquo;</span><br /> <br /><span style="font-size: 10pt;"> Brain+ has already demonstrated proof of concept by achieving rapid growth in parts of Europe, Asia, Africa and Australia.</span></p></div> electroCore’s funding US$10 million oversubscribed by all parties http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/electrocores-funding-us10-million-oversubscribed-by-all-parties 2014-07-02T11:52:00Z 2014-07-02T11:52:00Z <div id="ImageMain73" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/electrocores-funding-us10-million-oversubscribed-by-all-parties"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/gammaCore_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction73" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>electroCore has announced that its successful funding initiative of US$40 million, announced in April last year, has been oversubscribed by US$10 million by all parties including Merck&rsquo;s Global healthcare Innovation fund and private equity groups Easton Capital and Core Ventures. The final tranche of US$15 million of the US$40 million was optional but following discussions between the investors this was not only made compulsory but increased by US$10 million to a total of US$50 million.</strong></span></p> </div><div id="Text173" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">electroCore has developed and patented a non-invasive vagus nerve stimulation (nVNS) therapy for the treatment of a variety of conditions in neurology, psychiatry, gastroenterology and other conditions.</span></p> <p><span style="font-size: 10pt;"><br />Its focus, at present, is primary headache - cluster and migraine - where it is just concluding four randomised studies in Europe and the USA. The European randomised PREVA study, for the prevention and acute treatment of chronic cluster headache, last week achieved statistical significance on its primary endpoint by reducing the number of cluster headache attacks per week by 47.5% in patients treated with nVNS compared to 12.1% in patients treated with the best available standard of care.</span></p> <p><span style="font-size: 10pt;"><br />In Europe, the nVNS technology, as delivered by electroCore&rsquo;s gammaCore device is considered CE markable, and a CE mark has been awarded in primary headache, bronchoconstruction, epilepsy, gastric motility disorders and depression and anxiety. In the US the pivotal trial for headache is just finishing and an application for a US license will follow.</span></p> <p><span style="font-size: 10pt;"><br />Surgically implanted vagus nerve stimulation (VNS) has been proven for more than twenty years, and in more than 100,000 patients, to be an effective and safe therapy for the treatment of refractory epilepsy and depression but because of its high cost and invasiveness it has been relegated to the end of the continuum of care.</span></p> <p><span style="font-size: 10pt;"><br />JP Errico chief executive officer and founder comments: &ldquo;It has been known for years that vagus nerve stimulation relieved a whole variety of conditions including headache, bronchoconstruction, and many other symptoms but because of its US$30,000 cost it was not considered. We believe that we have revolutionised this effective treatment by proving that our inexpensive nVNS therapy is just as effective as surgically implanted and can be used by millions of patients to self-treat their particular condition. Our nVNS therapy does one thing, it reduces the over expression of the excitatory neurotransmitter glutamate which has been implicated in a number of these disorders. This appears to be born out from the very encouraging signals we are getting from our clinical programme in headache as well as observational and open label studies across a number of these conditions.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />At the Royal Free Hospital in London the company is running a double-blind, parallel, sham controlled trial in patients with two of the most common gastrointestinal complaints; Irritable Bowel Syndrome and functional dyspepsia. This follows a successful proof of concept assessment in patients with gastroparesis. &nbsp; &nbsp;&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />electroCore is involved in clinical trials in universities across Europe and plans to extend this to the US after receiving FDA approval.</span></p></div> Agenus brain cancer vaccine shows extended survival in phase 2 final data analysis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/agenus-brain-cancer-vaccine-shows-extended-survival-in-phase-2-final-data-analysis 2014-07-02T11:23:00Z 2014-07-02T11:23:00Z <div id="Introduction74" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Agenus&nbsp;has announced final results from a single-arm, multi-institutional, open-label, phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus&rsquo; Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected.</strong></span></p> </div><div id="Text174" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">In this phase 2 study, 50% of the patients lived for two years, an encouraging result for a cancer that often kills patients within one year. Prophage patients demonstrated a median overall survival of approximately 24 months and 33% of patients remain alive at two years and continue to be followed for survival.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;These data suggest that Prophage is generating an effective immune response which is translating into an extension in survival far beyond what is historically seen in patients with glioblastoma multiforme. These data provide the impetus for a definitive, randomised clinical trial,&rdquo; says&nbsp;Andrew Parsa, principal investigator of the study and the Michael J Marchese professor and chair of the&nbsp;Department of Neurological Surgery&nbsp;at the Feinberg School of Medicine at Northwestern University. &ldquo;Glioblastoma tumours are often resistant to standard therapies and the extended progression-free survival and proportion of long-term survivors is very encouraging.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">In addition to the long-term survival data, vaccine treated patients had a median progression-free survival (PFS) of nearly 18 months, approximately two to three-times longer than patients treated with radiation and temozolomide alone. Importantly, 22% of patients were alive and without progression at 24 months and continue to be followed for survival.</span></p> <p><br /><span style="font-size: 10pt;">Interestingly, the response to Prophage seems to be more pronounced in those patients with less expression of the checkpoint ligand PDL-1 on the white blood cells, suggesting that combinations of Prophage with checkpoint modulators like PD-1 antagonists might make Prophage even more effective in a greater percentage of patients with glioblastoma multiforme.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;We believe that Prophage may play an important role in changing the treatment paradigm for patients with glioblastoma multiforme,&rdquo; says Garo Armen, chief executive officer and chairman of Agenus. &ldquo;We are exploring partnerships for phase 3 studies of Prophage in glioblastoma multiforme. Additionally, we are excited about the potential combinations of Prophage with PD-1 antagonists and other checkpoint modulators in glioblastoma multiforme.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Prophage is an autologous cancer vaccine, and each patient receives vaccine prepared from their own surgically resected tumour. As a result, the vaccine appears to help stimulate the patient&rsquo;s immune system to attack the tumour based on the spectrum of mutant proteins expressed by their own tumour. Since most cancers result from an accumulation of random mutations, which produce different mutant proteins in each patient, this approach is intended to individually tailor each patient&rsquo;s vaccine to optimally target the immune attack to that patient&rsquo;s actual tumour.</span></p></div> Scotland’s National Epilepsy Centre reports 100% success rate in first year http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/scotlands-national-epilepsy-centre-reports-100-success-rate-in-first-year 2014-07-02T11:13:00Z 2014-07-02T11:13:00Z <div id="Introduction75" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A new national centre of excellence for the treatment of epilepsy in Scotland, which integrates health care with social care, has recorded a 100% success rate in its first year.</strong></span></p> </div><div id="Text175" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The William Quarrier Scottish Epilepsy Centre (WQSEC), a not-for-profit partnership between charity Quarriers and the NHS, welcomed 96 patients in the 12 months after opening in April 2013, its first annual report has revealed.</span></p> <p><br /><span style="font-size: 10pt;">During 2013/14 the centre enjoyed a 100% success rate in transforming lives through accurate diagnosis, including being more accessible for people with disabilities (27% of patients).</span></p> <p><br /><span style="font-size: 10pt;">A devastating, sometimes fatal, neurological condition, it is expected more than 2,000 Scots will this year be told they have epilepsy. The WQSEC has capacity to accommodate up to 170 patients annually while over the lifetime of the building the centre will transform more than 10,000 lives and reduce deaths.</span></p> <p><br /><span style="font-size: 10pt;">The first anniversary of the WQSEC was marked with a special patient celebration event attended by around a third of those admitted to the centre during its first year.&nbsp;</span></p> <p><br /><span style="font-size: 10pt;">Gerard Gahagan, head of Epilepsy Services at WQSEC, says: &ldquo;We are extremely proud of what has been achieved in our first year, with the voluntary sector and NHS working together so effectively to deliver a world-class centre of excellence.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;While patients benefit from clinical innovation, quality of care, and long-term improvements leading to better lives, health boards have experienced reduced waiting lists, a reduced drugs bill and less pressure on Accident &amp; Emergency, inpatient beds and outpatient clinics.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;What sets the WQSEC apart, however, is the ability to diagnose the most complex cases; those that are particularly severe, or where there are issues that complicate diagnosis such as disabilities or psychological problems. This ability has been taken to a new level with our new, world-leading Video Observation System diagnostic technology and the design features of the new building itself.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;These capabilities have attracted significant interest from European clinicians who consider the WQSEC to be a model they could replicate across the continent. The fact that Scotland hosts this centre of excellence is being noticed internationally and there are opportunities for research of international significance.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">He adds: &ldquo;For so many of our patients to return to join in a celebration is a demonstration of the centre&rsquo;s people-centred approach and strong patient participation and engagement.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">The WQSEC is also improving knowledge and understanding of epilepsy, with more than 450 medical students now being trained at the centre throughout the year.&nbsp; The centre and its team has hosted an international conference &ndash; Challenging Epilepsy &ndash; attended by 100 practitioners, pioneered a research programme with the University of Glasgow and chaired the government&rsquo;s National Neurological Advisory Group Epilepsy team. It also has outreach services which help people across the country while epilepsy awareness days have been organised at for companies and public sector bodies.</span></p> <p><br /><span style="font-size: 10pt;">Importantly, another of WQSEC&rsquo;s key objectives has been met with a marked increase in admissions from outwith West of Scotland reflecting the national status. Since opening, patients being referred to the centre from other parts of Scotland now represent 39% of all admissions, compared with 30% last year and 25% the year before (to the previous facility).</span></p> <p><br /><span style="font-size: 10pt;">Reasons for referral are as follows:</span><br /><br /></p> <p><span style="font-size: 10pt;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To clarify diagnosis &ndash; 68%</span></p> <p><span style="font-size: 10pt;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To review medication &ndash; 13%</span></p> <p><span style="font-size: 10pt;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To clarify seizures &ndash; 13%</span></p> <p><span style="font-size: 10pt;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For video-telemetry only &ndash; 3%</span></p> <p><span style="font-size: 10pt;">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To investigate sleep issues &ndash; 3%</span><br /><br /></p> <p><span style="font-size: 10pt;">Diagnoses found that 49% of patients had epilepsy, 27% had non-epileptic seizures while 24% had a complex mixture of both epileptic and non-epileptic seizures which can be very difficult to diagnose. With these diagnoses, the WQSEC is able to provide treatment tailored to each individual, improving seizure control, or reducing the powerful side-effects of drugs by rationalising medication. In every case, treatment radically increases quality of life, while in many cases, it is life-saving.</span></p> <p><br /><span style="font-size: 10pt;">Bill Scott, Patron of the Scottish Epilepsy Centre, says: &ldquo;Having finished the construction of the William Quarrier Scottish Epilepsy Centre, it could be tempting to sit back in satisfaction with a job well done. However, 54,000 Scots live daily with this cruel condition. Lives continue to be shattered by epilepsy and the social and economic cost is huge.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The WQSEC was conceived and designed to meet this crisis. With the completion of the WQSEC, Quarriers has not only the platform, but indeed an obligation to strive to improve outcomes for all people with epilepsy in Scotland.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;With its world-class facilities, European treatment and diagnostic leadership the WQSEC will certainly transform hundreds of lives each year. We will use this as a catalyst which, combined with policy influencing, research and training programmes, will contribute to the delivery of improved life-changing services to tens of thousands in Scotland and beyond.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;In this way, the WQSEC is not the end of our ambition. In fact, it&rsquo;s just the beginning.&rdquo;</span></p></div> Omega-3 fats may significantly reduce damage from stroke http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/omega-3-fats-may-significantly-reduce-damage-from-stroke 2014-07-02T10:54:00Z 2014-07-02T10:54:00Z <div id="ImageMain76" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/omega-3-fats-may-significantly-reduce-damage-from-stroke"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Omega_3_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction76" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>New evidence shows that the&nbsp;omega-3 polyunsaturated fatty acids (PUFAs) found in seafood and marine oils,&nbsp;DHA&nbsp;and&nbsp;EPA, can significantly reduce damage from stroke in a mouse model when given immediately afterwards. Moreover, DHA and another PUFA demonstrate a positive effect on neurocognitive function in children. These findings and more were presented 29-30 June at the 11<sup>th</sup>Congress of the&nbsp;International Society for the Study of Fatty Acids and Lipids&nbsp;(ISSFAL) in&nbsp;Stockholm, Sweden.</strong></span></p> </div><div id="Text176" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">About 15 million people worldwide have a stroke each year and risk increases with age. Ischaemic stroke, caused by a blockage of a blood vessel that supplies blood to the brain, accounts for about 87% of all cases. Investigators at&nbsp;Goethe University&nbsp;of&nbsp;Frankfurt, Germany, explored ischaemic stroke in mice and the impact of an EPA and DHA emulsion administered 90 minutes afterwards, by examining the degree of damage, cellular function and neuroinflammation.</span></p> <p><span style="font-size: 10pt;"><br />Treatment with the omega-3 emulsion significantly decreased the stroke area by 21% and lowered the severity of stroke by 50%. It also significantly improved brain cell function and reduced markers of inflammation.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;This pilot study demonstrated that DHA and EPA might aid in early medical intervention in ischaemic stroke,&rdquo; says&nbsp;Gunter Eckert, associate professor of pharmacology and toxicology at Goethe. &ldquo;Further investigation is in order and holds promise for human trials.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />DHA&rsquo;s involvement in recovery from stroke was also explored by&nbsp;Nicolas Bazan, professor and director, Neuroscience Center of Excellence,&nbsp;Louisiana State University Health Sciences Center,&nbsp;New Orleans, USA. DHA encourages the production of special substances that allow for cell survival under excessive stress, neurodegeneration or ischaemic stroke.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;These substances are increased by DHA after ischaemic stroke in animals, followed by remarkable neurological recovery,&rdquo; notes Bazan.</span></p> <p><span style="font-size: 10pt;"><br />The benefits of DHA in brain health have also been demonstrated in humans.&nbsp;Kathleen Gustafson, research assistant professor,&nbsp;University of Kansas Medical Center,&nbsp;Kansas City,&nbsp;USA, and colleagues investigated the effect of DHA and arachidonic acid (ARA), an omega-6 PUFA, on response inhibition in a follow-up study of 54 term infants randomised to receive formula with or without PUFAs from birth to 12 months. At roughly 5.5 years, children participated in a go/no-go task requiring rule learning and inhibitory control. Supplemented children responded more effectively and less impulsively.</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Data from this trial have consistently demonstrated benefits of PUFA supplementation in visual, cardiac and cognitive function out to 6 years of age,&rdquo; says Gustafson. &ldquo;This suggests that supplementation with DHA and ARA has a programming effect in the brain during a critical period of development, which is long-lasting.&rdquo;</span></p></div> FDA clears Surgical Theater’s SNAP http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/fda-clears-surgical-theaters-snap 2014-07-01T14:44:00Z 2014-07-01T14:44:00Z <div id="ImageMain77" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/fda-clears-surgical-theaters-snap"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/SNAP_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction77" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Surgical Theater has received US Food and Drug Administration (FDA) clearance on the recently launched Surgical Navigation Advanced Platform (SNAP). The SNAP integrates with operating room technology to provide advanced 3D capabilities and augmented reality, allowing surgeons to enhance their surgery performance and &ldquo;see what cannot be seen&rdquo;.</strong></span></p> </div><div id="Text177" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The SNAP is the second of the company&rsquo;s line of products combining flight simulation technology with advanced CT/MRI imaging for use in brain surgery to receive FDA clearance. It enables surgeons to perform a real-life &ldquo;fly through&rdquo; of a &ldquo;patient-specific&rdquo; surgery and receive unique virtual-reality guidance to determine the safest and most efficient pathway to remove cerebral tumours and treat vascular anomalies.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />With the SNAP, surgeons can execute their surgery plan while in the operating room utilising a patient&rsquo;s CT/MRI scans, allowing enhanced accuracy and efficiency. It provides the ability to rotate the image or make it semi-transparent in order to see behind arteries and other critical structures, something not possible until now, affording for accuracy to be sustained during complex procedures. Also, SNAP&rsquo;s augmented reality and simulation capabilities allow surgeons to analyse virtual &ldquo;what if&rdquo; scenarios before making the actual incision. This precision enables surgeons to gain clinical insight that was previously unavailable.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We have used the SNAP in the operating room in a handful of surgeries. The SNAP&rsquo;s realistic 3D imaging is one-of-a-kind and has been introduced as an integrated operating room device for the first time at our medical centre,&rdquo; says Warren R Selman, chairman, Department of Neurological Surgery, University Hospitals Case Medical Centre, USA.&nbsp; &ldquo;It is just like watching a football game when multiple cameras are located around the arena and an editor can freeze the image, rotate, zoom in, zoom out and see things that he could not otherwise see. In my recent surgeries, I was able to pause the navigation scene during the surgery to rotate the image and to verify that I removed the entire tumour and to make sure that I was within a safe distance from a vital artery while removing the tumour. With the SNAP connected to the operating room navigation platform, the operating room team coordination is enhanced, and we are utilising the best imaging technology tool to benefit our patients.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Surgical Theater&rsquo;s first product, the Surgical Rehearsal Platform (SRP), paved the way to the operating room by providing surgeons with a way to plan and rehearse their surgeries outside of the operating room. To-date it is estimated that the SRP has been utilised by surgeons wanting to pre-live their procedure more than 500 times. Now the SNAP will be utilised to take the pre-planned pathway into the operating room to be used during the surgical procedure thanks to its ability to integrate into operating room navigation equipment. In addition, the flight simulator technology used in the software permits remote connection of multiple platforms; participants anywhere in the world can simultaneously work together and practice the same case with real-time feedback and collaboration.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are extremely excited to expand our offerings beyond planning and rehearsing surgeries outside the operating room,&rdquo; says Moty Avisar, Surgical Theater chief executive officer and co-founder. &ldquo;The SNAP, our advanced imaging platform, allows us to connect to the operating room navigation system and become a part of the surgery as its performed, enabling a surgeon and operating room team to achieve their goal of delivering the best care and outcome for the patient. We are witnessing strong anticipation from the medical community about this new technology, with multiple pre-orders for the SNAP already placed from hospitals across the country.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Since Surgical Theater obtained FDA clearance on their first product in February 2013, SRPs have been installed in leading research and teaching hospitals across the United States. Hospitals include: University Hospitals Case Medical Center, University Hospitals Rainbow Babies and Children&rsquo;s Hospital, The Ronald Reagan UCLA Medical Center, The Mount Sinai Hospital, Mayo Clinic, NYU Langone Medical Center, and others.</span></p></div> Lemtrada approved in Argentina for treatment of multiple sclerosis http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/lemtrada-approved-in-argentina-for-treatment-of-multiple-sclerosis 2014-07-01T14:28:00Z 2014-07-01T14:28:00Z <div id="ImageMain78" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/lemtrada-approved-in-argentina-for-treatment-of-multiple-sclerosis"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/038/Lemtrada_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction78" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Genzyme has announced that Argentina&rsquo;s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved Lemtrada&nbsp;(alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.</strong></span></p> </div><div id="Text178" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;The Lemtrada clinical trial data demonstrating the treatment&rsquo;s positive impact on relapse rates and disability progression support its potential as a transformational new treatment for relapsing-remitting multiple sclerosis,&rdquo; says Norma Deri, Hosptial Fernandez, Buenos Aires, Argentina. &ldquo;The approval of Lemtrada is good news for people living with active MS, who are in need of additional treatment options that may offer greater efficacy.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br />Lemtrada is supported by a comprehensive and extensive clinical development programme that involved nearly 1,500 patients and 5,400 patient-years of follow-up. In addition to Argentina, Lemtrada is approved in the European Union, Australia, Canada, Mexico, Brazil and Guatemala. Lemtrada is currently not approved in the United States. Genzyme recently announced that the US Food and Drug Administration (FDA) has accepted for review the company&rsquo;s resubmission of its application seeking approval of Lemtrada. Genzyme expects FDA action on the application in the fourth quarter.</span></p> <p><span style="font-size: 10pt;"><br />Lemtrada 12mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtrada is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later.<br /></span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We are pleased by the continued global support for Lemtrada,"&nbsp;said Genzyme President and CEO, David Meeker.&nbsp;"We are launching the treatment in more than 30 countries this year, and look forward to additional approvals where Lemtrada is still under review.&rdquo;</span></p></div> AHA funds new research network aimed at preventing heart disease, stroke http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/aha-funds-new-research-network-aimed-at-preventing-heart-disease-stroke 2014-07-01T11:24:00Z 2014-07-01T11:24:00Z <div id="Introduction79" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The American Heart Association is funding a new research network to help people make behaviour changes to prevent heart disease and stroke, the two leading causes of death in the world.</strong></span></p> </div><div id="Text179" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Four institutions are banding together as the Strategically Focused Prevention Research Network Centers, funded by a US$15 million grant from the American Heart Association, which is designed to help people live longer, healthier lives.</span></p> <p><br /><span style="font-size: 10pt;">Obesity, high blood pressure and heart failure are among the study areas at the collaborative network, which is made up of investigators from Northwestern University in Chicago, Vanderbilt University in Nashville, the Icahn School of Medicine at Mount Sinai in New York and the University of Texas-Southwestern Medical School in Dallas, USA. The work will begin July 1.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Heart attack and stroke can strike suddenly, and frequently without warning. The best way to reduce premature death from cardiovascular diseases and stroke is to prevent the development of the risk factors that lead to these conditions,&rdquo; says American Heart Association president Elliott Antman, professor of medicine at Harvard Medical School and a senior physician in the Cardiovascular Division of the Brigham and Women&rsquo;s Hospital in Boston. &ldquo;Scientists working in these research centres are seeking to discover mechanisms that will allow all Americans to live healthier lives, and help lead us to a culture of health.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">A culture of health is an environment where the default choices people make are the healthy ones. For example, the air is smoke-free, nutritious foods are easy to find, safe places to exercise are abundant and quality healthcare is accessible.</span></p> <p><span style="font-size: 10pt;"><br />The culture of health concept is also important to the association&rsquo;s goal to improve the cardiovascular health of all Americans by 20% while reducing deaths from cardiovascular diseases and stroke by 20% by 2020.</span></p> <p><span style="font-size: 10pt;">Getting America healthier means making headway in important areas like smoking, physical activity, diet, blood pressure, cholesterol and blood sugar. Northwestern Universitywill take a closer look at why heart-health measures decline from childhood to middle age and see if the latest techniques can help maintain ideal heart health and reverse declines. The goal is to learn how to implement behaviour change programmes on a large scale to benefit the most people.</span></p> <p><br /><span style="font-size: 10pt;">Two major hurdles &ndash; an overly salty, heart-hurting diet and the frequent need to take multiple, expensive medications &ndash; is spurring Vanderbilt University to develop new approaches for preventing high blood pressure. The goals are to understand how salt causes tissue injury, develop a method to detect and lower excess salt, and determine if a simple treatment in one pill can improve cardiovascular health.</span></p> <p><br /><span style="font-size: 10pt;">Nearly one-third of adults and children in the United States are obese, with rates even higher in Hispanic and African-American communities. The Icahn School of Medicine at Mount Sinai will aim to build a culture of health in Harlem, New York, USA with an urban-based health programme. Obesity is closely linked to heart disease, stroke, type 2 diabetes and certain types of cancer, among the leading causes of preventable death.</span></p> <p><br /><span style="font-size: 10pt;">Heart failure, when the heart cannot pump enough blood to the organs, is one of the most common reasons people 65 and older go into the hospital. Since there are no proven therapies to prevent heart failure with preserved ejection fraction, which affects about half of these patients, the University of Texas-Southwestern Medical School wants to shift the focus to prevention. The centre expects to find new interventions that can help heart failure patients in clinical settings.</span></p> <p><br /><span style="font-size: 10pt;">Each network centre will receive about US$3.8 million over the next four years.</span></p></div> China to build ‘brain database’ http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/china-to-build-brain-database 2014-07-01T10:47:00Z 2014-07-01T10:47:00Z <div id="Introduction80" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Chinese scientists are planning to build a &ldquo;brain database&rdquo; in a bid to identify clues to tackling cerebral diseases and related disorders.</strong></span></p> </div><div id="Text180" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;The creation of a unified general and patient database will help us to identify the biomarkers of brain diseases, which we can then use as the basis for early diagnosis and treatment,&rdquo; says Poo Mu-ming, director of the Institute of Neuroscience under the Chinese Academy of Sciences.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;It will also be a useful resource for scientists around the world who are involved in brain research,&rdquo; he adds.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Though few details of the project have been made public, Poo says one of its primary goals will be to find treatments for conditions such as autism and Alzheimer&rsquo;s disease. Autism is a neurodevelopmental disorder whose incidence is on the rise globally. According to official figures, about one million Chinese children are affected by the condition. The World Health Organisation, however, said in 2008 that the country had 7.8 million autistic children. Meanwhile, 50% of the global population aged over 85 has Alzheimer&rsquo;s disease. By 2050, there could be as many as nine million seniors in China with the condition.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;There is currently no cure for Alzheimer&rsquo;s disease, but one of the goals of the brain database is to find ways to delay its onset,&rdquo; Poo says.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The announcement of the project was made yesterday at the Shanghai Science and Technology Museum, where scientists from the United States and Europe also gave details of their research projects in the field. Last year, European scientists launched the one billion euro (US$1.4 billion) &ldquo;Human Brain Project.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Its aim is to develop the infrastructure for neuroscience and related research that will help improve understanding of the human brain and its diseases, Kazinform has learnt from Xinhua.</span></p></div> Little or poor sleep may be associated with worse brain function when ageing http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/little-or-poor-sleep-may-be-associated-with-worse-brain-function-when-ageing 2014-06-30T16:31:00Z 2014-06-30T16:31:00Z <div id="Introduction81" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Research published in <a href="http://www.plosone.org/" target="_blank"><em>PLOS ONE</em></a> by researchers at the University of Warwick, UK indicates that sleep problems are associated with worse memory and executive function in older people.</strong></span></p> </div><div id="Text181" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Analysis of sleep and cognitive (brain function) data from 3,968 men and 4,821 women who took part in the English Longitudinal Study of Ageing (ELSA), was conducted in a study funded by the Economic and Social Research Council (ESRC). Respondents reported on the quality and quantity of sleep over the period of a month.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The study showed that there is an association between both quality and duration of sleep and brain function which changes with age.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />In adults aged between 50 and 64 years of age, short sleep (8hrs per night) were associated with lower brain function scores. By contrast, in older adults (65-89 years) lower brain function scores were only observed in long sleepers.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Michelle A Miller says, &ldquo;Six to eight hours of sleep per night is particularly important for optimum brain function, in younger adults. These results are consistent with our previous research, which showed that six to eight hours of sleep per night was optimal for physical health, including lowest risk of developing obesity, hypertension, diabetes, heart disease and stroke.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Interestingly, in the younger pre-retirement aged adults, sleep quality did not have any significant association with brain function scores, whereas in the older adults (&gt;65 years), there was a significant relationship between sleep quality and the observed scores.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Sleep is important for good health and mental wellbeing,&rdquo; says Francesco Cappuccio. &ldquo;Optimising sleep at an older age may help to delay the decline in brain function seen with age, or indeed may slow or prevent the rapid decline that leads to dementia.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Miller concludes that &ldquo;if poor sleep is causative of future cognitive decline, non-pharmacological improvements in sleep may provide an alternative low-cost and more accessible Public Health intervention, to delay or slow the rate of cognitive decline&rdquo;.</span></p></div> Philips and Salesforce.com announce a strategic alliance http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/philips-and-salesforcecom-announce-a-strategic-alliance 2014-06-30T14:52:00Z 2014-06-30T14:52:00Z <div id="Introduction82" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Royal Philips and salesforce.com have announced a strategic alliance to deliver an open, cloud-based healthcare platform, leveraging Philips&rsquo; leading positions in medical technology, clinical applications and clinical informatics and salesforce.com&rsquo;s leadership in enterprise cloud computing, innovation and customer engagement. Patient relationship management will be at the centre of the envisioned platform, allowing caregivers to collaborate closely in support of their patients. The platform will enable medical device and data interoperability &ndash;&nbsp; the collection of data and subsequent analysis to enhance clinical decision making by professionals and enabling patients to take a more active role in managing their personal health.</strong></span></p> </div><div id="Text182" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The collaboration has already resulted in two clinical applications to be launched on the new platform later this summer: &ldquo;Philips eCareCoordinator&rdquo; and &ldquo;Philips eCareCompanion.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />These care collaboration applications will allow the care team to monitor patients with chronic conditions in their homes and will facilitate Philips&rsquo; Hospital to Home clinical programmes, such as Banner iCare, being piloted at Banner Health, a pioneer accountable care organisation in Arizona, USA. Similar telehealth-based care delivery models for hospitals utilising the Philips eICU programme were shown to reduce mortality by 26% and length of stay by 20% in a recent large, multicentre study.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;With this strategic alliance, Philips is making great strides to deliver real-time, digital healthcare solutions,&rdquo; says Frans van Houten, chief executive officer of Royal Philips. &ldquo;Healthcare data exists in many different forms and in many different systems today. Together with salesforce.com, we have a tremendous opportunity to reshape and optimise the way healthcare is delivered and provide better access to data across the continuum of care.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We have entered a new transformative era for healthcare and technology is enabling the industry to connect to, care for and engage with patients and each other in a profound new way,&rdquo; says Marc Benioff, chairman and chief executive officer, salesforce.com. &ldquo;Together with Philips, we are creating an open health platform and ecosystem to benefit everyone that cares about one of the most important issues of our time.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Philips and salesforce.com envision that apps will cover the continuum of care: from self-care and prevention, to diagnosis and treatment through recovery and wellness. The envisioned platform, based on the Salesforce1 Platform, will enable collaboration and workflow, as well as integration of data from multiple sources worldwide, including electronic medical records, diagnostic and treatment information obtained through Philips&rsquo; imaging equipment, monitoring equipment, personal devices and technologies like Apple&rsquo;s HealthKit. Moreover, the cloud-based platform is designed to be highly scalable with built-in privacy and data security. By combining the data, the platform will allow for analysis that will enhance decision making by professionals and engage patients. Both Philips and salesforce.com foresee that the platform, will utilise Philips&rsquo; clinical data stores and medical device interoperability. It is intended to be open to developers and is expected to result in a vibrant ecosystem of partners creating applications. As a result, the envisioned platform has the potential to transform both professional healthcare delivery and continuous personal health management.</span></p></div> Lemtrada (alemtuzumab) 12mg IV, shortlisted for the 2014 Prix Galien Innovative Product Award http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/lemtrada-alemtuzumab-12mg-iv-shortlisted-for-the-2014-prix-galien-innovative-product-award 2014-06-27T17:06:00Z 2014-06-27T17:06:00Z <div id="ImageMain83" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/lemtrada-alemtuzumab-12mg-iv-shortlisted-for-the-2014-prix-galien-innovative-product-award"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/038/Lemtrada_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction83" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Genzyme, a Sanofi company, has announced that it has been shortlisted for a Prix Galien award, in the Innovative Drug Award Category, for its multiple sclerosis therapy Lemtrada. A Prix Galien award is widely regarded as the highest distinction to be bestowed upon a pharmaceutical product. In recent years, the Prix Galien &lsquo;stamp&rsquo; has become synonymous with new treatment options that add significant value to health systems and improve outcomes for patients.</strong></span></p> </div><div id="Text183" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The award nomination reinforces Lemtrada&rsquo;s status as an innovative new therapy option for people with relapsing-remitting multiple sclerosis (RRMS). The development of Lemtrada, led by UK scientists at Cambridge University with the support of Genzyme, demonstrates the high calibre of scientific ingenuity which is needed when developing additional treatment options for patients &ndash; and is a key characteristic of the UK&rsquo;s world renowned research and development industry, which Genzyme is proud to support and be part of.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The shortlisting of Lemtrada in the innovative drug category at these prestigious awards is testament to the pioneering research at Cambridge University and the collaboration with Genzyme to bring this new treatment option for people with relapsing-remitting multiple sclerosis.&nbsp; For people living with multiple sclerosis Lemtrada could really reshape the management of their condition and demonstrates Genzyme&rsquo;s focus on putting patients at the heart of everything we do,&rdquo; comments Brendan Martin, general manager for Genzyme UK and Ireland.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The submission for Lemtrada for the Prix Galien award focused on the drug&rsquo;s pivotal efficacy and safety data from the CARE-MS trials (Comparison of alemtuzumab and rebif efficacy in multiple sclerosis). The results of these trials were published in <a href="http://www.thelancet.com/" target="_blank"><em>The Lancet</em></a>.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Having been involved with the clinical development of Lemtrada for more than 20 years, I am delighted that the innovative concept of lymphocyte depletion and reconstitution, and the evidence for efficacy in relapsing-remitting multiple sclerosis, are recognised by shortlisting for this important award. The research community in Cambridge is proud of our focus on improving outcomes for people with neurological disease through clinical application of pioneering basic science,&rdquo; says Alastair Compston, professor of neurology and head of the Department of Clinical Neurosciences, University of Cambridge.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The 2014 UK Prix Galien awards ceremony will take place on Wednesday 1st October at the House of Commons, London, where the winners of the awards will be announced. The Rt. Hon. Sir Kevin Barron, MP &ndash; former chair of the Health Select Committee and chair of several all-party Parliamentary groups relating to the pharmaceutical industry and health &ndash; will be the Parliamentary sponsor for the awards this year. Genzyme has previously won a UK Prix Galien Gold Medal for Myozyme in 2006.</span></p></div> New device allows brain to bypass spinal cord and move paralysed limbs http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-device-allows-brain-to-bypass-spinal-cord-and-move-paralysed-limbs 2014-06-27T16:27:00Z 2014-06-27T16:27:00Z <div id="ImageMain84" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-device-allows-brain-to-bypass-spinal-cord-and-move-paralysed-limbs"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Burkhart_web_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction84" style="clear:both;"> <p><strong><span style="font-size: 11pt;">For the first time ever, a paralysed man has moved his fingers and hand with his own thoughts after an electronic neural bypass for spinal cord injuries that reconnects the brain directly to muscles, allowing voluntary and functional control of a paralysed limb. This innovation comes from a partnership between The Ohio State University Wexner Medical Center and Battelle.</span></strong></p> </div><div id="Text184" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Ian Burkhart, a 23-year-old quadriplegic from Dublin, USA, is the first patient to use Neurobridge, an electronic neural bypass. Burkhart is the first of a potential five participants in a clinical study.</span><br /><br /><span style="font-size: 10pt;">&ldquo;It is much like a heart bypass, but instead of bypassing blood, we are bypassing electrical signals,&rdquo; said Chad Bouton, research leader at Battelle. &ldquo;We are taking those signals from the brain, going around the injury and going directly to the muscles.&rdquo;</span><br /><br /><span style="font-size: 10pt;">The Neurobridge technology combines algorithms that learn and decode the user&rsquo;s brain activity and a high-definition muscle stimulation sleeve that translates neural impulses from the brain and transmits new signals to the paralysed limb. In this case, Burkhart&rsquo;s brain signals bypass his injured spinal cord and move his hand.</span><br /><br /><span style="font-size: 10pt;">The project investigating the Neurobridge was a six-month, Food and Drug Administration (FDA)-approved clinical trial at Ohio State&rsquo;s Wexner Medical Center.</span><br /><br /><span style="font-size: 10pt;">Working on the internally-funded project for nearly a decade to develop the algorithms, software and stimulation sleeve, Battelle scientists first recorded neural impulses from an electrode array implanted in a paralysed person&rsquo;s brain. They used the data to illustrate the device&rsquo;s effect on the patient and prove the concept.</span><br /><br /><span style="font-size: 10pt;">Two years ago, Bouton and his team began collaborating with Ohio State neuroscience researchers and clinicians Ali Rezai and Jerry Mysiw to design the clinical trials and validate the feasibility of using the Neurobridge technology in patients.</span><br /><br /><span style="font-size: 10pt;">During a three-hour surgery on 22 April, Rezai implanted a chip onto the motor cortex of Burkhart&rsquo;s brain. The tiny chip interprets brain signals and sends them to a computer, which recodes and sends them to the high-definition electrode stimulation sleeve that stimulates the proper muscles to execute his desired movements. Within a tenth of a second, Burkhart&rsquo;s thoughts are translated into action.</span></p></div><div id="Text284" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;The surgery required the precise implantation of the micro-chip sensor in the area of Burkhart&rsquo;s brain that controls his arm and hand movements,&rdquo; Rezai says.</span><br /><br /><span style="font-size: 10pt;">He said this technology may one day help patients affected by various brain and spinal cord injuries such as strokes and traumatic brain injury.</span></p> <p><span style="font-size: 10pt;">Battelle also developed a non-invasive neurostimulation technology in the form of a wearable sleeve that allows for precise activation of small muscle segments in the arm to enable individual finger movement, along with software that forms a &lsquo;virtual spinal cord&rsquo; to allow for coordination of dynamic hand and wrist movements.</span><br /><br /><span style="font-size: 10pt;">The Ohio State and Battelle teams worked together to investigate the correct sequence of electrodes to stimulate and allow Burkhart to move his fingers and hand functionally. For example, Burkhart uses different brain signals and muscles to rotate his hand, make a fist or pinch his fingers together to grasp an object, Mysiw explains. As part of the study, Burkhart worked for months using the electrode sleeve to stimulate his forearm to rebuild his atrophied muscles so they would be more responsive to the electric stimulation.</span><br /><br /><span style="font-size: 10pt;">&ldquo;I have been doing rehabilitation for many years, and this is a tremendous stride forward in what we can offer these people,&rdquo; said Mysiw, chair of the Department of Physical Medicine and Rehabilitation at Ohio State. &ldquo;Now we are examining human-machine interfaces and interactions, and how that type of technology can help.&rdquo; &nbsp;</span></p></div> Covidien announces European launch of Pipeline Flex embolisation device http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/covidien-announces-european-launch-of-pipeline-flex-embolisation-device 2014-06-27T14:14:00Z 2014-06-27T14:14:00Z <div id="ImageMain85" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/covidien-announces-european-launch-of-pipeline-flex-embolisation-device"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/pipeline_flex_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction85" style="clear:both;"> <p><strong><span style="font-size: 11pt;">Covidien announced the European launch of its Pipeline Flex embolisation device at the annual Live Interventional Neuroradiology and Neurosurgery Course (LINNC, 23&ndash;25 June, Paris, France). This next-generation flow diversion device received CE mark earlier this year.</span></strong></p> </div><div id="Text185" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Designed to divert blood flow away from an aneurysm, the Pipeline Flex device features a braided cylindrical mesh tube that is implanted across the base or neck of the aneurysm. The device cuts off blood flow to the aneurysm, reconstructing the diseased section of the parent vessel. The device is repositionable and designed for even more accuracy and controlled placement. Among other features, it includes an instant braid release system that makes it even easier to place, a press release from the company states.</span><br /><br /><span style="font-size: 10pt;">&ldquo;The Pipeline Flex embolisation device is the next advancement in flow diversion, combining our clinically-proven braid design with a new delivery system designed to offer even more accuracy and control when performing these advanced procedures inside the brain,&rdquo; said Brett Wall, president, Neurovascular, Covidien.</span><br /><br /><span style="font-size: 10pt;">In Europe, the Pipeline Flex device is intended for the endovascular embolisation of cerebral aneurysms. The first-generation Pipeline embolisation device has been used to treat patients in Europe since 2009. It has been the only flow diversion device commercially available in the USA since it was approved by the US Food and Drug Administration in April 2011. The Pipeline Flex device is not currently approved for use in the USA.</span></p></div> New Neuro-Oncology chair for Ohio Clinical Trials Collaborative http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-neuro-oncology-chair-for-ohio-clinical-trials-collaborative 2014-06-27T11:32:00Z 2014-06-27T11:32:00Z <div id="ImageMain86" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-neuro-oncology-chair-for-ohio-clinical-trials-collaborative"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Barnholtz_Sloan_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction86" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>The Ohio Clinical Trials Collaborative (OCTC) has appointed Jill Barnholtz-Sloan as chair of its Neuro-Oncology Working Group. Barnholtz-Sloan is an associate professor at Case Western Reserve University School of Medicine, associate director for Clinical Informatics, Institute for Computational Biology and a member of the Case Comprehensive Cancer Centre.</strong></span></p> </div><div id="Text186" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Because Ohio is uniquely positioned as a stronghold of individual brain tumour investigators, novel neuro-oncology, basic science and clinical research, the OCTC has a world-class interdisciplinary team with the ability to study the genetic changes responsible for the onset, spread and recurrence of brain tumours,&rdquo; says Barnholtz-Sloan.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The OCTC will establish Ohio as one of the most efficient and effective states in which to develop new medicines and treatment strategies,&rdquo; James Chmiel, chief executive and director of the OCTC says. &ldquo;The development of new treatments for brain tumours is critical because patient survival has not improved substantially in 30 years.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The OCTC provides centralised access to Ohio&rsquo;s premier medical centres for clinical trial development. The pharmaceutical industry faces a challenging and expensive process for conduct of clinical trials. The OCTC streamlines the contracting, budgeting, approval of human subject use and patient recruitment/enrolment processes so medical discoveries can move to market faster.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;I am enthusiastic about leading this extraordinary statewide team to advance clinical trials in neuro-oncology and achieve our goal of developing new treatments for brain tumour patients,&rdquo; says Barnholtz-Sloan.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The adult component of this working group will be co-chaired by David Peereboom, professor of medicine at Cleveland Clinic Lerner College of Medicine and director, Clinical Research at The Rose Ella Burkhardt Brain Tumour &amp; Neuro-Oncology Centre and the paediatric component of this working group will be co-chaired by Jonathan Finlay, professor and director of Paediatric Neuro-Oncology at Nationwide Children&rsquo;s Hospital.</span></p></div> Pilot study shows gammaCore for the prevention of migraine is safe and reduces number of headache days http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/pilot-study-shows-gammacore-for-the-prevention-of-migraine-is-safe-and-reduces-number-of-headache-days 2014-06-27T09:46:00Z 2014-06-27T09:46:00Z <div id="ImageMain87" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/pilot-study-shows-gammacore-for-the-prevention-of-migraine-is-safe-and-reduces-number-of-headache-days"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/036/gammaCore_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction87" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Two poster presentations at the American Headache Society (AHS) meeting in California, USA, reported the results of the sham controlled pilot study that examined the use of electroCore&rsquo;s non-invasive vagus nerve stimulation therapy (nVNS) to prevent chronic migraine. The study met its endpoint of safety, and also demonstrated a reduction in the number of headache days per month for patients using the active device. The study further suggests that patients who remained on therapy for longer periods of time, may enjoy progressively larger decreases in headache days over the period they are on therapy.</strong></span></p> </div><div id="Text187" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Stephen Silberstein, professor of neurology at the Jefferson Medical College and director of the Jefferson Headache Centre comments: &ldquo;In this pilot study we showed that nVNS was able to demonstrate an increasingly meaningful decrease in headache days in those patients who were treated with nVNS for a number of months. Our trial suggests that nVNS is a safe and effective alternative to drug therapies. I look forward to participating in larger studies in migraine to further confirm and expand on these findings.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The study which ran over nine months at six sites across the US comprised a run-in period of one month, a double-blind comparison period of two months, and an open-label phase of six months during which all patients used electroCore&rsquo;s gammaCore device on daily basis to reduce the occurrence of their chronic migraines. The 59 adult migraine patients who were enrolled in the study had to have had more than 15 headache days per month in the three months preceding the trial, in accordance with the ICHD definition of Chronic Migraine.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />During the comparative period, the patients were randomised and given either an active gammaCore device or a sham device that appeared identical but did not stimulate the vagus nerve. Neither the patient, nor the physician, nor the clinical trial monitors were aware of which device each patient was given. The patients self-administered the treatment by placing the gammaCore device on the right sides of their necks, over their vagus nerves, three times daily. Each treatment consisted of two 90-second stimulations, five to ten minutes apart.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />In the two month comparative phase, there was a decrease of 1.9 headache days per 28 days with three nVNS treated patients having more than a 50% decrease, and one having a 75% decrease in headache days. No sham control patients achieved a significant reduction. During the open label phase, the drop in headache days continued to grow, with patients originally randomised to the active therapy and remaining on therapy through the full six-month open label phase, experiencing more than an eight day drop in headache days per month. Among the entire group of patients remaining on therapy for the defined six months, 38% experienced a 50% reduction in headache days per month.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />JP Errico founder and chief executive officer of electroCore comments, &ldquo;We continue to be pleased by the clinical studies that consistently demonstrate nVNS therapy to be a safe, easy to use, preventative treatment that reduces the burden of severe headache for many patients. Although only a pilot study, these results confirms our intention to continue with larger scale studies in the prevention of migraine. We look forward to the full presentation of this data, and are continuing to explore the efficacy of nVNS in a range of related diseases and disorders.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Data from all the 59 patients are included in the safety study. Twenty-six patients from the nVNS arm and 23 from the sham control arm completed the two-month comparative phase. No serious adverse events were reported.</span></p></div> Lingraphica introduces iPad app to help survivors of stroke and traumatic brain injury recover language skills http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/lingraphica-introduces-ipad-app-to-help-survivors-of-stroke-and-traumatic-brain-injury-recover-language-skills 2014-06-25T12:31:00Z 2014-06-25T12:31:00Z <div id="Introduction88" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Lingraphica has introduced the iPad app component of TalkPath Therapy, its integrated cloud-based speech therapy solution for the millions of adults with aphasia, a speech disorder that affects the ability to speak, write or comprehend language, and the clinicians who work with them to improve language skills. The company, which has researched and produced rehabilitative speech-generating devices and assistive technology for adults with aphasia since 1990, is offering the subscription-based solution, available on the iPad and the Web, for free during its extended trial period.</strong></span></p> </div><div id="Text188" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">TalkPath Therapy for the iPad has been named best mobile commerce app in the 2014 New Jersey Technology Council&rsquo;s Mobile Apps Forum competition, which fielded entries from companies based in multiple states and several countries.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />With one account users can access more than 4,600 scientifically designed speech therapy exercises online or offline from the iPad and online from a Web browser.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />TalkPath Therapy was designed under the guidance of a team of speech-language pathologists and the company conducted significant usability testing with members of its Lingraphica Aphasia Users&rsquo; Group &ndash; each of whom is working to rebuild speech lost because of stroke. The company&rsquo;s own research shows that with continued practice using TalkPath Therapy&rsquo;s proprietary icons and content, users can recover language lost to due to a stroke or other brain injury.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;TalkPath Therapy is a truly mobile speech therapy solution that meets the needs of individuals with aphasia and their clinicians,&rdquo; says Andrew Gomory, chief executive officer of Lingraphica. &ldquo;We used our three decades of experience to transform our offerings into an even more meaningful and effective rehabilitative solution.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Clinicians using TalkPath Therapy have access to extensive reporting features including task-based reports and detailed activity reports. These features make it easy to show improvement and adjust plans in real time. No other solution on the market allows for this functionality on multiple platforms.</span></p></div> Imperial College London initiates study to investigate genetics of Parkinson’s disease http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/imperial-college-london-initiates-study-to-investigate-genetics-of-parkinsons-disease 2014-06-25T11:41:00Z 2014-06-25T11:41:00Z <div id="Introduction89" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Researchers at the Imperial College London will study individuals with genetic mutations associated with Parkinson&rsquo;s disease as one of 32 clinical sites of the Parkinson&rsquo;s Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J Fox Foundation for Parkinson&rsquo;s Research. The study is seeking volunteers of Ashkenazi Jewish background to participate.</strong></span></p> </div><div id="Text189" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">Overall, PPMI will enrol participants with a known mutation of the LRRK or SNCA [alpha-synuclein] gene. At Imperial College London, the researchers will look specifically at the LRRK2 mutation. Previous research has shown that both mutations are associated with Parkinson&rsquo;s disease, and account for a greater number of Parkinson&rsquo;s disease cases among certain ethnic populations and families, notably the LRRK2 mutation in those of Ashkenazi (Eastern European) Jewish, Basque and North African Berber descent. The insight gleaned from these research volunteers will fortify current efforts to develop a disease-modifying therapy, something that currently eludes the field.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Studying individuals with genetic mutations associated with Parkinson&rsquo;s can accelerate our research toward a Parkinson&rsquo;s disease biomarker and more effective treatments,&rdquo; says Nicola Pavese, the co-principal investigator of the PPMI study at Imperial College London. &ldquo;Although known genetic mutations currently account for only 5 to 10% of all Parkinson&rsquo;s cases, this population can provide invaluable information about the intricacies of the disease for all patients.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />PPMI is studying clinical and imaging data and biological samples of people with a genetic mutation to identify biomarkers and speed clinical trials. PPMI will enrol 250 people with the LRRK2 mutation and Parkinson&rsquo;s and 250 people with the mutation but without Parkinson&rsquo;s. Since the SNCA mutation is rarer, the study is recruiting 50 people with Parkinson&rsquo;s and the mutation and 50 people with the SNCA mutation but without Parkinson&rsquo;s disease. These participants will be followed for five years.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Launched in 2010, PPMI is a longitudinal clinical study that collects standardized clinical, imaging and biologic data. Now taking place at 32 clinical sites around the world, the study completed initial enrollment of 423 recently diagnosed Parkinson&rsquo;s patients and 196 controls in April 2013. That month PPMI began recruiting individuals with the known Parkinson&rsquo;s risk factors of smell loss and REM sleep behavior disorder.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;In the fourth year of PPMI, it is evident that a large-scale biomarker study is not only possible in Parkinson&rsquo;s disease, but is already yielding scientific insights that could help transform the field of Parkinson&rsquo;s research,&rdquo; says Todd Sherer, chief executive officer of The Michael J Fox Foundation. &ldquo;The exceptional investigators at sites around the world, such as at Imperial College London, have created the infrastructure that allows us to make such strides, by working together.&rdquo;</span></p></div> Neuralstem’s NSI-189 novel neurogenic compound shows significant effect in major depressive disorder http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuralstems-nsi-189-novel-neurogenic-compound-shows-significant-effect-in-major-depressive-disorder 2014-06-25T11:14:00Z 2014-06-25T11:14:00Z <div id="Introduction90" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Neuralstem has announced that two sets of data from the NSI-189 clinical trial in major depressive disorder (MDD) were reported at two recent academic conferences: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, and the International College of Neuropyschopharmacology (CINP) Annual Meeting. NSI-189 is Neuralstem&rsquo;s lead proprietary neurogenic compound.</strong></span></p> </div><div id="Text190" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">At the CINP meeting, a poster presentation on quantitative EEG (qEEG) measurements, an electrophysical biomarker of depression, taken during the course of study showed that patients in the active treatment arm of the study:<br /><br /></span></p> <ul> <li><span style="font-size: 10pt;">Had significantly increased brain wave patterns in the hippocampal region of the brain. Specifically, qEEG measurements at day 28 showed statistical significance between the treatment and the placebo group in the electrical wave patterns emanating from specific areas of the brain, namely the left posterior temporal lobe and parietal region (p&lt;0.02).</span></li> <li><span style="font-size: 10pt;">Showed increased electrical coherence in the prefrontal cortical region, which is a pro-cognitive signal.<br /><br /></span></li> </ul> <p><span style="font-size: 10pt;">Researchers concluded that these electrophysiological changes are consistent with the neurogenic hypothesis of the drug mechanism, which involves long-term structural changes in the hippocampus.<br /><br /></span></p> <p><span style="font-size: 10pt;">These results follow the 28-day clinical data presented at the ASCP meeting, which showed a significant and large treatment effect in the improvement of both depression and cognitive symptoms in the active therapy patients, compared to placebo, which continued eight weeks after treatment stopped, specifically:<br /><br /></span></p> <ul> <li><span style="font-size: 10pt;">In a comprehensive assessment scale for depression (Symptoms of Depression Questionnaire or SDQ), the combined treatment group showed statistically significant improvement (p=0.02) after 28 days of the drug treatment compared to its randomised, double-blinded, placebo control group.&nbsp; There was a large effect size of 0.90.</span></li> <li><span style="font-size: 10pt;">As measured by the assessment scale of cognitive and functioning deficits specifically designed for depressed patients (Cognitive and Physical Functioning Questionnaire or CPFQ), the treatment group was significantly better than the placebo group (p=0.01) at day 28 with a large effect size of 0.94.</span></li> <li><span style="font-size: 10pt;">As measured by both by SDQ and CPFQ, NSI-189&rsquo;s significant and large treatment effects continued for eight weeks even after the drug was withdrawn.<br /><br /></span></li> </ul> <p><span style="font-size: 10pt;">&ldquo;This is a small study, but we should acknowledge the importance of showing such a powerful signal in such a small study in an indication with a very high placebo effect, historically,&rdquo; says Richard Garr, Neuralstem&rsquo;s president and chief executive officer.&nbsp; &ldquo;Additionally, we believe that no approved antidepressants have shown this type of long-term disease modifying property. If these large effect sizes and stable improvements in both depression and cognition are replicated with larger cohorts, we will pursue a breakthrough designation, with accelerated development prospects and reimbursement advantages. We plan to launch a large, multi-site phase II study by the first quarter of 2015.&rdquo;<br /><br /></span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;">&ldquo;We believe this qEEG data confirms that NSI-189 is affecting key circuitry common in both mood control and cognition, involving hippocampal neurogenesis and synaptogenesis,&rdquo; says Karl Johe, Neuralstem&rsquo;s chairman and chief scientific officer. &ldquo;The next clinical trial will test two doses (40mg QD and 40mg BID), along with a randomised, double-blinded, placebo control group, in approximately 150 patients with confirmed diagnosis of recurrent MDD, with the aim of confirming these extremely promising results in a larger clinical setting.&rdquo;</span></p></div> Neuro Resource Group’s hospital presence continues to expand http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neuro-resource-groups-hospital-presence-continues-to-expand 2014-06-24T12:40:00Z 2014-06-24T12:40:00Z <div id="Introduction91" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Neuro Resource Group continues to expand the utilisation of its new InterX 900 ISSDE Pain Management System for post-surgical pain management in hospitals and surgery centres.</strong></span></p> </div><div id="Text191" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The InterX System, which consists of the InterX 900 Driver and InterX Sterile Self-Adhesive Dual Electrode, (ISSDE,) provides non-drug, non-invasive neurostimulation pain relief. Scientific research has shown that InterX produces a significantly greater physiological response than a standard neurostimulation device. The unique product design and waveform of InterX allows more focused, higher amplitude stimulation thus providing a reliable and consistent pain management solution for a broad range of patient conditions. </span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Utilisation of the InterX 900 ISSDE System in our initial hospital use continues to clinically validate the effectiveness of the technology and its ability to reduce the need of narcotic drugs for pain control following surgery. Hospitals using the system have reported that patients are experiencing improved pain management and reduced rehabilitation times, thus enabling an earlier release from the hospital,&rdquo; states Dave Turner, NRG&rsquo;s chief executive officer.</span></p></div> New Philips NeuroSuite reveals the brain’s vascular network like never before http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-philips-neurosuite-reveals-the-brains-vascular-network-like-never-before 2014-06-23T17:29:00Z 2014-06-23T17:29:00Z <div id="ImageMain92" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-philips-neurosuite-reveals-the-brains-vascular-network-like-never-before"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/NeuroSuite_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction92" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Royal Philips has announced the introduction of NeuroSuite, a new integrated solution designed to support and enhance minimally invasive image-guided neurological interventions. Philips&rsquo; new interventional X-ray solution offers more effective device guidance and placement in every neuroradiology procedure.</strong></span></p> </div><div id="Text192" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The first NeuroSuite system was recently installed at Karolinska University Hospital, Stockholm, Sweden. This hospital is one of the world&acute;s leading medical universities and a centre of excellence for stroke treatment.</span></p> <p><span style="font-size: 10pt;"><br />Neuroradiology is a branch of radiology that involves the diagnosis and minimally invasive treatment of the brain, head, neck and spine. These treatments require the insertion of a catheter, which must be navigated through a very narrow (with vessels less than 2mm wide) and tortuous vasculature to the treatment site with the aid of live image guidance. New devices (eg. stents and flow diverters) offer new treatments for ischaemic stroke or large neck aneurism, but their increasingly smaller designs make the devices more difficult to see with X-ray imaging. This can present additional challenges for placement and treatment assessment.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />To cope with these challenges Philips&rsquo; NeuroSuite consists of a bi-plane interventional X-ray system with a unique combination of two new detectors: Philips&rsquo; frontal FD20 detector delivers live 2D and 3D imaging to provide live navigation and immediate therapy feedback. The smaller, lateral FD15 detector can be positioned beyond the shoulders and very close to the head. This shorter distance and unique combination of detectors provides sharp, full brain imaging at lower X-ray dose and 3D imaging optimised for neuro and spine interventions.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;In image-guided interventions the ultimate goal is to see clearly and navigate effectively, while managing X-ray dose for patients, staff and clinicians,&rdquo; says Ronald Tabaksblat, general manager Interventional X-ray at Philips Healthcare. &ldquo;Developed in collaboration with clinical partners around the world, Philips NeuroSuite has been designed for that purpose and underpins Philips&rsquo; global leadership position in live-image guidance technologies.&rdquo;</span></p> <p><span style="font-size: 10pt;"><br /><br />&ldquo;In interventional neuroradiology the performance of the angiographic system is crucial to patient safety,&rdquo; says Michael S&ouml;derman, associate professor and chief of Neuroangiography and Stereotaxy, Department of Neuroradiology, Karolinska University Hospital. &ldquo;Philips&rsquo; latest innovation is NeuroSuite with a new 20 inch detector on the frontal plane, providing superb 3D-images and big enough for spine imaging. On the lateral plane, the new 15 inch detector brings visualization of the complete cerebral vasculature, with reduced collision risks and enhanced projection freedom.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />At the heart of NeuroSuite is Philips AlluraClarity, lowering radiation dose by as much as 73% without compromising image quality: and VasoCT that visualises intracranial devices in vessel context and vessel morphology down to perforator vessels.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;Over the last years a lot of progress was made on high resolution device visualisation,&rdquo; says Jacques Moret of the faculty of medicine Bichat-Beaujon at the University of Paris, France. &ldquo;The next step in our collaboration with Philips is the NeuroSuite bringing enhanced vessel and device visualisation and full head coverage. The new detector combination could be especially useful for stroke treatment.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />Philips NeuroSuite will be officially launched at the Live Interventional Neuroradiology &amp; Neurosurgery Course (LINNC) in Paris from 23-25 June 2014.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />NeuroSuite is currently not available in the USA.</span></p></div> Gold for Airo Mobile Intraoperative CT in 2014 Medical Design Excellence Awards http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/gold-for-airo-mobile-intraoperative-ct-in-2014-medical-design-excellence-awards 2014-06-20T16:57:00Z 2014-06-20T16:57:00Z <div id="ImageMain93" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/gold-for-airo-mobile-intraoperative-ct-in-2014-medical-design-excellence-awards"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/037/Airo_main_Main.jpg" border="0" vspace="5" /></a></div><div id="Introduction93" style="clear:both;"> <p><strong><span style="font-size: 11pt;">Airo&nbsp;Mobile Intraoperative CT, developed and manufactured by Mobius Imaging and distributed by Brainlab, was awarded gold in the Radiological and Electromechanical Device category of the 17</span><span style="font-size: 12px;">th</span><span style="font-size: 11pt;">&nbsp;Annual&nbsp;Medical Design Excellence Awards (MDEA) competition. Award winners were announced on June 11, 2014 at&nbsp;MD&amp;M East&rsquo;s&nbsp;main networking event&mdash;the&nbsp;2014 Medical Design Excellence Awards&nbsp;ceremony held in New York. This distinction comes just months after Airo was honoured with a 2014 Red Dot Product Design Award.</span></strong></p> </div><div id="Text193" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The&nbsp;2014 MDEA Juror Panel&nbsp;selected 33 winning products from among 54 exceptional finalist products in 11 medical technology product categories. Selected products excel in five areas: manufacturing and technological innovation; design and engineering advancements; patient benefits; business benefits; and overall improvement to healthcare industry.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;We are proud and honoured to receive MDEA gold for Airo,&rdquo; says Gene Gregerson, chief executive officer Mobius Imaging. &ldquo;This recognition validates the work we have put into this exceptional product. By answering true clinical needs with this product, we help ensure that it can be intuitively incorporated into everyday clinical practice. The system&rsquo;s flexibility and mobility make Airo a valuable extension for several environments and a range of surgical clinical applications. We even worked directly with operating personnel including surgeons, anaesthetists and nurses to help verify numerous surgical workflows.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Created to operate inside existing operating room suites, Airo design boasts an ultra-small footprint which incorporates advanced CT technology for intraoperative imaging as well as custom-built components to help address various challenges of mobility and sterility within the operating room. With the largest gantry opening on the market, Airo is suitable for cranial, spine and trauma procedures, making it a highly versatile intraoperative imaging system.</span></p> <p><br /><span style="font-size: 10pt;">MDEA entries are judged by an impartial panel of experts from a range of disciplines&mdash;from engineers to designers to clinicians. </span><br /> <br /><span style="font-size: 10pt;"> <strong>&ldquo;</strong>We applaud our partner, Mobius Imaging, for achieving this gold award for design excellence&rdquo; says Stefan Vilsmeier, president and chief executive officer of Brainlab. &ldquo;As the exclusive distributor of Airo, and primary collaborator on the graphical user interface for Airo, we strongly believe it has the potential to positively alter the surgical space in many clinical fields. For us, the MDEA gold only confirms this potential.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">The first Airo systems went into clinical use in April 2014.</span></p></div> Researchers reveal combinatorial code for the developing brain http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/researchers-reveal-combinatorial-code-for-the-developing-brain 2014-06-20T16:42:00Z 2014-06-20T16:42:00Z <div id="Introduction94" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Researchers at the Allen Institute for Brain Science have mapped the development of the mouse brain from the embryo to the adult, creating a preliminary genetic key that allows them to pinpoint the age and location of regions of the developing brain. This work lays the foundation for tracking regions of the mouse brain through development, which could have valuable implications for translational work in human brain developmental disorders. The research, profiling the publicly available Allen Developing Mouse Brain Atlas, is published in the journal <a href="http://www.cell.com/neuron/home" target="_blank">Neuron</a>.</strong></span></p> </div><div id="Text194" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">In order to identify individual brain regions, and their age, researchers frequently turn to using genes that can be found exclusively in that particular region and time point. But truly specific so-called &ldquo;marker&rdquo; genes are actually quite rare, explains Michael Hawrylycz, investigator at the Allen Institute for Brain Science. &ldquo;Rather than relying on single genes, we were able to identify combinations of genes and use those combinations to create a unique code that can be used to place regions of the brain in space-time,&rdquo; says Hawrylycz.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The research team also captured evidence of how the brain develops from its earliest form of stacked primordial plates to its adult form with the more familiar geographic regions that begin to correspond to specialised functional divisions of the brain.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;We can now place this important organisational transition from plates to regions within developmental time,&rdquo; says Carol Thompson, lead author and scientific programme manager at the Allen Institute for Brain Science. &ldquo;We already knew this transition took place, but now we understand the mechanics behind it at a much more detailed, molecular level.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />The Allen Developing Mouse Brain Atlas serves as an expansion of the original Allen Mouse Brain Atlas and identifies where genes are active in the brain over seven different ages, ranging from prenatal to adult. Rather than profiling every gene in the mouse genome, the researchers selected approximately 2,100 genes with particular importance in development, and used those to identify individual brain regions at different time points.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />&ldquo;The Allen Developing Mouse Brain Atlas works like a Rosetta stone for the developing brain,&rdquo; says Allan Jones, chief executive officer of the Allen Institute for Brain Science. &ldquo;We can translate how and when genes are expressed into what is happening in the brain developmentally, making this resource a promising tool for better understanding and eventually treating brain developmental disorders and diseases.&rdquo;</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><span style="font-size: 10pt;"><br />As with all Allen Brain Atlas resources, the data from the Allen Developing Mouse Brain Atlas are publicly available through the Allen Brain Atlas data portal at brain-map.org.</span></p></div> Study proves navigated TMS fundamentally improves treatment and outcomes for brain tumour patients http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/study-proves-navigated-tms-fundamentally-improves-treatment-and-outcomes-for-brain-tumour-patients 2014-06-19T17:08:00Z 2014-06-19T17:08:00Z <div id="Introduction95" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A study published in the Oxford Journal&nbsp;<a href="http://neuro-oncology.oxfordjournals.org/" target="_blank"><span style="color: #800000;"><em>Neuro-Oncology</em></span></a>, &lsquo;Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumours in motor eloquent areas&rsquo;, looked at the outcomes of 365 motor eloquent brain-tumour patients. The study proved that integrating navigated transcranial magnetic stimulation (nTMS) into the surgical workflow to pre-operatively localise motor function has a significant impact on treatment and outcome.</strong></span></p> </div><div id="Text195" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The authors from Charit&eacute; University in Berlin, looked at using Nexstim&rsquo;s Navigated Brain Stimulation (NBS) System for pre-operative motor mapping. The study enrolled 250 consecutive patients and compared their outcomes to a matched pre-nTMS control group on 115 patients. The results of the NBS mapping impacted the surgical plan in 68% of the cases:</span><br /><br /></p> <ul> <li><span style="font-size: 10pt;">Disproving suspected involvement of the primary motor cortex in 25.1% of the cases</span></li> <li><span style="font-size: 10pt;">Expanded surgical indication by 14.8%</span></li> <li><span style="font-size: 10pt;">Achieved 18% more total resections</span></li> <li><span style="font-size: 10pt;">Progression free survival increased by 45% in patients with low grade gliomas</span></li> </ul> <p><br /><span style="font-size: 10pt;"> &ldquo;This is why we work to get this amazing technology to the clinics. Helping patients to get better care and provide neurosurgeons more tools for their important pre-operative&nbsp;planning is driving us further.&rdquo; &ndash; Janne Huhtala, chief executive officer, Nexstim.</span></p> <p><br /><span style="font-size: 10pt;">In their conclusions, the authors stated &ldquo;the impact of this study should go far beyond the neurosurgical community because it could fundamentally improve treatment and outcome, and its results will likely change clinical practice.&rdquo; The use of NBS for pre-surgical mapping provided crucial data that improved surgical planning and patient communication. nTMS has now been proven to enable more patients to undergo surgery, which in turn may lead to better neurological outcomes and higher survival rates in brain tumour patients.</span></p></div> Neurim Pharmaceuticals announces publication of positive effects of add-on Circadin in Alzheimer&apos;s disease patients http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/neurim-pharmaceuticals-announces-publication-of-positive-effects-of-add-on-circadin-in-alzheimers-disease-patients 2014-06-19T16:55:00Z 2014-06-19T16:55:00Z <div id="Introduction96" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Neurim Pharmaceuticals has announced publication of the results from an exploratory phase 2 randomised placebo-controlled clinical trial evaluating the safety and efficacy of add-on Circadin (Prolonged Release melatonin 2mg) to standard therapy in Alzheimer&rsquo;s disease patients. The study, published in the <a href="https://www.dovepress.com/clinical-interventions-in-aging-journal" target="_blank"><em>Clinical Interventions in Aging Journal</em></a>, demonstrates positive effects of the drug on cognitive performance and sleep maintenance in the Alzheimer&rsquo;s disease patients.</strong></span></p> </div><div id="Text196" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;Endogenous melatonin levels are reduced already at preclinical Alzheimer&rsquo;s disease stages. Because melatonin is important for good sleep quality and because poor sleep quality has recently been linked to Alzheimer&rsquo;s disease, it was important to investigate whether replenishing the missing hormone would be beneficial in AD patients and whether such effects would be related to the improvement in sleep,&rdquo; says Tali Nir, head of clinical trials at Neurim Pharmaceuticals.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><br /><span style="font-size: 10pt;">In this study, 80 patients diagnosed with mild-to-moderate Alzheimer&rsquo;s disease, with and without insomnia co-morbidity, receiving standard therapy (acetylcholinesterase inhibitors with or without memantine) were randomly assigned in a double-blind manner to 2mg of Circadin or placebo treatment nightly for 24-weeks. The paper reports that patients treated with Circadin for six months had significantly better cognitive performance than those with placebo as measured by Instrumental Activities of Daily Living (IADL) and Mini Mental State Examination (MMSE). Mean Alzheimer&rsquo;s Disease Assessment Scale - cognition (ADAS-Cog) did not differ between groups. Sleep efficiency as measured by Pittsburgh Sleep Quality Index (PSQI) Component 4 also improved with Circadin. In a subgroup of patients suffering from comorbid insomnia, Circadin treatment resulted in significant and clinically meaningful effects vs. placebo in mean IADL (p=0.032), MMSE (+1.5 vs. -3 points, p=0.0177) sleep efficiency (p=0.04), and median ADAS-Cog values (-3.5 vs. +3 points, p=0.045). The treatment was well tolerated.</span></p> <p><span style="font-size: 10pt;">&nbsp;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;We are very pleased with the encouraging data demonstrating efficacy and safety of add-on Circadin for six months on cognitive functioning and sleep in patients with mild-moderate Alzheimer&rsquo;s disease. This publication comes at an exciting time when the causal relationship between sleep disturbance and the Alzheimer&rsquo;s disease-relevant accumulation of beta amyloid in brain was discovered,&rdquo; says Zisapel, chief science officer of Neurim Pharmaceuticals. &ldquo;This study demonstrates the significance of good sleep quality and melatoninergic mechanisms in improving both cognition and sleep problems in Alzheimer patients and calls for further focus of this mechanism in Alzheimer&rsquo;s disease treatment.&rdquo;&nbsp;</span></p></div> Floridian Community Bank supports NSU Concussion Management Clinic http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/floridian-community-bank-supports-nsu-concussion-management-clinic 2014-06-17T12:43:00Z 2014-06-17T12:43:00Z <div id="Introduction97" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Floridian Community Bank has announced that it will sponsor the Nova Southeastern University Concussion Management Clinic, one of the largest community-based sport concussion initiatives in the state of Florida.</strong></span></p> </div><div id="Text197" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">The bank recently made a financial contribution to the NSU Clinic, which provides state-of-the-art concussion management services to the thirty-two public and private high schools in the Broward County Athletic Association. Services to high school students include baseline testing, education and outreach and post-injury care. These services help to advise doctors and parents of the severity of a head injury, treatment needed and when the student athlete can get return to the field/court.</span></p> <p><br /><span style="font-size: 10pt;">Joseph Marzouca, Floridian Community Bank chief executive officer, comments, &ldquo;At the bank, we like to give back to the communities we serve, whenever we can. When this opportunity was brought to us &ndash; we jumped on it. We hope to support similar efforts in the future as well.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">Bank president Lee Frankhouser adds, &ldquo;We&rsquo;re very happy to be working with the team at Nova Southeastern on a cause that many of us at the bank feel so strongly about. We have all learned in the past few years how critically important concussion testing and treatment is, and we feel it is a necessity to support for South Florida&rsquo;s high school athletes.&rdquo;</span></p></div> Positive top-line results from phase 3 study investigating daclizumab high-yield process in MS http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/positive-top-line-results-from-phase-3-study-investigating-daclizumab-high-yield-process-in-ms 2014-06-17T12:36:00Z 2014-06-17T12:36:00Z <div id="Introduction98" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>Biogen Idec&nbsp;and&nbsp;AbbVie&nbsp;have announced positive top-line results from the phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN &beta;-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study&rsquo;s primary endpoint, demonstrating a statistically significant 45% reduction in annualised relapse rate (ARR) compared to IFN &beta;-1a (p&lt;0.0001).</strong></span></p> </div><div id="Text198" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;The results of the DECIDE study are compelling, with DAC HYP demonstrating robust efficacy compared to a current standard of MS care,&rdquo; says Gilmore O&rsquo;Neill, vice president, Global Neurology Clinical Development, Biogen Idec. &ldquo;As a potential once-monthly therapy with a novel mechanism of action, we believe that, if approved, DAC HYP will be an important treatment option for people living with MS.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;The positive results in the DECIDE study represent achievement of an important milestone in the development of DAC HYP as a potential new treatment option for MS patients,&rdquo; says Michael Severino, executive vice president, Research and Development and chief scientific officer, AbbVie. &ldquo;Together, the companies are committed to working with regulatory agencies on filing plans for DAC HYP.&rdquo;</span></p> <p><br /><span style="font-size: 10pt;">DAC HYP showed superiority on the first secondary endpoint, number of new or newly enlarging T2-hyperintense lesions at week 96, with a 54% reduction relative to IFN &beta;-1a (p&lt;0.0001). On the second secondary endpoint, DAC HYP reduced the risk of three month confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS) by 16% over IFN &beta;-1a, which was not statistically significant (p=0.16). Using a pre-specified sensitivity analysis that accounted for 67 patients who did not have a confirmatory disability assessment, DAC HYP showed a 21% reduction in the risk of sustained disability progression (p=0.047).</span></p> <p><br /><span style="font-size: 10pt;">The safety profile of DAC HYP in the study was consistent with what has been observed in prior studies. The overall incidence of adverse events was comparable across the DAC HYP and IFN &beta;-1a treatment groups. In patients treated with DAC HYP compared to IFN &beta;-1a, there was an increased incidence of serious infections (4% vs. 2%), serious cutaneous reactions (2% vs. &lt; 1%), and elevations of liver transaminases greater than five times the upper limit of normal (6% vs. 3%). There were four deaths in the IFN &beta;-1a group and one death in the DAC HYP group, none of which was considered treatment related.</span></p> <p><br /><span style="font-size: 10pt;">Biogen Idec and AbbVie plan to work with regulatory agencies to determine appropriate timelines for filing. The companies intend to present detailed results from DECIDE at a future medical conference.</span></p></div> New insight into how the brain regulates its blood flow http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-insight-into-how-the-brain-regulates-its-blood-flow 2014-06-17T12:31:00Z 2014-06-17T12:31:00Z <div id="ImageMain99" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/new-insight-into-how-the-brain-regulates-its-blood-flow"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Brain_power_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction99" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>In a new study&nbsp;published online in the&nbsp;<a href="http://jaha.ahajournals.org/content/3/3/e000787.full" target="_blank"><em>Journal of the American Heart Association</em></a>, researchers at&nbsp;Columbia Engineering&nbsp;report that they have identified a new component of the biological mechanism that controls blood flow in the brain. Led by&nbsp;Elizabeth M C Hillman, associate professor of biomedical engineering, the team has demonstrated for the first time that the vascular endothelium plays a critical role in the regulation of blood flow in response to stimulation in the living brain.</strong></span></p> </div><div id="Text199" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">&ldquo;We think we have found a missing link in our understanding of how the brain dynamically tunes its blood flow to stay in sync with the activity of neurons,&rdquo; says Hillman, who has a joint appointment in Radiology. &ldquo;Earlier studies identified small pieces of the puzzle, but we did not believe they formed a cohesive &lsquo;big picture&rsquo; that unified everybody&rsquo;s observations. Our new finding seems to really connect the dots.&rdquo;</span><br /><br /><span style="font-size: 10pt;">Understanding how and why the brain regulates its blood flow could provide important clues to understanding early brain development, disease, and ageing. The brain increases local blood flow when neurons fire, and this increase is what is detected by a functional magnetic resonance imaging (fMRI) scan. Hillman found that the vascular endothelium, the inner layer of blood vessels, plays a critical role in propagating and shaping the blood flow response to local neuronal activity. While the vascular endothelium is known to do this in other areas of the body, until now the brain was thought to use a different, more specialised mechanism and researchers in the field were focused on the cells surrounding the vessels in the brain.</span><br /><br /><span style="font-size: 10pt;">&ldquo;Once we realised the importance of endothelial signalling in the regulation of blood flow in the brain,&rdquo; Hillman adds, &ldquo;we wondered whether overlooking the vascular endothelium might have led researchers to misinterpret their results.&rdquo;</span><br /><br /><span style="font-size: 10pt;">&ldquo;We really hope that our work will encourage others to take a closer look at the vascular endothelium in the brain. So far, we think that our findings have far-reaching and really exciting implications for neuroscience, neurology, cardiovascular medicine, radiology, and our overall understanding of how the brain works,"&nbsp;she continues.</span><br /><br /><span style="font-size: 10pt;">The research was carried out in Hillman&rsquo;s&nbsp;Laboratory for Functional Optical Imaging, led by PhD student and lead author on the study, Brenda Chen. Other lab members who assisted with the study included PhD and MD/PhD students from Columbia Engineering, Neurobiology and Behavior, and Columbia University Medical Center.&nbsp;</span><br /><br /><span style="font-size: 10pt;">To tease apart the role of endothelial signalling in the living brain, they had to develop new ways to both image the brain at very high speeds, and also to selectively alter the ability of endothelial cells to propagate signals within intact vessels. The team achieved this through a range of techniques that use light and optics, including imaging using a high-speed camera with synchronised, strobe LED illumination to capture changes in the colour, and thus the oxygenation level of flowing blood. Focused laser light was used in combination with a fluorescent dye within the bloodstream to cause oxidative damage to the inner endothelial layer of blood brain arterioles, while leaving the rest of the vessel intact and responsive. The team showed that, after damaging a small section of a vessel using their laser, the vessel no longer dilated beyond the damaged point. When the endothelium of a larger number of vessels was targeted in the same way, the overall blood flow response of the brain to stimulation was significantly decreased.</span><br /><br /><span style="font-size: 10pt;">&ldquo;Our finding unifies what is known about blood flow regulation in the rest of the body with how it is regulated in the brain,&rdquo; Hillman explains. &ldquo;This has wider reaching implications since there are many disease states known to affect blood flow regulation in the rest of the body that, until now, were not expected to directly affect brain health.&rdquo; For instance, involvement of the endothelium might explain neural deficits in diabetics; a clue that could lead to new diagnostics tests and treatments for neurological conditions associated with broader cardiovascular problems."</span><br /><br /><span style="font-size: 10pt;">&ldquo;Improving our fundamental understanding of how and why the brain regulates its blood flow is key to understanding how and when this mechanism could be altered or broken,&rdquo; she says. &ldquo;We think this could extend to studies of early brain development, ageing, and diseases such as Alzheimer&rsquo;s and dementia.&rdquo;</span><br /><br /><span style="font-size: 10pt;">The team&rsquo;s research findings may also explain the effects of some drugs on the brain, and on the fMRI response to stimulation, since the vascular endothelium is exposed to chemicals in the bloodstream. &ldquo;Overall, this work could dramatically improve our ability to interpret fMRI data collected in humans, perhaps making it a better tool for doctors to understand brain disease,&rdquo; she adds.</span><br /><br /><span style="font-size: 10pt;">Hillman plans next to address the broad range of implications her latest finding may have. She wants to explore the effects of drugs and disease states on the coupling of blood flow to neuronal activity in the brain, and is now starting studies to explore fMRI data from a range of different disease states to see whether she can find signs of neurovascular dysfunction. She is also working on characterising the co-evolution of neuronal and haemodynamic activity during brain development and is beginning to develop new imaging tools that will enable non-invasive, inexpensive monitoring of brain haemodynamics in infants and children who cannot be imaged within an MRI scanner.</span><br /><br /><span style="font-size: 10pt;">This research is supported by the National Institutes of Health (through the National Institute of Neurological Disorders and Stroke) as well as the National Science Foundation, the Human Frontier Science Programme and the Rodriguez family.</span></p></div> Foreign body retrieval could be new indication for Trevo ProVue in the cerebrovascular system http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/foreign-body-retrieval-could-be-new-indication-for-trevo-provue-in-the-cerebrovascular-system 2014-06-17T11:44:00Z 2014-06-17T11:44:00Z <div id="ImageMain100" style="clear:both;" align="center"><a href="http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/foreign-body-retrieval-could-be-new-indication-for-trevo-provue-in-the-cerebrovascular-system"><img src="http://www.cxvascular.com/AcuCustom/Sitename/DAM/039/Enterprise_coil_retrieval_main.jpg" border="0" vspace="5" /></a></div><div id="Introduction100" style="clear:both;"> <p><span style="font-size: 11pt;"><strong>A case report has described the novel use of a stent for the removal of a foreign body from the cerebrovascular system.</strong></span></p> </div><div id="Text1100" style="clear:both; text-align:left"><p><span style="font-size: 10pt;">According to the authors, Mouhammed R Kabbani <em>et al</em>, the case was a man with a large left cavernous internal carotid artery cerebral aneurysm. Primary coiling was initially attempted and when this failed, stent-assisted coiling was performed later on. During the primary coiling, a 10mmx40cm Complex Standard Penumbra coil (Penumbra) was used to frame the aneurysm. It prematurely detached and migrated into the anterior cerebral artery and could not be retrieved when negative suctioning was applied to the microcatheter (PX Slim, Penumbra).</span></p> <p><br /><span style="font-size: 10pt;">Kabbani and colleagues say that multiple failed attempts were made to retrieve the coil using 2mm and 4mm microsnares (Amplatz GooseNeck). Following these attempts the Trevo ProVue (Stryker) was used successfully.</span></p> <p><br /><span style="font-size: 10pt;">After the coil retrieval, a cerebral angiogram demonstrated a mild vasospasm of the distal pericallosal artery with no evidence of vascular injury or branch occlusion.</span></p> <p><br /><span style="font-size: 10pt;">&ldquo;Strentrievers such as the Trevo ProVue and Solitaire (Covidien) are indicated for thrombectomy in acute ischaemic stroke. Because of their mechanical characteristics, they may be used as a reasonable additional tool [&hellip;] to retrieve foreign bodies from the cerebrovascular system when other devices fail,&rdquo; Kabbani <em>et al</em> say.</span></p> <p><br /><span style="font-size: 10pt;">Kabbani, speaking to <em>NeuroNews</em> says that in the future this device could be used more often for retrieval of foreign bodies in the cerebrovascular system but more case reports, such as his, are needed to support its use.</span></p></div>